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A doença de Alzheimer é uma doença crónica neurodegenerativa e uma das 
formas mais comuns de demência. Está associada à perda de memória, 
declínio cognitivo, incapacidade física e comportamental, e, em última análise, 
pode levar à morte. A doença de Alzheimer é uma doença complexa, 
ocorrendo na maioria dos casos esporadicamente, sendo a idade o  principal 
fator de risco. A produção e acumulação do péptido beta-amilóide no sistema 
nervoso central é um facto importante no desenvolvimento da doença de 
Alzheimer. 
O principal objetivo deste projeto consiste na síntese de ligandos beta-
amilóide, de compostos fluoróforos e transportadores de fármacos através da 
barreira hematoencefálica para o diagnóstico e tratamento da doença de 
Alzheimer. Serão sintetizados diversos ligandos do péptido beta-amilóide e 
estudada a capacidade destes compostos interatuarem com as placas beta-
amilóides através de espectroscopia de ressonância magnética nuclear. Será 
também realizado um estudo de otimização do composto líder. Já foram 
identificados muitos compostos naturais e sintéticos capazes de interagir com 
o péptido beta-amilóide, entre eles um conjunto de pequenas moléculas nas 
quais se constata que a parte aromática possui um papel importante na 
inibição da sua agregação, nomeadamente compostos hetero-aromáticos 
policíclicos, tais como as tetraciclinas. Porém as tetraciclinas apresentam 
instabilidade química, baixa solubilidade em água e possuem atividade 
antibacteriana, a qual é neste contexto indesejada. De modo a ultrapassar 
estas limitações, um dos objectivos deste trabalho é sintetizar compostos 
análogos de tetraciclinas, possuindo uma estrutura policíclica com uma 
melhor estabilidade química e solubilidade em água e possivelmente não 
possuindo atividade antibacteriana, mas conservando a capacidade de 
interação com o péptido beta-amilóide. As tetraciclinas possuem em comum 
um quarto ciclo sem carácter aromático e possuindo diferentes grupos 
funcionais. Com este projeto pretende-se sintetizar derivados nos quais este 
quarto ciclo é constiuído por uma entidade glucídica, portanto, possuindo 
diferentes posições funcionalizáveis ou criar derivados nos quais se irá 
acrescentar ou diminuir o número de anéis fundidos. De modo a criar um 
potencial fármaco, estas moléculas deverão também possuir as corretas 
propriedades físico-químicas. A entidade glucídica, não estando diretamente 
envolvida na interação com o péptido beta-amilóide, assegura possíveis 
derivatizações, tais como a conjugação a outras entidades moleculares 
(nanopartículas, suportes poliméricos, etc.) e a funcionalização com outros 
grupos funcionais capazes de modularem as propriedades lipofílicas e 
hidrofílicas. Estes compostos só serão úteis se atravessarem a barreira 
hematoencefálica e serem de algum modo detetados para fins de diagnóstico. 
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abstract 
 
Alzheimer’s disease is a chronic progressive neurodegenerative disease and is 
the most common form of dementia (estimated 50−60% of all cases), 
associated with loss of memory (in particular episodic memory), cognitive 
decline, and behavioural and physical disability, ultimately leading to death. 
Alzheimer’s disease is a complex disease, mostly occurring sporadically with 
no apparent inheritance and being the age the main risk factor. The production 
and accumulation of amyloid-beta peptide in the central nervous system is a 
key event in the development of Alzheimer’s disease. 
This project is devoted to the synthesis of amyloid-beta ligands, fluorophores 
and blood brain barrier-transporters for diagnosis and therapy of Alzheimer’s 
disease. Different amyloid-beta ligands will be synthesized and their ability to 
interact with amyloid-beta plaques will be studied with nuclear magnetic 
resonance techniques and a process of lead optimization will be performed. 
Many natural and synthetic compounds able to interact as amyloid-beta ligands 
have been identified. Among them, a set of small molecules in which aromatic 
moieties seem to play a key role to inhibit amyloid-beta aggregation, in 
particular heteroaromatic polycyclic compounds such as tetracyclines. 
Nevertheless tetracyclines suffer from chemical instability, low water solubility 
and possess, in this contest, undesired anti-bacterial activity. In order to 
overcome these limitations, one of our goals is to synthesize tetracyclines 
analogues bearing a polycyclic structure with improved chemical stability and 
water solubility, possibly lacking antibacterial activity but conserving the ability 
to interact with amyloid-beta peptides. Known tetracyclines have in common a 
fourth cycle without an aromatic character and with different functionalisations. 
We aim to synthesize derivatives in which this cycle is represented by a sugar 
moiety, thus bearing different derivatisable positions or create derivatives in 
which we will increase or decrease the number of fused rings. In order to 
generate a potential drug-tool candidate, these molecules should also possess 
the correct chemical-physical characteristics. The glycidic moiety, not being 
directly involved in the binding, it assures further possible derivatizations, such 
as conjugation to others molecular entities (nanoparticles, polymeric supports, 
etc.), and functionalization with chemical groups able to modulate the 
hydro/lipophilicity. In order to be useful such compounds should perform their 
action within the brain, therefore they have to be able to cross the blood brain 
barrier, and to be somehow detected for diagnostic purposes. 
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Glc glucose 
GSH glutathione 
GSK-3β glycogen synthase kinase 3 
GSSG oxidized glutathione 
HBTU O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro phosphate 
HD Huntington’s disease 
HSQC 
1
H/
13
C heteronuclear single quantum coherente spectroscopy 
i-Pr isopropyl 
J coupling constant (in NMR spectroscopy) 
LDA lithium diisopropylamide 
logP logarithm of partition coefficient 
m multiplet 
m/z mass-to-charge ratio (mass spectrometry) 
M+ parent molecular ion 
MAPK mitogen-activated protein kinase 
MARK microtubule affinity-regulating kinase  
MCI mield cognitive impariment 
MD molecular dynamics 
MDB microtubule-binding main domain 
Me methyl 
MHz megahertz 
Mix mixing time 
MLV multilamellar vesicle (liposome) 
MM molecular mechanics 
Mol, mol mole(s) 
MRI magnetic resonance imaging 
Ms methanesulfonyl 
MW Molecular weight 
NBS N-bromosuccinimide 
NFT neurofibrillary tangle(s) 
NGF nerve growth factor 
NMO N-methylmorpholine-N-oxide 
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NMR nuclear magnetic resonance 
NOE nuclear Overhauser effect 
NOESY 
1
H/
1
H nuclear Overhauser effect spectroscopy 
Np Nanoparticle(s) 
Ns number of scans 
NSAID non-steroidal anti-inflammatory drug 
ºC degrees celsius 
oQDMS ortho-quinodimethanes 
PBS phosphate buffered saline 
PD Parkinson’s disease 
Pd palladium 
PDFT proline density functional theory 
PdI polydispersity index 
PE endothelial permeability 
PEG polyethylene glycol 
PES potential energy surface 
PET positron emission tomography 
PHFs paired helical filaments 
PKA protein kinase a 
PMB p-methoxybenzyl 
ppm part per million 
PS1 protein preselin 1 
PS2 protein preselin 2 
Py pyridine 
RCM ring closing metathesis 
RNS reactive nitrogen species 
ROS reactive oxygen species 
rt/r.t. room temperature 
s singlet 
SAA serum amyloid A protein 
SAR structure-activity relationship 
SCA spinocerebellar ataxia 
SOD superoxide dismutase 
STD saturation transfer difference 
SUV small unilamellar vesicle (liposome) 
sym-Collidine 2,4,6-trimethylpyridine 
TBAF tetra-N-butylammonium fluoride 
TC tetracycline(s) 
TEA triethylamine 
TEER trans-endothelial-electrical resistance 
TEM transmission electron spray microscopy 
TES triethylsilane  
TFA trifluoroacetic acid 
TFAA trifluoroacetic anhydride 
Tg transgenic 
THF tetrahydrofuran 
ThT thioflavin 
 xi 
TLC thin layer chromatography 
TMOF trimethyl orthoformate 
TMSOTf trimethylsilyl trifluoromethanesulfonate 
tr-NOESY transferred nuclear Overhauser effect spectroscopy 
TRR transthyretin 
TS transition state 
TSE transmissible spongiform encephalopathie(s) 
Water-LOGSY water-ligand observed via gradient spectroscopy 
 specific rotation 
 observed optical rotation in degrees 
 chemical shift in parts per milion donwfield from tetramethylsilane 
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1. State of the art 
 
 
It was in 1906 that Alois Alzheimer first presented 
at a scientific meeting a case of progressive 
dementia in a 51 years old patient. Postmortem 
analysis revealed two pathologies, namely, senile 
plaques and neurofibrillary tangles. In 1910 Emil 
Kraeplin, Alzheimer’s mentor, named this disease 
after its discover. 
1
 
 Protein misfolding and human disease 1.1.
The correct activity of a network of thousands of proteins is fundamental to ensure that 
cells and organisms function properly. The function of a protein depends on its three-
dimensional structure, which is determined by its amino acids sequence. Chaperone 
proteins supervise protein folding in order that, in most cases, mistakes are avoided and 
malfunctioning proteins are removed. Nevertheless, under certain circumstances a protein 
or a specific peptide fails to adopt or remain in its native functional conformational state 
leading to a broad range of human diseases. These pathological conditions are generally 
referred as protein misfolding diseases. Evidence is accumulated that protein misfolding 
and aggregation is the most likely cause of various neurological and systemic diseases.
2-4
  
They include pathological states in which impairment in the folding efficiency of a given 
protein results in a quantity reduction of the protein available to play its normal role. This 
reduction may occur as the result of one of several post translational processes, such as an 
increase probability of degradation via the quality control system of the endoplasmic 
reticulum, as in the case of cystic fibrosis, or the improper trafficking of a protein, as seen 
in early-onset emphysema. Althought the largest group of misfolding diseases is associated 
with the conversion of specific peptides or proteins from their soluble functional states 
ultimately into highly organized fibrillar aggregates. These structures are generally 
described as amyloid fibrils or plaques when they accumulate extracellularly, but the term 
“intracellular inclusions” has been suggested as more appropriate when fibrils 
morphologically and structurally related to extracellular amyloid form inside the cell. It is 
also becoming clear that fibrillar species with amyloid characteristics can have a number of 
biological functions in living organisms, provided they are formed under controlled 
conditions.
3
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Pathogenic amyloid formation can lead to a wide range of protein misfolding diseases 
known as amyloidosis, these diseases include:  
a. systemic amyloidoses in which deposits may occur in any part of the body, such as: 
32 amyloid light-chain (AL), amyloidosis due to the accumulation of immunoglobulin 
light chain amyloid fibrils; amyloid A (AA), or reactive systemic amyloidosis 
resulting from deposits of catabolic products of the serum amyloid A protein 
(SAA); transthyretin-related hereditary amyloidosis (ATTR) due to transthyretin 
(TTR) accumulation;  
 
b. amyloidosis in which a single organ is affected — possibly including pancreatic 
accumulation of islet amyloid polypeptide in type 2 diabetes.  
 
c. many protein-misfolding diseases affect the nervous system. Interestingly, certain 
proteins specifically aggregate and are toxic in the central nervous system (CNS) 
despite the fact that they are ubiquitously expressed. These neurodegenerative 
diseases include (Table 1.1)
3
: 
- Alzheimer’s disease (AD);  
- Parkinson’s disease (PD); 
- Huntington’s disease (HD) (and related polyglutamine disorders including 
several forms of spinocerebellar ataxia or SCA);  
- transmissible spongiform encephalopathies (TSEs), (also known as prion 
disorders, include Creutzfeldt–Jakob disease, fatal familial insomnia, 
Gerstmann–Straussler syndrome, bovine spongiform encephalopathy and 
scrapie); 
- amyotrophic lateral sclerosis (ALS).  
Table 1.1: Clinical and pathological features of neurodegenerative diseases. 
Disease Clinical features Protein involved Affected regions of the brain 
Alzheimer’s Progressive dementia Amyloid- and tau Hippocampus, cerebral cortex 
 
Parkinson’s 
Movement disorder α-Synuclein Substantia nigra, hypothalamus 
Huntington’s 
 
Dementia, motor and 
psychiatric problems 
Huntungtin Striatum, cerebral cortex 
Amyotrophic lateral 
sclorosis 
 
Movement disorder Superoxide dismutase Motor cortex, brainstem 
Transmissible 
spongiform 
encephalopathies 
Dementia, ataxia, 
psychiatric problems 
or insomnia 
Prion protein 
Various regions depending on the 
disease 
State of the art 
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Until recently, it was considered impossible to find a common molecular mechanism 
among this group of diseases. However, despite their obvious differences in clinical 
symptoms and disease progression, these disorders share some common features: most of 
them (except HD and SCA) have both sporadic and inherited origins, while all of them 
appear later in life (usually after the fourth or fifth decade), and their pathology is 
characterized by neuronal loss and synaptic abnormalities. 
The hallmark feature of conformational disorders is that a particular protein can fold into a 
stable alternative conformation, which in most cases results in its aggregation and 
accumulation in tissues as fibrillar deposits. These deposits have some similar 
morphological, structural and staining characteristics (Figure 1.1),
3
 but it is likely that 
different protein deposits may also have distinct biochemical or biological features, 
particularly depending on whether the aggregates accumulate intra- or extracellularly.
3,5
 
 
 
Figure 1.1: Aggregates staining in neurodegenerative diseases.  
Reprinted with permission from. Soto, C. Nature Reviews Neuroscience 2003, 4, 49. Copyright 2013 Nature 
Publishing Group. 
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 The Alzheimer’s disease 1.2.
AD is a chronic progressive neurodegenerative disease and is the most common form of 
dementia (estimated 50−60% of all cases) associated with loss of memory (in particular 
episodic memory), cognitive decline, and behavioral and physical disability, ultimately 
leading to death. AD is a complex disease, mostly occurring sporadically with no apparent 
inheritance and being the age the main risk factor. The perceived complexity of AD 
implies that the disease has a broad clinical spectrum aggravated by a plurality of genetic 
and environmental factors and is affected by many genes of small but cumulative 
significance. Exogenous risk factors include: brain trauma, smoking, obesity, diabetes, 
hypertension, cholesterol, elevated homocysteine levels (hyperhomocysteinemia) and 
exogenous metal exposure, including lead, mercury, and aluminum. 
Genetic risk factors are now known to cause AD in rare cases, most notably due to 
mutations in amyloid precursor protein (APP) or presenilin, which is a constituent of the γ-
secretase enzyme complex that degrades APP into amyloid-beta peptide (Aβ) giving rise to 
familial AD, and due to isoforms of the cholesterol transporter apolipoprotein E (APOE), 
APOE4.
6
 Humans possess three common APOE alleles: APOE2, APOE3 and APOE4. The 
possession of an APOE4 allele can bring forward considerably the age of disease onset, 
APOE3 can be considered to be neutral, and APOE2 is thought to be protective. How the 
different APOE proteins mediate their effects in AD is not known.
7
 
The disease is pathological characterized by the presence of extracellular senile plaques, 
which consists of a core of A, and intracellular neurofibrillary tangles (NFTs), as well as 
the selective loss of neurons and synaptic connections. NFTs are composed of paired 
helical filaments (PHFs) that consist of aggregation of hyperphosphorylated tau protein 
(Figure 1.2),
8
 associated with the microtubule protein, whereas Ais rich in senile plaques. 
The causes that induce the above pathological characteristics are poorly known at 
present.
9,10
 
Although debated until now, according to the so-called amyloid hypothesis, tangles are 
considered only a secondary event in the disease progression, being a consequence of the 
formation of A plaques.9 
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While the etiology of AD remains unclear, there is an increase of the genetic evidence that 
altered cellular processing of APP is a causative factor in many cases. However, citoxicity 
of A is not only due to the ability to form fibrillar aggregates in the extracellular 
environment, but also to the presence of soluble A oligomers into the intracellular 
environment. Both forms or their intermediates, produce different damages to cell 
membrane and different organelles inducing alteration of physiological biochemical 
pathways and leading to oxidative stress, inflammation and, at the end, to cell death. 
9
 
The two main disease mechanisms-based approaches, which have been studied for more 
than 10 years, are based on the involvement of the two proteins – A and tau .11 
1.2.1. A 
The production and accumulation of A in the CNS are key events in the development of 
AD. Levels of Ain the brain are regulated by the activity of enzymes involved in its 
production, degradation and clearance.
12
 
A is present in the brain of healthy humans throughout life and the mere presence of A 
does not imply neuropathy. In contrast, when neuronal injury appears, the aggregation of 
physiologically secreted soluble A into oligomers and large A fibrils is currently 
considered to be a crucial event in AD onset. The main question remains, why the A, 
which normally circulates in soluble form in the cerebrospinal fluid (CSF) and in plasma, 
 
Figure 1.2: Example of a healthy neuron and a diseased neuron.
8 
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becomes prone to aggregate, forming highly toxic oligomers and protofibrils and mature 
fibrils accumulating in plaques.
9
 
A derive from proteolysis of the large transmembrane protein amyloidbeta percursor 
protein (APP) (Figure 1.3),6 which is a type I integral membrane glycoprotein 
(abundantly expressed in the brain) produced in three predominant forms, 695, 751 or 770 
amino acids.
12
 
 
Figure 1.3: The Aβ sequence within APP and the main secretase cleavage positions.  
Reprinted with permission from Kepp, K. P. Chemical Reviews 2012, 112, 5193. Copyright 2013 American 
Chemical Society. 
The A is derived through endoproteolytic processing of APP by sequencial enzymatic 
actions of alpha-site APP cleaving enzyme -secretase, denominated the 
nonamyloidogenic pathway and beta-site APP-cleaving enzyme (BACE-1), a secretase, 
and -secretase, a protein complex with presenilin 1 at its catalytic core, corresponding to 
the amyloidogenic process (Figure 1.4).
13
 
 
Figure 1.4: Processing of amyloid precursor protein.  
Reproduced with permission from Querfurth, H. W.; LaFerla, F. M. The New England Journal of Medicine 2010, 362, 
329. Copyright Massachusetts Medical Society. 
In the α-secretase pathway, α-secretase cleaves in the middle of the amyloid-β region to 
release a large soluble APP-fragment, sAPPα. The carboxy (C)-terminal C83 peptide is 
metabolized to p3 by γ-secretase. In the amyloid-forming β-secretase pathway, β-secretase 
releases a large soluble fragment, sAPPβ. The C-terminal C99 peptide is then cleaved by γ-
secretase at several positions, leading to the formation of amyloid-β40 (Aβ40) and the 
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pathogenic amyloid-β42 Aβ(1-42) in the extracellular space. γ-Secretase cleavage also 
releases the APP intracellular domain (AICD), which could have a role in transcriptional 
regulation.  The soluble Aβ tends to aggregate.11  
The C-terminal 12 amino acid residues of the Aβ are hydrophobic and confer to the peptide 
the ability to self-aggregate and polymerise into amyloid fibrils. The term β of Aβ 
indicates, indeed, its propensity to form partial β-plated sheet structures once it aggregates 
into amyloid fibrils.
9
 
Depending on the exact point of cleavage by γ-secretase, three principal forms of Aβ, 
comprising 39, 40, and 42 amino acid residues, respectively, are produced. The relative 
amount of Aβ(1-42) is particularly important because it has more tendency to oligomerize 
and form amyloid fibrils with respect to the shorter peptides.
9
 
Aβ production is a normal process but in a small number of individuals an imbalance 
between production, clearance, and aggregation of peptides causes A to accumulate, and 
this excess may be the initiating factor in AD. This idea, called the “amyloid cascade 
hypothesis”, is based on studies of genetic forms of AD, and evidence that A142 is 
toxic to cells.
13
 A number of studies have confirmed that A142) is the more neurotoxic 
form of A. It has been shown that A140) and A142) possess different biochemical 
properties, and A142) is considered to be the major etiologic agent in the pathogenesis 
of AD due to its aggressive aggregation or oligomerization properties Figure 1.5).14 The 
mutations associated with inherited forms of AD provide strong evidence that the 
aggregation of A142) is a causative factor in the etiology of AD because the mutations 
increase the relative amount of A142).15,16 
a) b) 
Figure 1.5: “Typical” Aβ-fibril morphology by transmission electron microscopy (TEM), obtained from 
incubated 50 μM solutions of (a) Aβ(1-40) and (b) Aβ(1-42).  
Reprinted with permission from Hamley, I. W. Chemical Reviews 2012, 112, 5147. Copyright 2013 American 
Chemical Society. 
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1.2.2. Tau 
NFTs are filamentous inclusions in pyramidal neurons that occur in AD and other 
neurodegenerative disorders named tauopathies. The number of NFTs is a pathologic 
marker of the severity of AD. The major component of the tangles is an abnormally 
hyperphosphorylated and aggregated form of tau. Normally an abundant soluble protein in 
axons, tau promotes assembly and stability of microtubules, and self-associates into paired 
helical filament structures. Enzymes that add and those that remove phosphate residues 
regulate the extent of tau phosphorylation.
13
 
The microtubule-binding main domain (MDB) of tau (Figure 1.6),
13
 is formed by repeated 
sequences (R1-R4). Normal phosphorylation of tau occurs on serine (S; inset, above 
horizontal bar) and threonine (T; inset, below horizontal bar) residues, numbered according 
to their position in the full tau sequence. When followed by proline (P), these amino acids 
are phosphorylated by glycogen synthase kinase 3 (GSK-3β), cyclin-dependent kinase 
(cdk5), and its activator subunit p25, or mitogen-activated protein kinase (MAPK). 
Nonproline-directed kinases — Akt, Fyn, protein kinase A (PKA), calcium–calmodulin 
protein kinase 2 (CaMKII), and microtubule affinity-regulating kinase (MARK) — are also 
shown. KXGS (denoting lysine, an unknown or other amino acid, glycine, and serine) is a 
target motif. Hyperphosphorylated sites specific to paired helical filament tau in AD tend 
to flank the MBD. Tau binding promotes microtubule assembly and stability. Excessive 
kinase, reduced phosphatase activities, or both cause hyperphosphorylated tau to detach 
and self-aggregate and this causes the destabilization of microtubules.
13
 
It is commonly accepted that blocking tau pathology could have therapeutic benefit, even 
though tau pathology might be downstream from amyloid in the pathogenic cascade. In 
general, tau has received much less attention from the pharmaceutical industry than 
amyloid, because of both fundamental and practical concerns. At the fundamental level, 
the amyloid cascade hypothesis (Figure 1.7)
14
 indicates that tau pathology might be too far 
downstream in the cascade. However, more importantly, tractable targets in the pathway 
from tau to tangle formation remain to be identified. Tau kinases have been proposed as 
targets, but the role of tau phosphorylation and of specific kinases in tangle formation is 
not completely understood.
13
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Figure 1.6: Tau structure and function. 
Reproduced with permission from Querfurth, H. W.; LaFerla, F. M. The New England Journal of Medicine 2010, 
362, 329. Copyright Massachusetts Medical Society.  
Also, well-characterized mouse models of tangle formation have only recently become 
available. Although there are several lines of evidence that CDK5 could have a crucial role 
in tangle formation, the generation of highly specific tau kinase inhibitor drugs that are 
suitable for the chronic treatment of AD is likely to represent a considerable challenge.
13
 
 Alzheimer’s disease pathogenesis 1.3.
During the past decade, three main hypotheses on the pathogenesis of AD have emerged 
that focus on different features of the disease and are in some extent seen as competing: the 
amyloid cascade hypothesis, the metal ion hypothesis, and the oxidative stress 
hypothesis.
6,7
  
a. The amyloid cascade hypothesis states that impaired balance between Aβ 
production and clearance is the main cause of AD and that amyloids are the main 
neurotoxic substances in AD. Consequently, this hypothesis favors treatments that 
inhibit Aβ production or enhance Aβ clearance in the AD brain.  
Synthesis of new A-ligands useful in diagnosis of Alzheimer’s Disease 
12 
b. The metal ion hypothesis states that the underlying cause of AD is impaired metal 
homeostasis, in particular of Zn, Cu, and Fe, with Aβ imbalance being a 
consequence of this. This hypothesis favors treatments such as chelators that 
address the metal ion imbalances supposedly causing amyloid accumulation.  
 
c. The oxidative stress hypothesis claims that age-enhanced or genetically and 
environmentally enhanced oxidative stress results in accumulated gene defects and 
declining mitochondrial function. This subsequently leads to neurological 
disorders, either gradually or when reaching a critical threshold that initiates 
apoptosis in neurons. Apoptosis occurs in a wide range of neurological disorders 
and by a range of pathways that can be triggered, for example, by lesions, 
misfolded proteins, oxidative stress, excitotoxicity, or Ca
2+
 dyshomeostasis.
6,7
 
1.3.1. The amyloid cascade hypothesis 
The amyloid cascade hypothesis for AD has been very influential in the research 
conducted both in academia and in the pharmaceutical industry. This hypothesis 
synthesises histopathological and genetic information, and claims that the deposition of 
A in the brain parenchyma initiates a sequence of events that ultimately lead to AD 
dementia.
7
  
The “amyloid cascade hypothesis” (Figure 1.7)14 is initiated by the generation of A42. In 
familial early onset AD, A42 is overproduced owing to pathogenic mutations. In sporadic 
AD, various factors can contribute to an increased load of A42 oligomers and aggregates. 
A oligomers might directly injure the synapses and neurites of brain neurons, in addition 
to activating microglia and astrocytes.
11,14
 
Preventing A aggregation is therapeutically attractive because this process is believed to 
be an exclusive pathological event, and compounds targeting this mechanism are more 
likely to have a better safety profile compared to some other approaches currently being 
followed. In addition although soluble oligomers can be on a pathway to A fibrils and 
ultimately amyloid plaque.
15
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Figure 1.7: The amyloid cascade hypothesis. 
Reprinted with permission from Hamley, I. W. Chemical Reviews 2012, 112, 5147. Copyright 2013 American 
Chemical Society. 
A simplified scheme of the A aggregation pathways that generate toxic assemblies is 
showed in Figure 1.8.
17
 Once A is stabilized as its monomeric form or as non-toxic 
oligomeric forms, these species might be expected to be cleared by normal pathways.
15
 
 
Figure 1.8: A aggregation pathways.  
Reprinted with permission from. Invernizzi, G.; Papaleo, E.; Sabate, R.; Ventura, S. The International Journal of 
Biochemistry & Cell Biology 2012, 44, 1541. Copyright 2013 Elsevier. 
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1.3.2. The metal ion hypothesis 
The brain is a specialized organ that requires metal ions for a number of important cellular 
processes. Therefore, the brain contains a relatively high concentration of a number of 
transition metals, such as Fe, Zn, and Cu. They take part in the neuronal activity within the 
synapses [Zn(II) in particular] and ensure the function of various metalloproteins 
(cytochrome C-oxidase, Cu/Zn superoxyde dismutase...). A breakdown of these 
mechanisms, or absorption of metals with no known biological function, alter the ionic 
balance and can result in a disease state, including several neurodegenerative disorders as 
AD.
18
 Many studies have shown that the most important biometals, i.e., copper, zinc, and 
iron as well as nonphysiological aluminium are involved in AD. They are suggested to 
have two distinct roles in the pathophysiology of AD, namelly aggregation of A peptide, 
and production of reactive oxygen species induced by A.19 
The metal hypothesis of AD asserts that the interactions between metal ions and A, as 
well as abnormal metal ion homeostasis, are connected with AD neuropathogenesis.
20-23
 
Based on this hypothesis, disruption of metal-A interactions via metal chelation therapy 
has been proposed in order to reduce neurotoxicity of metal-Aspecies and restore metal 
ion homeostasis in the brain.
20
 However, in order to be used as potential drugs in the 
treatment of neurodegenerative diseases, chelators must have particular properties. They 
must have a low molecular weight, be poorly or not charged to favor blood-brain-barrier 
(BBB) crossing and stable. They must selectively target certain metal ions, because a 
strong non-specific chelation would result in a general depletion of metal ions, including 
those of metalloenzymes, which are essential. Once the chelator is in the brain, the 
molecule must be able to complex the metal ions present in excess in the aggregated 
proteins so as to allow their dissolution and elimination. Finally, successful treatment with 
any chelator requires low toxicity and minimum side effects of the drug itself. To date, 
several metal chelators have been used as agents for metal ion chelation therapy in AD 
(Figure 1.9).
19
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Figure 1.9: Examples of metal chelators used as agents for metal chelation therapy. 
Among the few chelators tested so far, clioquinol (CQ) was the first to reach the pilot 
phase II clinical trial, which demonstrates the applicability of this exogenous metal 
chelator. Whilst the use of CQ has been suspended in AD research, a new and promising 
oxine based analogue PBT2 is presently under development, which clearly indicates that 
this strategy will be favored. Combining antioxidant activity and binding functionality into 
a single drug would broaden the chances of success in AD therapy.
19
 
1.3.3. The oxidative stress hypothesis 
Oxidative stress is caused by an imbalance in the pro-oxidant/antioxidant systems and 
might cause reversible and/or irreversible modifications on sensitive proteins leading to 
structural, functional and stability modulations. Protein modifications such as 
carbonylation, nitration and protein–protein cross-linking are generally associated with loss 
of function and may lead to either the unfolding and degradation of the damaged proteins, 
or aggregation leading to accumulation as cytoplasmic inclusions, as observed in age-
related neurodegenerative disorders.
24-27
 
The oxidative hypothesis, postulates that the age-related accumulation of reactive oxygen 
species (ROS) or reactive nitrogen species (RNS) results in damage to the major 
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components of cells: nucleus, mitochondrial DNA, membranes, and cytoplasmic proteins. 
The imbalance between the generation of free radicals and ROS or RNS may be involved 
in the pathogenesis of AD, since brain tissue has multiple potential sources of ROS and a 
large oxidative capacity, but its ability to combat oxidative stress is limited.
25,28-30
 
Glutathione (GSH) is a well-known antioxidant that is synthesized in the cell cytoplasm 
and is present in higher concentrations in the mitochondrial matrix. Because most oxidized 
GSH (GSSG) forms are under oxidative stress, several different enzymes are necessary to 
reduce GSSG to maintain the GSH/GSSG ratio. Under severe conditions of oxidative 
stress, cells are not able to maintain the appropriate GSH/GSSG ratio, causing an 
accumulation of GSSG and resulting in protein modifications. The level of GSSG is a key 
factor in determining neuronal susceptibility to ROS or RNS mediated neuronal injury.
31,32
 
It is estimated that approximately 1−3% of all normal O2 is converted into ROS in 
mammals, due to inefficiencies of the electron transport chain, and this ROS production 
can be enhanced if mitochondria are not working optimally due to hypoxic or hyperoxic or 
other stress-related conditions.
33
 ROS that escape the organisms’ antioxidant defenses then 
oxidatively modify nearby proteins and lipids, sometimes rendering them less stable or 
functional, or nucleic acids of the DNA, leading to mutations.
34
 
The RNS are primarily derived from nitric oxide radical, which is produced by nitric oxide 
synthase and serves signaling and immune defense roles in the healthy organism, in the 
form of peroxynitrite. When peroxynitrite is overproduced due to reduced proficiency of 
superoxide dismutase (SOD), it reacts with bicarbonates to generate carbonate radicals but 
will also react readily with heme proteins and sulfur and selenium groups of relevance to 
metal homeostasis and oxidative stress control.
35
 
Metal ions play key roles in both ROS and RNS as ligands, and both copper an iron 
produce hydroxyl radical in solvent exposed cellular environments, notably via variations 
of the simplest form of the Fenton reaction:
6,36
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The Fenton chemistry unites metal ion dyshomeostasis, which shifts balance from bound to 
free metal ions, with oxidative stress pathogenesis, which is predominantly aggravated by 
free Cu and Fe. Thereby, in the absence of direct toxicity of soluble Cu(II)−Aβ oligomers, 
disturbed metal homeostasis resulting in increased concentrations of free intracellular 
metal ions that will itself generate ROS that could lead to oxidative stress. Consequently, 
the two hypotheses are intimately related via a vast number of Cu-, Zn-, and Fe-containing 
proteins involved in oxidative stress modulation.
37,38
 
 Intervention strategies for Alzheimer’s disease  1.4.
Researchers in AD are moving forward with the development of treatments that target the 
known neuropathologic hallmarks of the illness (Table 1.2)
5
, the amyloid plaques and tau-
based neurofibrillary tangles.
39
 
 
Table 1.2: Summary of therapeutic strategies for protein aggregation diseases. 
Approach Therapy Expected effect Current status 
Inhibition 
of amyloid 
formation 
1. -Secretase inhibitors 
and modulators 
Reduced carboxy-terminal 
cleavage of APP to form 
A40 or A42 
Phase II and III clinical 
trials 
2. -Secretase inhibitors 
Reduced amino-terminal 
of A-containing 
aggregates 
Phase I clinical trials 
Promotion 
of amyloid 
clearance 
3. Aimmunotherapy 
4. Enhanced clearance of 
Acontaining aggregates 
Phase II and III clinical 
trials 
5. Prion immunotherapy 
6. Enhanced clearance of       
PrPSc-containing 
aggregates; prevention of 
the invasion of prions into 
neurons 
Preclinical 
Inhibition 
of amyloid 
aggregation 
7. Scyllo-inositol 
8. Prevention of the 
formation of higher-order 
aggregates 
Phase II clinical trials 
9. Tafamidis 
10. Stabilization of the native 
state of transthyretin 
Phase II and III clinical 
trials 
1.4.1. Targeting A production 
The accumulation of A has been postulated as being the earliest factor in the development 
of AD. The only known genetic forms of the illness are caused by mutations in A or the 
enzymes that are involved in its formation.
39
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Steady state levels of A monomers are controlled by its rates of production and 
degradation. Above a certain critical concentration A monomers can self-associate to 
form dimers, trimers and larger oligomers (Figure 1.10).
40
 Consequently, inhibition of A 
production (Figure 1.10(1)) or stimulation of A degradation (Figure 1.10(2)) should 
decrease or prevent formation of oligomers and then amyloid fibrils. Certain proteases can 
degrade both A monomers and polymers, so stimulation of such enzymes would serve to 
lower A monomer levels and hence reduce again the formation of oligomers while also 
facilitating removal of pre-existing A polymers.40 
Small molecules or biologics that bind to and stabilize A monomers (Figure 1.10(3)) 
should prevent oligomerization and allow for the natural removal of monomers by the 
brain’s degradative machinery. Similarly, agents capable of disrupting pre-formed 
oligomers (Figure 1.10(4)) should reduce the concentration of toxic oligomers. 
40
 
Small molecules or antibodies capable of binding to a variety of A assemblies (Figure 
1.10(5)) could neutralize both small and large A assemblies and facilitate their 
elimination.
40
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Figure 1.10: Strategies for targeting neurotoxic A oligomers.  
Reprinted with permission from Walsh, D. M.; Selkoe, D. J. Journal of Neurochemistry 2007, 1172. Copyright 
2013 John Wiley and Sons. 
Thereby, five strategies to reduce A production have been proposed: immunotherapy, 
inhibition of -secretase, inhibition of -secretase, stimulation of -secretase and inhibition 
of A aggregation. 
1.4.1.1 Immunotherapy targeted to reduce Aβ 
Anti-amyloid immunotherapy for AD has received considerable attention following the 
publication of the Elan Corporation’s paper, that reported amyloid pathology reduction in 
an APP transgenic mouse model after vaccination with aggregated A42.41 
Over the last years, A immunotheraphy has emerged from preclinical studies in 
transgenic mouse models of AD to enter clinical trials in humans (Table 1.3 and 1.4).
41
 At 
least 13 different A immunotherapies are in clinical trials worldwide.  
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Table 1.3: Examples of ongoing clinical trials of passive A immunotherapies. 
Therapy Sponsors Antibody 
Phase and 
number of 
trials 
Estimated 
patient 
enrollment 
Primary outcome 
measures 
Bapineuzumab 
(AAB-001)* 
 
Elan; Wyeth; 
JANSSEN 
Alzheimer 
Immunotherapy 
Anti-A amino 
terminal MAb 
III; one trial 1,350 Safety and efficacy 
Bapineuzumab 
(AAB-001)* 
 
Elan; Wyeth; 
JANSSEN 
Alzheimer 
Immunotherapy 
Anti-A amino 
terminal MAb 
III; five trials 4,650 
Cognition and 
global function 
Solanezumab 
(LY2062430) 
Eli Lilly 
Anti-A mid-
region MAb 
III; two trials 2,000 
Cognition and 
global function 
Table 1.4: Examples of ongoing clinical trials of active Aimmunotherapies. 
Therapy Sponsors Vaccine 
Phase and 
number of 
trials 
Estimated 
patient 
enrollment 
Primary outcome 
measures 
ACC001 
Elan; 
Weyth 
A amino-terminal 
conjugate 
II; three trials 360 
Safety, tolerability and 
treatment-related 
adverse effects 
V950 Merck 
A amino-terminal 
peptides conjugated 
to ISCO-MATRIX 
I; one trial 124 Safety and tolerability 
Several types of immunotheraphy for AD are under investigation; presently there are three 
different approaches to generate antibodies directed against A. The first strategy involves 
active-immunization with full length A, which contains 42 amino acids (Figure 
1.11(a)).
42
 After injection, the peptide uptaken by antigen-presenting cells, and fragments 
of the peptide are presented to T-cells. Subsequently, various B cells that can recognize 
epitopes on A42 are engaged and proliferate. These eventually produce anti-A 
antibodies. It is thought that these antibodies are key to effecting the reduction in 
pathogenic A that has been seen in a number of APP transgenic mouse models after A42 
immunization.
42
 
The second type of active-immunization approach involves the administration of small 
fragments of A conjugated to an unrelated carrier protein (Figure 1.11(b)).42 This 
immunoconjugate approach is similar to the first strategy with the exception that the        
T-cells are stimulated by the carrier protein rather than by the A fragment (which lacks T-
cell epitopes). This approach also yields a strong antibody response to a region of the A.42 
The third strategy envolves the administration of anti-A antibodies directly (Figure 
1.11(c)).
42
 This approach does not require any type of immunological response from the 
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host and then has the potential to be useful in individuals that might not otherwise generate 
an immune response to A administration.42 
 
Figure 1.11: Strategies for A immunotherapy. 
Reprinted with permission from Schenk, D. Nature Reviews 2002, 3, 824. Copyright 2013 Nature Publishing 
Group. 
Active vs passive A immunization 
Both active and passive Aimmunotherapies have their advantages and disadvantges. 
Active Aimmunotherapies have the potential to be more cost-effective and long-lasting 
than passive immunization, which requires monthly infusions of costly humanized 
monoclonal antibodies. Active therapies might have additional benefits. One study has 
reported that Avaccination in non-human primates led to an increase in the production of 
cross-reactive, potentially protective Aauto-antibodies. Such antibodies are typically 
lower in patients with AD than in age-matched healthy individuals, therefore, boosting the 
levels of these proteins might be beneficial.
41
 
In some cases, a passive A immunotherapy might be beneficial. Vaccination usually 
involves delivery of a strong adjuvant to boost antibody production. Such adjuvants could 
potentially induce an undesirable immune response, especially in elderly individuals in 
whom proinflammatory cytokines are already above normal levels. Another problem for 
active therapies is that if an adverse event does occur, the immune response to the active 
vaccine can be difficult to stop quickly. Passive Aimmunotherapies, on the other hand, 
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can be stopped at any time. Another advantage to the passive therapeutic approach is the 
use of antibodies that are specific for a particular Aconformation or species thought to be 
most toxic, thereby avoiding removal of all Afrom the brain. Although one disadvantage 
of this approach is the potential for patients to eventually develop neutralizing antibodies 
against the passive therapy.
41
 
1.4.1.2 Mechanism of Aβ clearence 
Several mechanisms could explain how antibodies directed at Apromote the clearance of 
this peptide in vivo. When anti-Aantibodies form complexes with A, the fragment 
crystallizable region (Fc) portion of the antibodies might bind the Fc receptor on microglia, 
inducing phagocytosis of these complexes. This mechanism would require that anti-
Aantibodies cross the BBB and bind Awithin the CNS. Some evidences have been 
reported to support this mechanism, although, two studies showed that Fc-mediated 
phagocytosis is not required for immunotherapy-induced Aclearance.41 
In an alternative mechanism, anti-A antibodies in the blood might cause a shift in the 
concentration gradient of A across the BBB, thus resulting in an increase in Aefflux 
from the brain to the periphery. A antibodies might bind and remove small A 
aggregates, therefore neutralizing the effects of toxic Aspecies on synapses. These 
proposed mechanisms of Aclearance by immunotherapy are not mutually exclusive and 
might be disease stage-dependent.
41
 
In the future, Aimmunotherapy might be an effective treatment for preventing AD. 
Imaging and biomarkers have improved dramatically over the past years, increasing the 
probability of identifying at-risk individuals before clinical symptons onset and allowing 
the Aimmunotherapy response to be monitored. If given early, before AD pathogenesis 
is well underway, Aimmunization might be able to prevent aggregation of neurotoxic 
forms of A, thereby preventing downstream effects, such as synaptic dysfunction, 
neuronal damage and cognitive impairment.
41
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1.4.1.3 Secretase inhibitors targeted to reduce Aβ 
While anti-Aantibodies target the amyloid cascade at the level of A aggregation and 
accumulation, the inhibitors of secretases approach the amyloid cascade at its root, namely, 
production of A. This could be the “cleanest” approach which would remove all the 
monomeric A and subsquent oligomers and aggregates.  Therefore, pharmacological 
inhibition of the enzymes responsible for A formation (-secretase and -secretase) is a 
prime strategy for blocking A production.5,43 
The potential problem with secretase inhibitors is the physiological function of secretases. 
Both cleave a number of additional substrates and the inhibition of these other cleavages 
can limit the clinical utility of inhibitors. This limitation is very clear for -secretase 
inhibitors, but it is also a potential threat for -secretase inhibitors.43 
a) -secretase 
The -secretase complex consists of four proteins, the catalytic activity of which is thought 
to be mediated by the presenilin 1 (PS1) and PS2 proteins. The -secretase complex is 
responsible for the carboxy-terminal cleavage of APP to produce A4 or A42. Potent 
small-molecule inhibitors of -secretase can dramatically reduce A4 and A42 
production. The primary caveat to targeting -secretase for AD therapeutics is that APP is 
not the only substrate of -secretase. The disadvantage of this is that potent -secretase 
inhibitors have serious gastrointestinal and immunological side effects.
5
 
As a result of this drawback, the field has shifted towards the development of -secretase 
modulators. These compounds either selectively inhibit -secretase cleavage of APP, or 
alter -secretase cleavage to favor A4 production rather than A42. The less abundant 
42 amino acid isoform of A A42seems to be more strictly associated with the 
development of amyloid pathology than its counterpart A4.5 
Drugs that modulate -secretase activity in this manner include non-steroidal anti-
inflammatory drugs (NSAIDs), such as ibuprofen and compounds that interact with ATP-
binding motif PS1 near the -secretase active site.5 
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One such -secretase-modulating compound, the NSAID (R)-flurbiprofen (also known as 
tarenflurbil), effectively reduced amyloid plaque formation and rescued memory deficits in 
APP-transgenic mice. However, (R)-flurbiprofen failed to enhance cognitive performance 
of patients with AD in phase III clinical trials and has been abandoned as a potential 
therapy.  
The compound screening approach may identify additional promising small-molecule -
secretase modulators, and other compounds may be more successful than (R)-flurbiprofen 
in human trials, for example, semagacestat from Lilly and Elan is currently in phase III 
trials.
b) -secretase 
The amino-terminal cleavage of APP to form both A4 and A42 results from -
secretase activity. After the discovery that -secretase cleavage of APP seemed to be due 
to the activity of a single aspartic protease, -secretase 1 (BACE1; also known as 
memapsin 2 and ASP2), there was much interest in the possibility of targeting -secretase 
for the treatment of AD.
5
 
Inhibition of BACE1 activity can block the production of A, prevent the development of 
amyloid pathology in the brain and rescue AD-related memory deficits in mice. Althought, 
despite nearly a decade has passed since the initial identification of BACE1 as the -
secretase, researchers still continue to struggle with the development of effective BACE1 
inhibitors that are active in the CNS.
5
 
The large BACE1 active site requires the identification of large compounds for potent 
BACE1 inhibition that also readily penetrate the BBB and are reasonably stable, but the 
slow progress of the BACE1 inhibitor field is a testament to the fact that such molecules 
are relatively rare.
5
 
1.4.1.4 Inhibition of Aβ aggregation 
Preventing A aggregation is therapeutically attractive because this process is believed to 
be an exclusive pathological event, and compounds targeting this mechanism are more 
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likely to have a better safety profile compared to some other approaches currently being 
adopted.
15
 
The strategy of inhibiting Aaggregation using small molecules is principally attractive, 
considering their lower cost and easier administration compared to antibodies. This 
approach is, however, complicated by several potential obstacles. Preventing 
Aaggregation either by blocking intermolecular interactions necessary for 
polymerization, or by stabilising the “native” structure of Awould potentially stop the 
pathogenic process before any toxic species could be formed. However, since there is no 
consensus as to what aggregates are the most toxic, finding out what step on the 
aggregation pathway to target is an unresolved key issue. The structural flexible nature of 
soluble, monomeric A, and possibly also of Aoligomers, probably makes it difficult to 
find ligands that bind strongly to one particular structure.
44
 
A large number of diverse compounds, including peptides and small organic molecules, 
have been shown to interfere with Aaggregation in vitro. Early studies concentrated on 
finding molecules that would prevent fibril formation, since the fibrils were believed to be 
the causative agent. However, when the idea of toxic oligomers appeared, other 
compounds that could inhibit aggregation into early stages were presented.  
Examples of compounds identified as inhibitors of aggregation, regardless the mode of 
action, include congo red, polyphenols, nicotine, rifampicin, tetracyclines, curcumin, 
scyllo-inositol, and peptide-based inhibitors (Figure 1.12).
44
 Molecules capable of 
disrupting pre-formed oligomers have not come to clinical trials. 
 
Figure 1.12: Structures of myrcetin, quercetin. (cont.) 
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Figure 1.12: (cont.) Structures of curcumin and tetracycline. 
1.4.2. Targeting Tau 
Accumulation of hyperphosphorylated tau as paired helical filaments within NFTs and in 
neuritic processes is the intracellular hallmark of AD pathogenesis. Both genetic and 
animal modeling studies closely link abnormal tau metabolism to neuronal dysfunction and 
death. Some investigators have proposed that tau pathology appears independently of A 
pathology, and that AD, at least in some circumstances, may represent a convergence of 
two distinct pathological processes – an A amyloidosis and a taupathy rather than a linear 
cascade in which the A amyloidosis drives the thaupathy.45 
The relative scarcity of tau therapeutics can be attributed to:  
 the uncertainty regarding the relationship between specific alterations in tau and 
induction of neurodegeneration;  
 
 scarcity of clearly defined druggable targets that directly modulate tau in a way that 
should be protective from neurodegeneration.  
Despite these uncertainties, there are some strategies that may be promising in a near 
future, such as targeting tau production, altering tau aggregation, altering tau 
phosphorylation and tau immunotherapy.
45
 
1.4.2.1 Targeting tau production 
Even though the exact neurotoxic species of tau has not been definitively identified, 
decreasing tau synthesis or a specific tau isoform is proposed to decrease the probability 
that tau will aggregate into a neurotoxic species. Therapeutics targeting tau production 
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remains in the conceptual stage, though some preclinical studies do provide proof of 
concept that lowering tau production can have a beneficial disease modifying effect.
45
 
1.4.2.2 Altering tau aggregation 
Even if a large number of tau aggregation inhibitors have been identified, these compounds 
are only effective in vitro, no proof of concept study has shown them capable of inhibiting 
tau aggregation in vivo. Nevertheless, the concept that a small molecule inhibitor could 
block aggregation of multiple proteins involved in neurodegeneration is intriguing. Future 
results studying the effect of these compounds in animal models are awaited.
45
 
1.4.2.3 Altering tau phosphorylation 
Tau contains multiple phosphorylation sites and phosphorylation seems to control the 
binding affinity for microtubules. Increased phosphorylation of the tau protein from an 
average of two to three phosphates in normal brain to an average of nine phosphates per 
molecules is seen in AD. Hyperphosphorylated, abnormally folded tau or tau aggregates 
may exert direct toxic effects on neurons. It is still debated whether phosphorylation of tau 
drives aggregation, results in toxicity, or is a consequence of aggregate formation. In any 
case, the link between phosphorylation and tau pathology has provided the impulse to 
examine the role of kinase inhibitors as potential therapeutics targeting tau.
45
 
1.4.2.4 Tau immunotherapy 
Antibodies targeting the pathological conformers of tau might clear or suppress tau 
pathology. Though theoretically attractive, there are concerns that antibodies are not 
optimal agents for targeting intraneuronal proteins. Additionally, the lack of clarity 
regarding which conformer of tau should be targeted remains a concern.
45
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In conclusion, all these premises strongly suggest a possible approach to AD, relying on 
brain A as a target for therapy of the disease.  This goal could be pursued either seeking 
an interaction with A plaques, or through an interaction with soluble circulating A, 
preventing amyloidogenesis.  
In addition, several experimental evidences suggest that A in the blood is in equilibrium 
with soluble A in the brain, through the BBB. It can be predicted that this equilibrium 
may be shifted towards the circulating A pool, whether peripheral molecules specifically 
interacting with A are inducing its sequestration, eventually withdrawing brain A and 
leading to plaque disappearance. Therefore, circulating A is also a potential candidate 
target for the therapy of AD. 
 Nanoparticles for drug delivery through blood brain barrier 1.5.
The number of drugs developed for treatment of CNS disorders has been growing 
constantly, however, only a few new drugs acting on the CNS enter the market.
46
 There is 
a lack of potential new pharmaceutical entities, thus at present for many neurological 
disorders no satisfactory treatment exists. This group of diseases includes AD, PD, HD, 
ALS, lysosomal storage diseases, HIV infection of the brain, brain tumors, and CNS 
intoxications, for instance, with organophosphorous compounds. Drugs that are intended to 
act in the CNS can be administered systemically, if they have the ability to circumvent the 
BBB, or have to be introduced directly in the CNS by invasive methods, if such 
circumvention is limited. The BBB is essential for the maintenance of the unique 
neuroparenchymal environment but represents an invincible obstacle for a multiplicity of 
therapeutically important drugs.
47,48
 
A variety of novel strategies have been proposed to improve the permeability of drugs into 
the CNS, including BBB disruption, alternative routes to CNS drug delivery, chemical 
drug delivery, biological drug delivery. One of the possibilities to deliver drugs to the brain 
is the employment of nanoparticles (NPs).
49
 NPs can act as carriers for several classes of 
drugs, such as anticancer agents, antihypertensive, immunomodulators, and hormones, and 
macromolecules, such as nucleic acids, proteins, peptides, and antibodies.
48
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The mechanism of passive diffusion of the molecule across the BBB is dependent on its 
structural and physicochemical properties, such as molecular size, charge, hydrogen 
bonding potential, and lipophilicity. Besides compounds essential for brain homeostasis, 
such as amino acids, hexoses, neuropeptides, and proteins, which are transported into the 
brain via specific carriers, only small lipophilic molecules of less than 500 Da are able to 
cross this complex barrier.
50-52
 
The strategies employed for enhancement the drug concentrations in the brain can be 
classified as invasive or non-invasive: 
 The invasive methods include the temporary increase of the BBB permeability (e.g. by 
the osmotic disruption), the direct intraventricular or intracerebral infusion of the agent, 
or the intracerebral implantation of depot formulations for a controlled-release of the 
drug, such as the GLIADEL® Wafer (polifeprosan 20 with carmustine implant) 
indicated for patients with newly-diagnosed or recurrent high-grade malignant glioma 
in addition to radiation and/or surgery. As expected, all invasive techniques are 
associated with a high risk of complications, such as intracranial infections or brain 
edema. These procedures are also rather expensive and demand long reconvalescence 
periods.
48,53
 
 
 The non-invasive strategies for brain delivery include modification of the drug 
molecules using chemical (i.e. synthesis of prodrugs) or biochemical approaches (i.e. 
conjugation with specific antibodies), as well as the employment of the olfactory route. 
However, in the latter case the quantities of drugs in olfactory lobes do not exceed 
nanomolar levels with bioavailabilities ranging from 0.01% to 0.1%. In addition, 
inhibition of the efflux transporters as well as the delivery via endogenous transporters 
such as the carrier-mediated transport system for glucose or amino acids are possible 
approaches to enhance brain delivery.
48,51,54
 
A promising way to deliver drugs to the targets within the CNS is the employment of 
colloidal carriers, in particular, biodegradable polymeric NPs. As shown by a number of 
studies, surface modification of the NPs enables their entry into the brain after intravenous 
administration via receptor-mediated pathways. Another important advantage of this 
technology is that it does not require any modification of the drug molecule for the brain 
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delivery, which is achieved by masking the unfavorable physicochemical characteristics of 
the incorporated molecule.
48
 
Drugs or other groups may be dissolved into the NPs, entrapped, encapsulated and/or 
adsorbed or attached. The aim in using NPs is to increase the specificity towards cells or 
tissues, to improve the bioavailability of drugs by increasing their diffusion through 
biological membranes and/or to protect them against enzyme inactivation.
49
 
The field of nanoparticle drug technology is not yet well developed in AD research but 
NPs are promising candidates in the investigation of AD, because they are capable of: 
55
 
- opening tight juntions;  
- crossing the BBB; 
- high drug loading capacities; 
- targeting towards mutagenic proteins of AD. 
1.5.1. Liposomes 
First described in the late sixties, liposomes are one of the first NP platforms to be applied 
in medicine. Today, there are more than a dozen of formulations approved for clinical use, 
with many more in clinical and preclinical development. Liposomal drug formulations 
typically improve the pharmacokinetics and biodistribution of a drug.
56
 
A liposome is a tiny bubble (vesicle), made out of the same material as a cell membrane. 
Liposomes can be filled with drugs, and used to deliver drugs for cancer and other 
diseases. Membranes are usually made of phospholipids, which are molecules that have a 
head group and a tail group. The head is attracted to water, and the tail, which is made of a 
long hydrocarbon chain, is repelled by water.  In nature, phospholipids are found in stable 
membranes composed of two layers (a bilayer). A liposome can be formed at a variety of 
sizes as uni-lamellar or multi-lamellar construction, and its name relates to its structural 
building blocks, phospholipids, and not to its size.
57
 
The lipid bilayer closes in on itself due to interactions between water molecules and the 
hydrophobic phosphate groups of the phospholipids. This process of liposome formation is 
spontaneous because the amphiphilic phospholipids self-associate into bilayers. Drug 
loading into liposomes can be achieved through:
58
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(i) liposome formation in an aqueous solution saturated with soluble drug;  
(ii) the use of organic solvents and solvent exchange mechanisms;  
(iii) the use of lipophilic drugs; 
(iv)  pH gradient methods. 
Liposomes have been considered for brain targeting in several pathologies through both 
intracerebral and intravenous administrations. An enhanced transport of liposome-
encapsulated drugs has been observed in several reported studies (Table 1.5).  
Table 1.5: Examples of liposomes used as brain drug delivery during CNS diseases. 
Molecule tested Liposome type CNS disease 
   
CM-Dil PEG-liposomes coupled 
with transferrin 
Ischemia 
Doxorubicin Pegylated liposomes 
(commercial formulation 
Caelyx®) 
Brain tumor 
IFN-b gene plasmid Cationic liposomes Brain tumor 
Most of the studies have focused on tumor therapies to deliver doxorubicin and other 
antineoplastic agents with the aid of either cationic or pegylated liposomes (i.e. liposomes 
sterically stabilized by a coating of PEG).
59
 
The generation of NPs properly loaded with antiamyloidogenic ligands, which could be 
concentrated at the brain surface and/or able to cross the BBB, represents a novel 
promising therapeutic approach.
60,61
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2. Objectives 
 
 
 
The aim of this project is the preparation of innovative amyloid-beta peptide (Aligands, 
which could be used for the generation of nanoparticles (NPs) suitables for diagnosis and 
therapy of Alzheimer’s disease (AD) (Figure 2.1). 
 
Figure 2.1: Strategy for functionalization of NPs or liposomes. 
Many natural and synthetic compounds able to interact as A ligands have been identified. 
Among them, we have paid attention to a set of small molecules in which aromatic 
moieties seem to play a key role. Unfortunately, many of these compounds lack solubility, 
chemical stability and/or show pharmacological activities not directly correlated to AD. 
Therefore, the correct therapeutic evaluation of these molecules towards AD cannot be 
performed in a straightforward manner. 
Since A are concentrated inside the brain or within the brain surface, the identified 
compounds must be concentrated near the blood brain barrier (BBB), for the interaction 
with circulating A, and have the ability to cross this barrier, for the interaction with A or 
plaques inside the brain.  
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The present project will be organized in the following steps: 
  Preparation of A ligands  2.1.
Different classes of putative ligands will be selected among the small molecules able to 
inhibit A aggregation, in particular we will focus on heteroaromatic polycyclic 
compounds such as tetracyclines (TCs). Among the different class of compounds with 
reported ability to interact with A, TCs are particularly attractive and are very versatile 
molecules, in some cases their structure-activity-relationship (SAR) are knowned, 
especially against bacteria. In other diverse fields of research, such as neurology, oncology 
and virology the activity of the tetracyclines (TCs) are being discovered.
62
  
 
 
 
Figure 2.2: Tetracyclines drugs. 
Example of therapeutic uses of TCs: 
- Antibacterial resistance;63 
- Target toward inflammation;64 
- Neurology: Huntington’s disease (HD), Parkinson’s disease (PD), AD and 
Prion diseases;
65-69
 
- Antiviral and Anticancer.70 
Nevertheless TCs suffer from chemical instability, low water solubility and possess, in this 
contest, undesired anti-bacterial activity.
71,72
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In order to overcome these limitations, one of our goals is to synthesize TCs analogues 
bearing a polycyclic structure with improved chemical stability and water solubility, 
possibly lacking antibacterial activity but conserving the ability to interact with A. We 
will start with the synthesis of a new class of potential A ligands based on a structure 
resembling that of TCs. Known that TCs have in common a fourth cycle without an 
aromatic character and with different functionalization’s, we aim to synthesize derivatives 
in which this cycle is represented by a sugar moiety, thus bearing different derivatisable 
positions or create derivatives in which we will increase or decrease the number of fused 
rings, but also bearing a sugar moiety.  
 
    
Figure 2.3: Synthetic scope. 
 
We propose two different synthetic approaches: 
2.1.1. Synthesis of glycofused tricyclic derivatives 
 Exploit hetero Diels-Alder (DA) reactions, using carbohydrates moieties as 
dienophiles, for example glycals. 
The retrosynthetic approach idealized for compound 1 is showed in Schemes 2.1 and 2.2. 
We thought in a hetero-DA reaction of 2-hydroxybenzaldehyde derivatives 9 with the 
sugar diene derivative 2. This kind of sugar derivatives containing a double bond, 
designated as “dehydro sugars”, are versatile building blocks for the synthesis of 
glycosides and other natural products. Of the unsaturated sugars, these with the double 
 
Scheme 2.1 
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bound between C-1 and C-2 are referred to as glycals. Their utility laws in the unique 
reactivity of the cyclic enol ether, with the ring oxygen influencing the regioselectivity of 
reactions and the nature and orientation of the ring substituents, contributing to the overall 
reactivity and stereochemical outcomes of the reactions.
73
 
 
Scheme 2.2 
2.1.2. Synthesis of glycofused tetracyclic derivatives 
 Synthesis of new sugar bicyclic scaffolds (compounds 6 and 10) to be employed in 
tandem Michael-Dieckmann reactions or in DA reactions to synthesize tetracyclic 
derivatives. 
To be able to achieve our aims in the most excellent way, it is necessary to find the best 
synthetic pathways, and for that, we have hypothesised some retrosynthetic approaches. 
Our synthetic analysis of tetracyclic compounds 4, 7, 9 and 11 is described in Scheme 2.3. 
The target molecules 4 and 9 could be made using a tandem Michael-Dieckamn reaction of 
compound 5 with compounds 6 or 10, respectively, whereas 7 and 11 could be realized by 
DA reaction of diene 8 with dienophiles 6 or 10, respectively. 
 
Scheme 2.3 
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Scheme 2.3 (cont.) 
Intermediate 5 could be obtained by esterification of acid 13, which in turn could be 
synthesized from nitro compound 14, by hydrolysis of a diazonium salt or by oxidation of 
dimethylanisole derivative 15. 
  
Scheme 2.4 
ortho-Quinodimethane 8, is a potent reactive intermediate, reported in literature,
74-77
 which 
could be synthesize from commercial available 2’-bromoacetophenone. 
 
 
Scheme 2.5 
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The synthetic route developed for compound 6a is depicted in the retrosynthetic Scheme 
2.6. Our analysis began with the straightforward functional group interconversion (FGI) to 
generate compound 19. From here, a double bond disconnection revelead the intermediate 
20, which could be obtained from Grignard reaction of 21 with vinyl magnesium bromide. 
Taking advantage of another FGI we would obtain compound 22. This intermediate could 
be synthesized from ketone 23, by another Grignard reaction. In both Grignard reactions 
we expect good diastereoselectivity. The reason is that magnesium can chelate with 
electronegative atoms in -position to the carbonyl group and the carbonyl group itself 
(Figure 2.4). The stereoselectivity is likely to be high if a cyclic transition state is involved, 
and chelation involves just such transition state.  
 
Figure 2.4: Chelation model for carbonyls groups’ alkylation with electronegative atoms in -position. 
We planned to construct intermediate 23 by oxidation and using different protecting 
groups, i.e., taking advantage from orthogonality of compound 24, which could be readily 
obtained from commercial available glycopyranoside 25. 
 
Scheme 2.6 
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The formation of bicyclic compound 6b is presented in Scheme 2.7. This compound could 
be achived by ring closing metathesis (RCM) and FGI of compound 27. The requisite 
compound 27 would be derived from compound 30, which in turn could be constructed by 
hydroboration of intermediate 31, obtained by a Wittig reaction of compound 23. Ketone 
23 could be prepared from the known glucose derivative 25, by simple functional group 
manipulation and functional group interconversion. 
 
 
Scheme 2.7 
Scheme 2.8 shows, in retrosynthetic format, the key carbon-carbon bond disconnections 
and FGI employed to devise the synthetic strategy towards compound 10a. This compound 
could be obtained from an allylic oxidation of compound 32, which in turn could be 
synthesised from RCM of 33, in the presence of Grubbs second generation catalyst. 
Precursor 33 could be prepared in diastereoselective manner by a Grignard reaction with 
ketone 34, whose origin was traced back to compound 35, through oxidation of the free 
hydroxyl group. Intermediate 35 could then be converted retrosynthetically to commercial 
available glycopyranoside 25 through a Sakurai reaction,
78
 followed by iodo cyclization 
and a elimination. 
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Scheme 2.8 
Finally, intermediate 10b could be obtained by RCM of 37 followed by Grignard reaction 
of 38. We planned to construct intermediate 41 by dihydroxylation of the key intermediate 
31. 
 
Scheme 2.9 
  Nuclear magnetic ressonance screening experiments 2.2.
Selected compounds will be screened for their affinity towards A, using solution nuclear 
magnetic ressonance (NMR) experiments that have the ability to probe at atomic resolution 
the molecular interaction between ligands and receptors. Specifically, saturation transfer 
difference (STD) and transferred nuclear Overhauser effect spectroscopy (tr-NOESY), will 
be used to screen A oligomer, fibril, plaque binders and A aggregation inhibitors.  
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2.2.1. Saturation transfer difference spectroscopy  
STD-NMR spectroscopy is one of the most powerful NMR techniques for detection and 
characterization of receptor–ligand interactions in solution. If the irradiation conditions are 
adequately chosen, it is possible to saturate very efficiently only protons of the protein, but 
not those of the ligand. In this situation, if binding occurs, magnetization from the receptor 
protons will be transferred to ligand protons that are close in space in the bound state 
(Figure 2.5). 
 
Figure 2.5: Schematic representation of STD-NMR experiment. 
These experiments will allow to map the interactions highlighting the functional groups 
involved and their correct reciprocal orientation and distance. The results will allow 
designing more efficient ligands. This part of the project will focus on the design, on the 
based NMR data, and synthesis of small libraries of selected natural ligand derivatives and 
the evaluation of their real ability to bind A. In case of positive results and improved 
binding with respect to the parent compounds, these derivatives will be used themselves to 
produce functionalised liposomes. 
2.2.2. Transferred nuclear Overhauser effect spectroscopy  
tr-NOESY is used to probe the conformation of a ligand while bound to its 
macromolecular receptor. It is primarily applied to systems for which exchange is fast, so 
that ligand protons show a single resonance peak averaged over the free and bound states.
79
   
Fast exchange generally corresponds to KD>10
-6 
M. The tr-NOESY method uses excess 
ligand (typical ligand:receptor site ratios range from 10 to 50), so that the resonance line 
shapes resemble those of the unbound ligand in solution, but the cross relaxation measured 
from the NOE spectrum is predominantly determined by internuclear distances within the 
ligand in the bound state.
79,80
 
Synthesis of new A-ligands useful in diagnosis of Alzheimer’s Disease 
44 
For a small molecule, the cross-peaks in the tr-NOESY spectrum have the opposite sign to 
the diagonal peaks, but in the presence of a receptor, the cross-peaks for the interacting 
compounds will change sign and become negative, due to the change in their effective 
rotational correlation time. The analysis of these negative cross-peaks provides information 
on the bound geometry of the ligand (Figure 2.6).
81
 
 
 
Figure 2.6: Schematic representation of the tr-NOESY experiment. 
 
 Functionalisation of A ligands 2.3.
A ligands will be linked to liposomes exploiting the following strategy:  
- Linker/spacer will be conjugated to A ligands for subsequent 
functionalisation of liposomes. 
Very few ligands are suitable as such to be linked to a spacer polyethylene glycol (PEG) or 
to be directly attached to a liposome, so in these cases the ligands have to be opportunely 
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modified with the introduction of a group suitable for ligation. Besides the traditional 
carboxylic acid/amine conjugation, exploiting the peptide synthesis procedures, 
chemoselective-coupling procedures will be performed involving an azido group and a 
triple bond to generate a triazole, belonging to very efficient reactions termed “click 
chemistry”. 
The chemistry developed and optimized for the conjugation of A ligands to liposomes 
will then be exploited to link also a contrast agents/fluorophore, useful as diagnostic tool, 
and/or a BBB transporter. The latest will allow the generation of liposomes able to pass the 
BBB with more efficacies with respect to the non-derivatized compounds. 
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3. Results and discussion 
 
 
 
 
In this section is described the synthetic achievements of this project, as mentioned early, 
one of our goals is to synthesize tetracyclines (TCs) analogues bearing a polycyclic 
structure, possibly lacking antibacterial activity, with improved chemical stability and 
water solubility but conserving the ability to interact with amyloid beta peptides 
(A. This tetracyclic structure will be glycofused, thus bearing different derivatisable 
positions; the number of fused rings will be changed, but likewise bearing a sugar 
moiety.  
 Synthesis of glycofused tricyclic derivatives 3.1.
 
a) Exploit hetero-Diels-Alder (hetero-DA) reactions, using carbohydrate 
moieties as dienophiles, for example glycals. 
The Diels-Alder (DA) reaction is arguably one of the most powerful reactions in the 
arsenal of the synthetic organic chemistry. By varying the nature of the diene and 
dienophile, many different types of carbocyclic structures can be built up. Nevertheless, 
the presence of electron-withdrawing groups in the dienophile and electron-releasing 
groups in the diene or vice-versa can drastically accelerate the process.
82
 
The use of carbohydrate derivatives containing a double bond in DA reactions are versatile 
building blocks to be used in organic synthesis and they have been extensively used in 
 
Scheme 3.1 
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hetero-DA reactions. Based on the retrosynthetic analysis was need to use a 1,2-anhydro 
sugars as dienophiles. 
The employed synthetic strategy exploits the reaction between o-hydroxybenzaldehydes 
and glycals using a catalytic amount of scandium triflate in the presence of trimethyl 
orthoformate (TMOF), as described by Yadav et al.
83
 In order to verify the influence of the 
various parts of the molecule on the interaction with the A, we generated a small library 
of glyco-fused benzopyran compounds, using differently substituted                                  
o-hydroxybenzaldehydes and employing both glucal (50) and galactal (49). In all cases, we 
obtained cis-fused pyrano[3,2-b]benzopyran (21–91% yield), but in contrast to previous 
reports,
83
 the reaction afforded a variable ratio of separable mixtures of two 
diastereoisomers at C5 (Scheme 3.2, Table 3.1).  
 
Scheme 3.2. reagents and conditions: a) Sc(OTf)3 (3% mol), TMOF (2.5 equiv.), CH2Cl2, rt. 
 
Table 3.1: Protected cis-fused glyco benzopyrans. 
o-hydroxy  
benzaldehyde D-glycal Protected products C5 R/S (yield%) 
42 R
1
,R
2
= H,H 49 51 R1,R2,R3,R4= H,H,H,OBn 92/8 (59%) 
43 R
1
,R
2
= NO2,H  49 52 R
1
,R
2
,R
3
,R
4
= NO2,H,H,OBn 100/0 (40%) 
44 R
1
,R
2
= OBn,H 49 53 R1,R2,R3,R4= OBn,H,H,OBn 100/0(35%) 
45 R
1
,R
2
= OMe,H 49 54 R1,R2,R3,R4= OMe,H,H,OBn 85/15 (73%) 
46 R
1
,R
2
= CH3,H 49 55 R
1
,R
2
,R
3
,R
4
= CH3,H,H,OBn 95/5 (91%) 
47 R
1
,R
2
= H, OMe 49 56 R1,R2,R3,R4= H,OMe,H,OBn 53/47 (64%) 
48 R
1
,R
2
= H,CH3  49 57 R
1
,R
2
,R
3
,R
4
= H,CH3,H,OBn 100/0 (45%) 
46 R
1
,R
2
= CH3,H 50 58 R
1
,R
2
,R
3
,R
4
= CH3,H,OBn,H 100/0 (66%) 
47 R
1
,R
2
= H, OMe 50 59 R1,R2,R3,R4= H,OMe,OBn,H 100/0 (37%) 
48 R
1
,R
2
= H,CH3  50 60 R
1
,R
2
,R
3
,R
4
= H, CH3, OBn,H 100/0 (21%) 
The reaction may proceed through the formation of o-quinone methides generated in situ 
from salicylaldehydes and TMOF as shown in Scheme 3.3. 
 
 
Scheme 3.3 
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The major isomer was then deprotected by hydrogenolysis to afford the final compounds 
61–70 (Scheme 3.4, Table 3.2).  
 
 
Scheme 3.4. reagents and conditions: a) H2, Pd(OH)2 (5% mol), AcOEt:MeOH (1:1), rt 
 
 
Compound 56 was chosen as an example to describe the structural charatcterization of 
these type of compounds. From 
1
H NMR spectrum (Figure 3.1) we found that JH-4a-H-5 is 
4.4 Hz for compound 56 (C5-S) and 2.2 Hz for compound 56 (C5-R), and JH-4a-H-10a is 2.9 
Hz for compound 56 (C5-S) and 3.3 Hz for compound 56 (C5-R), we can confirm that also 
in this molecule (C5-R) H-4a and H-10a are cis related. 
 
Scheme 3.5 
  
Figure 3.1: 
1
H NMR spectrum (400 MHz, CDCl3) of compounds 56 (C5-S) and (C5-R). 
Table 3.2: Deprotected cis-fused glyco benzopyrans. 
Protected products Deprotected compounds C5-R (yield%) 
51 R
1
,R
2
,R
3
,R
4
= H,H,H,OBn 61 R
1
,R
2
,R
3
,R
4
= H,H,H,OH (97%) 
52 R
1
,R
2
,R
3
,R
4
= NO2,H,H,OBn 62 R
1
,R
2
,R
3
,R
4
= NH2,H,H,OH (94%) 
53 R
1
,R
2
,R
3
,R
4
= OBn,H,H,OBn 63 R
1
,R
2
,R
3
,R
4
= OH,H,H,OH (100%) 
54 R
1
,R
2
,R
3
,R
4
= OMe,H,H,OBn 64 R
1
,R
2
,R
3
,R
4
= OMe,H,H,OH (96%) 
55 R
1
,R
2
,R
3
,R
4
= CH3,H,H,OBn 65 R
1
,R
2
,R
3
,R
4
= CH3,H,H,OH (95%) 
56 R
1
,R
2
,R
3
,R
4
= H,OMe,H,OBn 66 R
1
,R
2
,R
3
,R
4
= H,OMe,H,OH (97%) 
57 R
1
,R
2
,R
3
,R
4
= H,CH3,H,OBn 67 R
1
,R
2
,R
3
,R
4
= H,CH3,H,OH (97%) 
58 R
1
,R
2
,R
3
,R
4
= CH3,H,OBn,H 68 R
1
,R
2
,R
3
,R
4
= CH3,H,OH,H (98%) 
59 R
1
,R
2
,R
3
,R
4
= H,OMe,OBn,H 69 R
1
,R
2
,R
3
,R
4
= H,OMe,OH,H (97%) 
60 R
1
,R
2
,R
3
,R
4
= H, CH3, OBn,H 70 R
1
,R
2
,R
3
,R
4
= H, CH3, OH,H (98%) 
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To confirm that the tricyclic is cis-fused was performed a two-dimensional nuclear 
Overhauser effect spectroscopy (2D-NOESY) experiment of compound 56 (C5-R) (Figure 
3.2). The presence of nuclear Overhauser effect (NOE) contacts was observed between    
H-10a and H-5, H-10a and H-4a, while H-4 showed correlations with H-3 and H-2. 
Absence of a cross-peak between H-10a and H-4 shows that they are in opposite sides. 
These experimental evidences indicate that the stereochemistry indicated in the structure of 
compoumd 56 is the correct one.  
 
Figure 3.2: 2D-NOESY spectrum (400 MHz, CDCl3) of compound 56 (C5-R). 
3.1.1.  STD and tr-NOESY NMR experiments 
From the molecular recognition perspective, very recently, it was employed saturation 
transfer difference-nuclear magnetic ressonance (STD-NMR) experiments to characterize 
the interaction of tetracycline and thioflavin T (ThT) with Aβ(1-40) and Aβ(1-42) .67,84,85 
Thus, the same methodology has been applied herein to check the effect of benzopyran 
derivatives of the debenzylated compounds 61-70, on the Aβ(1-42)  oligomer recognition 
process. In particular, the interaction studies with the amyloid peptide Aβ(1-42) were 
carried out by using STD and transferred nuclear Overhauser effect spectroscopy (tr-
NOESY) NMR experiments.  
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STD-NMR experiments were performed using ligand:peptide 20:1 mixtures dissolved in 
deuterated phosphate buffer saline (PBS), pH=7.4, 25°C. Each mixture was analyzed 
irradiating the sample at -1.0 ppm to achieve the selective saturation of some aliphatic 
resonances of Aβ oligomers. The presence of NMR signals of the test molecule in the STD 
spectra is a non ambiguous demonstration of the existence of interaction. Conversely, the 
absence of NMR resonances in the STD spectra indicates that the employed molecule is 
not an Aβ ligand. In all cases, several NMR resonances of compounds 61-70 appeared in 
the corresponding STD spectra recorded in the presence of Aβ oligomers (Figure 3.3 and 
3.4), thus showing their ability to recognize and bind Aβ(1-42) , with the notable exception 
of compound 62, whose signals are absent (Figure 3.3B). 
 
Figure 3.3: Comparison between STD experiments acquired in the presence of compound 62 and 65. 
1
H (A 
and C) and 1D-STD (B and D) spectra recorded on Aβ:ligand mixtures dissolved in deuterated PBS, pH=7.5 
at 25°C and containing Aβ(1-42) (80 mM) and a test molecule (1.6 mM) (A and B, compound 62; C and D, 
compound 65). 
1
H NMR spectra were acquired with 64 scans, 1D-STD NMR spectra with 512 scans and 2 s 
of saturation time. 
Additional tr-NOESY experiments acquired on the same ligand:peptide mixtures supported 
these results. The change in the sign of the cross-peaks of the test molecule, from positive 
(blue color), in the absence of Aβ(1-42), to negative (red color) in presence of Aβ(1-42) , 
reflects an increase of its effective rotational motion correlation time, and supports its 
binding to a large molecular entity, here represented by the Aβ oligomers.85 
In agreement with the STD results, all tr-NOESY spectra of compounds 61-70 acquired in 
the presence of Aβ(1-42)  showed the key change, from positive to negative, of the 
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corresponding cross-peak signs, except for compound 62. In this case, the NOE cross-        
-peaks remained positive, indicating that this molecule does not bind to Aβ(1-42) in a 
significant manner (Figure 3.5). 
 
Figure 3.4: 
1
H NMR spectra (A, C, E, G, I, M, O, Q, S and U) and 1D-STD NMR spectra (B, D, F, H, L, N, 
P, R, T and V) of mixtures dissolved in deuterated PBS, pH=7.5 at 25°C containing Aβ(1-42)  (80 M) and 
a test molecule (1.6 mM) (A and B, compound 61; C and D, compound 62; E and F, compound 63; G and 
H, compound 64; I and L compound 65; M and N, compound 66; O and P, compound 67; Q and R, 
compound 68; S and T, compound 69 e U and V, compound 70). 
1
H NMR spectra were acquired with 64 
scans, 1D-STD spectra with 512 scans and 2 s of saturation time. 
Results and Discussion 
55 
 
Figure 3.5: 2D-NOESY spectra of compounds 62 (A) e 65 (C) dissolved in deuterated PBS, pH=7.5, 25°C, 
mixing time 0.9 s. tr-NOESY of mixture containing Aβ(1-42)  (80 M) and compound 62 (B) or compound 
65 (D) dissolved in deuterated PBS, pH=7.5, 25°C, mixing time 0.3 s. Positive cross-peak are blue, negative 
ones red. 
Since the STD intensity is proportional to the ligand binding affinity for the molecular 
target,
85
 we exploited competitive STD experiments to rank the affinity of compounds 61-
70 for the peptide. Due to extensive resonance overlapping, the acquisition of competitive 
STD spectra on a unique mixture containing all the molecules was not feasible. Hence, we 
performed three different competitive experiments of the different molecules in the 
presence of Aβ(1-42)  oligomers. Thus, separate experiments for mixtures containing the 
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D-galactose derivatives (61-67), the D-glucose analogues (68-70), or “the best ligands” 
identified from the two previous screenings (65 and 70) were performed. 
In the first and second competitive experiments, we measured the STD effect on H-6, and 
in the third experiment on H-10a (see Scheme 3.5). For each molecule, the fractional STD 
effect was calculated as (I-I0)/I0, where I is the intensity of the monitored signal in the STD 
spectrum and I0 is the intensity of the same signal in a reference spectrum. Compounds 65 
and 68 showed the same affinity for Aβ(1-42) , as their H-10a signals presented equal 
intensities. Hence, to compare the data obtained in the different competitive experiments, 
the fractional STD effects of 65 and 68 were set equal to 1 and, therefore, the relative 
intensities for the other molecules were calculated. The results are summarized in Figure 
3.6. 
 
Figure 3.6: Fractional STD effects calculated for compounds 61, 63, 64, 65, 66, 67, 68, 69 and 70. These 
values are proportional to compounds affinity for Aβ(1-42) oligomers. 
Thus, 65, 67, 68 and 70, whose aromatic rings are substituted with a methyl group, are the 
ligands with the highest affinities for Aβ oligomers, followed by 64, 66 and 69, which 
present a O-methyl group as substituent, and by 61, with no aromatic substituent. These 
molecules display fractional STD effects higher than 70%. Finally, 63, with a hydroxyl 
group at position 7, has the lowest affinity. These data, together with the absence of 
binding of 62 (with an amine substituent) to Aβ oligomers, clearly indicate that the lower 
the polarity of the substituents on the aromatic ring, the greater the compound affinity for 
Aβ(1-42) . Moreover, the position of substituents on the aromatic ring (position 7 or 8), as 
well as the nature of the saccharide entity, are not relevant, as supported by the evidence 
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that compounds 65, 67, 68 and 70 showed equal binding affinity, and the same applies for 
compounds 64, 66 and 69. 
These findings are in full agreement with the STD-based epitope-mapping, recorded with 
five different saturation times (0.5, 1.2, 2.0, 3.0, 5.0 s) (Figure 3.7). According to the STD 
relative intensities, the region of the ligand mainly involved in the interaction with Aβ (the 
binding epitope) is the aromatic ring, while protons of the saccharide portion showed the 
least intense STD signals. These evidences explain why the stereochemistry of sugar 
carbons does not influence the binding affinity, while the polarity of the aromatic 
substituents, as previously stated, plays a crucial role in the interaction. 
 
Figure 3.7: A) 
1
H NMR spectrum of the mixture containing Aβ(1-42) (80 M) and compound 65 (1.6 mM) 
in PBS, pH=7.5, 25°C; B-F) STD-NMR spectra of the same mixture acquired with different saturation 
times. (B 0.5 s; C 1,2 s; D 2,0 s; E 3,0 s; F 5,0 s). 
3.1.2.  Conformational analysis: molecular dynamics and molecular     
mechanics simulations  
In order to be sure that the observed difference in the binding ability was only due to the 
polarity of the substituent and not to a different molecular conformation induced by the 
substituent itself, we carried out a conformational analysis. This analysis was performed 
using molecular mechanics (MM) and molecular dynamics (MD) simulations. Calculations 
were performed by using MM3*14 force field, as implemented in the MacroModel 
program (Maestro Suite). After a first run of minimizations, a conformational search was 
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performed for each molecule. The conformation with the lowest energy was selected, 
minimized and submitted to MD simulations. 100 structures were sampled and further 
minimized. According to the modelling data, compounds 61-70 present the same 
conformation. The 30 conformations with the lowest energy found for compound 61-70 are 
reported in Figure 3.8.  
 
Figure 3.8: Superimposition of the 30 structures with the lowest energy calculated through MD simulations 
in water, 298K; A, compound 61; B, compound 62; C, compound 63 ; D, compound 64; E, compound 65; F, 
compound 66; G, compound 67; H, compound 68; I, compound 69; L, compound 70. 
The values of the key proton-proton distances H2-H3, H2-H4, H3-H4, H4a-H10a, H4a-H5 
and H5-H10a as well as the values of the dihedral angle H2-C2-C3-H3, H3-C3-C4-H4, 
H4a-C4a-C10a-H10a and H4a-C4a-C5-H5 were monitored during the MD. All compounds 
showed the same values of H2-H4, H4a-H5, H4a-H10a, and H5-H10a distances (Figure 
3.9), and of the dihedral angles H4a-C4a-C10a-H10a (average value θ=62°) and H4a-C4a-
C5-H5 (average value θ=-53°), which are the diagnostic parameters to identify molecule 
conformation. On the other hand, on the basis of  the distances H2-H3 and H3-H4 and the 
dihedral angles H2-C2-C3-H3 and H3-C3-C4-H4, molecules 61-70 could be clustered into 
two groups (61-67, with average θH2-C2-C3-H3=-60°, θH3-C3-C4-H4=60° and 68-70, 
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with average θH2-C2-C3-H3=-180°, average θH3-C3-C4-H4=180°), depending on C3 
stereochemistry (Figure 3.9). From these results was concluded that the differences in 
affinity for Aβ(1-42)  are due to the nature of the substituent on the aromatic ring and are 
not a consequence of conformational differences 
 
 Figure 3.9: Average values for H2-H3, H2-H4, H3-H4, H4a-H10a and H5-H10a interproton distances. 
Concerning H2-H3 and H3-H4, compounds 61-70 can be clustered into two groups (bottom). 
3.1.3. Functionalisation of glycofused tricyclic derivatives: generation of 
fluorescent-lipophilic derivatives 
The cis-glyco fused benzopyran compounds described above as new Aβ ligands, present 
key interesting features that make them attractive for the development of potential 
diagnostic and/or therapeutic tools. For these purposes the Aβ binding ability is a 
fundamental characteristic but, as such, is not sufficient, in order to generate a potential 
drug-tool candidate, the molecules should also possess the correct physical-chemical 
characteristics. The glycidic moiety, not being directly involved in the binding assures 
further possible derivatizations, such as conjugation to other molecular entities 
[nanoparticles (NPs), polymeric supports, etc.], and functionalization with chemical groups 
able to modulate the hydro/lipophilicity. In order to be useful such compounds should 
perform their action within the brain, therefore they have to be able to cross the blood-
brain-barrier (BBB), and to be somehow detected for diagnostic purposes.  
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3.1.3.1 Synthesis of fluorescent glycofused tricyclic compounds 
The scope of this part of the project consists in the synthesis of fluorescent tricyclic 
derivatives to verify the ability of the test compounds to pass through the BBB, using 
spetrofluorimetric techniques (Figure 3.10), and to be used as diagnostic tools to detect the 
presence of Aβ oligomers/plaques.  
  
 
 
Figure 3.10: Fluorescent derivatives of Aβ-peptides ligands (71-74). 
The choice of the fluorophore was done in order to modulate the hydrophilic properties of 
the molecule maintaining the molecular weight low enough for a diffusion mechanism, 
since we knew from previous experiments that the hydrophilicity of our derivative was too 
high to assure the permeation through the BBB.  
As fluorophore we selected coumarin derivatives (Figure 3.11), due to its relatively small 
dimension with respect to other commonly used fluorescent entities such as rhodamine and 
fluorescein. In this way we wanted to limit as much as possible the possible interference of 
the fluorophore in the ligand binding, which in any case should be assessed. Moreover, 
coumarin has a lipophilic character and its conjugation to the tricyclic compound would 
modulate the solubity affording the correct logP value to the derivative.  
For the conjugation we exploited the primary hydroxyl group of the glycidic moiety, since, 
as expected, previous binding studies of section 3.1.1. confirmed that the sugar moiety was 
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not or very poorly involved in the binding with the Aβ, and this hydroxyl group can be 
selectively functionalised. 
 
Figure 3.11: Coumarin derivatives. 
Our first approach was focused on the direct conjugation of the fluorophore to the Aβ 
ligand. Among the previously identified ligands, compounds bearing the methyl substituent 
at position C7 and/or C8 of the aromatic ring showed the best binding properties, thus 
compounds 65 and 67 were used in this section.  For the synthesis of compound 71 
(Scheme 3.6), ligand 65 was regioselectively acylated with bromoacetyl bromide at low 
temperature (-45°C) affording compound 78, that was reacted with coumarin derivative 75 
in basic conditions (CsCO3) to afford the final product 71 with a 37%, not optimized, 
overall yield.  
 
Scheme 3.6. reagents and conditions: a) BrCH2COBr (1.3 equiv.), dry DMF, sym-collidine (1.4 equiv.), -45°C, 
40 min., 54%; b) 75 (1.5 equiv.), CsCO3 (1.1 equiv.), dry DMF, rt, 1 h, 37%. 
For the synthesis of compound 72 (Scheme 3.7), the primary hydroxyl was first converted 
to the corresponding amine 81, by a tosylation (TsCl, dry Py) reaction followed by a 
nucleophilic azide substitution (NaN3, dry DMF) and final reduction (H2, Pd-Lindlar, 
MeOH). Compound 81 was then coupled with coumarin derivative 77, using standard 
coupling conditions (DIC, HBTU, DIPEA, dry DMF) affording the final product 72. 
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Scheme 3.7. reagents and conditons: a) TsCl (1.1 equiv.), DMAP (cat.), dry Py, 0°C-rt, 12 h, 98%; b) NaN3 
(7.0 equiv.), dry DMF, 100°C, 12 h, 60%; c) H2, Pd-Lindlar, MeOH, rt, 1 h; d) 77 (1.2 equiv.), DIC (1.5 
equiv.), HBTU (1.5 equiv.), DIPEA (3.0 equiv.), dry DMF, rt, 47% (over two steps).
 
1
H NMR spectrum of compound 72 (Figure 3.12) shows a doublet for proton H-5’ at         
 7.59 ppm with a J = 8.8 Hz, and analysis of 2D-COSY NMR shows only vicinal 
coupling with H-6’ at  6.76 ppm. For the coumarin scaffold we can also see from 1H 
NMR, a singlet at  6.16 ppm corresponding to H-3’ proton and proton H-8’ that appears 
between  6.68 – 6.58 ppm. The protons CH2CONH- appear between 3.81 – 3.71 ppm. 
In relation to the tryciclic part, H-10a appears as a doublet at  5.54 ppm showing only 
vicinal coupling with H-4a, J = 2.8Hz, confirming that these protons are cis related. 
 
Figure 3.12: 
1
H NMR spectrum (400 MHz, CD3OD) of compound 72. 
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In order to verify the influence of the fluorophore on the binding properties to Aβ, STD-    
-NMR experiments were carried out on both compounds. Unfortunately, compound 71 
resulted chemically unstable, as it hydrolyzed immediately after dissolution in aqueous 
buffer (data not shown), probably because of the presence of the ether linkage in α to the 
ester group.  
Conversely, compound 72 resulted stable to hydrolysis and, in order to verify the influence 
of the fluorophore on the binding properties to Aβ, its interaction with Aβ(1-42) was 
investigated by STD-NMR experiments.
67,84-88
 
NMR binding studies were carried out employing the same methodology previously 
described.
61
 In particular, compounds 72 ability to interact with Aβ(1-42)  oligomers was 
assessed by STD-NMR spectroscopy. STD-NMR experiments were performed using a 
ligand:peptide 10:1 mixture dissolved in deuterated PBS, pH=7.4, 37°C. The mixture was 
analyzed irradiating the sample at -1.0 ppm to achieve the selective saturation of some 
aliphatic resonances of Aβ oligomers. In general, the presence of NMR signals of the test 
molecule in the STD spectrum is a clear demonstration of the existence of interaction 
(Figure 3.13). 
 
Figure 3.13: A) 
1
H NMR spectrum of the compound 72 (0.5 mM) in PBS, pH=7.4, 37°C; B) Blank STD-
NMR spectrum of compound 72 acquired with a saturation time of 3.0 s and 2304 scans; C) 
1
H NMR 
spectrum of the mixture containing the peptide Aβ(1-42) (50 M) and compound 72 (0.5 mM) in PBS, 
pH=7.4, 37°C; D) STD-NMR spectrum acquired on the same mixture with a saturation time of 3.0 s and 
2304 scans. 
STD experiments evidenced the binding ability of compound 72, even if its STD signals 
were rather low in intensity, probably due to solubility problems in physiological 
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conditions. The poor quality of STD spectrum prevented the possibility to obtain a detailed 
epitope mapping and the acquisition of further NMR interaction experiments. In order to 
overcome the limitations encountered for derivatives 71 and 72, we planned to introduce a 
triethylene glycol spacer between the ligand and the fluorophore. This should increase both 
water solubility and chemical stability, avoiding the liable α-oxy ester group. 
For the preparation of this second set of derivatives we used Aβ ligand 67 (Scheme 3.8) 
that in our previous section showed the same binding properties of compound 65, and a 
more straightforward preparation from commercially available reagents. Secondary 
hydroxyls were protected with an isopropylidene group (DMP, dry CH3CN, CSA) and the 
free primary hydroxyl was reacted with triethylene derivative 83 (NaH, dry DMF), to 
afford intermediate compound 84. Removal of the protecting group (p-TsOH, H2O:CH3CN 
[0.5:1.5 / (v:v)] afforded derivative 85 bearing an azido functionality at the end of the 
triethylene moiety. For the synthesis of compound 73 the azido group was reduced (H2, Pd-
Lindlar, MeOH) and the resulting amine 86 was coupled with coumarin derivative 77 
(DIC, HBTU, DIPEA, dry DMF), while for the preparation of compound 74 the azido 
group was exploited in a chemoselective click cycloaddition reaction [CuSO4•5H2O, 
sodium ascorbate, t-BuOH:THF(1/1:v/v)] with the alkyne coumarin derivative 76, obtained 
from 75 through propargylation of the phenolic OH group(Scheme 3.8). 
1
H NMR spectrum 
of compound 74 shows the characteristic signal correspondig to the triazole proton H-10’ 
at δ 8.26 ppm as a singlet, while 13C NMR spectrum shows the characteristic lactone signal 
at 162.3 ppm. 19F spectrum shows a singlet at δ -62.2 ppm. 
 
Scheme 3.8. reagents and conditions: a) DMP (4.0 equiv.), CSA (1% mmol), dry CH3CN, rt, 1 h, 60%; b) 83 
(2.0 equiv.), NaH 60% (1.5 equiv.), dry DMF, 100ºC, 12 h, 75%; c) p-TsOH (0.01 equiv.), H2O:CH3CN 
(0.5/1.5:v/v), rt, 30 min., 90%; (cont.) 
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Scheme 3.8. (cont.) reagents and conditions: d) H2, Pd-Lindlar, MeOH, r.t, 1 h, 90%; e) 77 (1.2 equiv.), DIC 
(1.5 equiv.), HBTU (1.5 equiv.), DIPEA (3.0 equiv.), dry DMF, rt, 12 h, 20%; f) 76 (1.2 equiv.), 
CuSO4•5H2O (0.15 equiv.), sodium ascorbate (0.30 equiv.), t-BuOH:THF(1/1:v/v), rt, 12 h, 55%. 
As expected, the solubility of compound 73 in water allowed to perform both STD and      
tr-NOESY NMR experiments to verify its ability to interact with Aβ oligomers. Both the 
techniques were applied on a sample containing Aβ(1-42)  and compound 73 dissolved in 
deuterated PBS, pH=7.4, 25°C at the final concentrations of 80 µM and 0.5 mM 
respectively. Figure 3.14 reports the STD spectra recorded with five different saturation 
times (D 3 s; E 2 s; F 1.2 s; G 0.7 s; H 0.3 s). 
 
Figure 3.14: A) 
1
H NMR spectrum of a solution of compound 73 (0.5 mM) in PBS; B) Blank STD-NMR 
spectrum of the same solution acquired with 3.0 s of saturation time; C) 
1
H NMR spectrum of the mixture 
containing Aβ(1-42) (80 µM) and compound 73 (0.5 mM) in PBS, pH=7.5, 25°C; D-H STD-NMR spectra 
of the same mixture acquired with different saturation times. (D 3.0 s; E 2.0 s; F 1.2 s; G 0.7 s; H 0.3 s). 
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STD spectra clearly demonstrated compounds’ 73 ability to recognize and bind Aβ            
oligomers. The existence of interaction was also supported by the broadening of molecule 
73 resonances when the molecule was dissolved in the presence of the peptide (compare 
spectra A and C, Figure 3.14). This broadening reflects a decrease in proton relaxation 
times due to the formation of a receptor-ligand complex. 
To map the ligand binding epitope, the STD spectrum acquired with a saturation time of 
0.3 s was analysed in order to minimize the effect of relaxation on STD intensities.
89
 
Figure 3.15 reports schematically the fractional STD effect for some ligand protons (or 
groups of protons), calculated as (I0
 
- I)/I0*100, where I is the intensity of the monitored 
signal in the STD spectrum and I0 is the intensity of the same signal in a reference 
spectrum. The region of the ligand presenting the higher fractional STD effect (value 
around 40%), is the aromatic ring of the tricycle, thus resulting the ligand structural moiety 
mainly involved in the interaction with Aβ, in agreement with data obtained for the non-
functionalized ligand.
90
  
The coumarin moiety also participates to the interactions, but its contribution is less 
significant. 
 
Figure 3.15: Fractional STD effects calculated for different protons of compounds 73. 
The binding was further assessed by tr-NOESY experiments. A blank NOESY spectrum of 
compound 73 was recorded in the absence of the Aβ(1-42) (Figure 3.16A). An inversion of 
the sign of the NOESY cross-peaks of the molecule was observed between both spectra, 
passing from positive (red color), in the absence of Aβ(1-42), to negative (blue color) in 
the presence of Aβ(1-42) (Figure 3.16B). This change is due to an increase of the effective 
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rotational motion correlation time of the molecule in the presence of the Aβ oligomers, that 
demonstrated the existence of a binding between the small molecule and Aβ aggregates.91 
 
Figure 3.16: (A) 2D-NOESY spectrum of compound 73 dissolved in deuterated PBS, pH=7.5, 25°C, mixing 
time 0.9 s; (B) tr-NOESY of mixture containing Aβ(1-42) (80 µM) and compound 73 (0.5 mM) dissolved in 
deuterated PBS, pH=7.5, 25°C, mixing time 0.3 s. Positive cross-peaks are red, negative ones blue. 
The solubility of compound 74 in aqueous buffer was very poor. In particular, NMR 
binding experiments were performed on a sample containing the test molecule at a 
concentration of 0.5 mM in PBS, pH=7.5, 25°C, to which 5% of d6-DMSO was added to 
promote its dissolution. Aβ(1-42) was added at a final concentration of 80 µM. In these 
conditions we obtained an STD spectrum of low quality (Figure 3.17A-4), but sufficient to 
assess the existence of interaction with Aβ(1-42). The binding was further supported by the 
significant broadening of compound 74 
1
H Aβ(1-42) peptide (Figure 3.17A-3).  
In addition, we could exploit the presence of the CF3 substituent on the coumarin moiety, 
as a dramatic change also in its line width can be observed when the 
19
F NMR spectrum of 
the molecule alone (Figure 3.17B-1) is compared with the corresponding spectrum 
acquired on the ligand:receptor mixture (Figure 3.17B-2). 
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Figure 3.17: A-1) 
1
H NMR spectrum of the compound 74 (0.5 mM); A-2) blank STD-NMR spectrum of 
compound 74 acquired with a saturation time of 2.0 s and 5200 scans; A-3) 
1
H NMR spectrum of the 
mixture containing the peptide Aβ(1-42) (80 M) and compound 74 (0.5 mM); A-4) STD-NMR spectrum 
acquired on the same mixture with a saturation time of 2.0 s and 5200 scans. B) 
19
F NMR spectra of 
compound 74 dissolved in the absence (1) or in the presence (2) of Aβ oligomers. Samples were dissolved in 
PBS, pH=7.5, 25°C, adding 5% of d6-DMSO. 
3.1.3.2 Transport experiments to the brain: in vitro experiments 
The ability to pass the BBB was evaluated using in vitro experiments with a BBB model, 
in collaboration with the Department of Experimental Medicine, University of Milano–
Bicocca. Currently available in vitro models for BBB allow to evaluate quickly and in a 
reproducible way the predictive in vivo permeability of compounds and drugs under 
development.  
The development of a cell culture system that mimics an in vivo BBB requires endothelial 
cells to be cultured on microporous supports. hCMEC/D3 cells (passages 25-35) were 
seeded on 12-well Transwell® inserts coated with type I collagen in a density of 5x104 
cells/cm
2
 and cultured with 0.5 mL and 1 mL of culture medium in the upper and in the 
lower chamber, respectively as previously described.
92
  
Cells were treated with compound 73 when the trans-endothelial-electrical resistance 
(TEER) value was found to be the highest. The functional properties of monolayers were 
assessed by measuring the endothelial permeability of sucrose (between 0-180 min) as 
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described in literature.
89
 0.5 mL of 9.4 and 94 µM solution of compound 73 were added to 
the upper chamber and incubated between 0 and 180 min. After these periods of 
incubation, the fluorescence in the upper and lower chambers was measured (λex = 280 
nm) to calculate the endothelial permeability (PE) across the cell monolayers, taking 
account of the passage of compound 73 through the filter without cells.
89
 Each experiment 
was performed at least in triplicate. All the transport studies have been replicated in the 
presence of a paracellular marker [
14
C]-sucrose, in order to monitor potential toxic effects 
on the BBB exhibited by compound 73. 
 
Figure 3.18: PE values of compound 73 9.4 and 94 µM across the cell monolayers and PE values of sucrose 
100 µM alone and in presence of compound 73. 
The Aβ ligand compound 73 does not affect the tightness of the hCMEC/D3 cell 
monolayer, since the TEER value and the permeability of [
14
C]-sucrose did not change, 
within the experimental error (<3%), after hCMEC/D3 incubation with compound 73    
(PE sucrose=1.38±0.1x10
-3
 cm/min and in presence of curcumin derivative, PE sucrose= 
1.40±0.1x10
-3
 cm/min). hCMEC/D3 cells, grown on transwell membrane inserts, were 
incubated with fluorescent Aβ ligand compound 73 on day 12, when the maximal TEER 
value was registered (68±8 Ω∙cm2). Transport of [14C]-sucrose was measured, with PE 
values of 1.38±0.2x10
-3
 cm/min in agreement with the values reported in literature.
93
  
Different amounts of compound 73 were added in the upper compartment and amount in 
the lower compartment has been measured over time at 0, 60 and 180 min. The PE of 
fluorescent Aβ ligand compound 73 across the cell monolayers was                  
3.03±1.19x10
-3
 cm/min and 1.69±0.59x10
-3
 cm/min and these values are strictly correlated 
to the administered amount within the upper compartment respectively 94.0 µM vs         
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9.4 µM. The PE of compound 73 were closer of those of the transcellular marker 
propranolol, a reference point in term of lypophilic compound which can permeate the 
BBB.
93
 
3.1.3.3 Staining  
The ability of compound 73 to bind amyloid deposits was tested in brain sections from Tg 
CRND8 mice. This test was done in collaboration with Department of Molecular 
Biochemistry and Pharmacology, Mario Negri Institute for Pharmacological Research. Tg 
CRND8 mice carry a human APP with double mutations and accumulate Aβ deposits in 
brain parenchyma and at cerebrovascular level. Cryostatic sections of 20 µm were obtained 
from fresh tissue, mounted on gelatin coated microscope slides and used for a staining 
assay. Solutions of EtOH:H2O 50:50 (v/v) of test compound were layered on tissue 
sections. Fluorescent sections were viewed using fluoromicroscope equipped with FITC 
and DAPI filters. ThT at 3 µM was used as a reference. The test compound 73 was able to 
label amyloid plaques and vascular walls at a concentration of 6 µM, obtaining a result 
comparable to thioflavin (ThT) staining. These results suggested that tested compound 73 
is able to recognize the β-pleated sheet structure of amyloid fibrils similarly to ThT and 
without being involved in apecific binding to tissue preparations (Figure 3.19). 
 
Figure 3.19: Brain sections of Tg CRND8 mice incubated with ThT (A-B) at 3 μM and compound 73 (C-D) 
at 6 μM. Fluorescent sections were viewed using fluoromicroscope FITC for ThT staining and DAPI for 
compound staining. 
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In conclusion, in this section we demonstrate through NMR experiments the preserved 
ability of derivatives 73 and 74 to bind Aβ, moreover, fluorescence mesurements carried 
out with compound 73 indicate that its favorable physical–chemical properties, in terms of 
balanced hydrophylicity/lipophylicity, allow these compounds to permeate through the 
BBB, most probably exploiting a diffusion mechanism, and to stain amyloid plaques.  
These properties, taken together, suggest that these compounds could be very promising 
candidates for possible future applications both in the therapy and in the diagnosis of AD. 
3.1.3.4  Synthesis of a tricyclic derivative for the assembly of 
liposomes 
As previously discussed, NPs represent a promising tool for the delivery of drugs and/or 
contrast agents, in particular, properly functionalised NPs may be used for the delivery to 
the brain. For this reason we planned to generate nanoliposomes functionalised with our 
Aβ ligands. 
In order to fulfill the aim of this topic we designed and synthesised a derivative of the 
tricyclic product 65 bearing a PEG-cyclooctyne functionality (Scheme 3.9 and 3.10). The 
use of cyclooctyne has been recently reported by Bertozzi and co-workers.
94
 The choice 
fell on the cyclooctyne moiety for two main reasons: firstly because the liposomes adopted 
in the project are properly functionalized with an azido group that will chemoselectively 
react with the alkyne, secondly because the tensioned cyclooctyne entity allows to carry 
out the reaction without the use of the Cu(I) catalyst, which renders the product 
purification very difficult.
95-97
  
According to literature,
98
 bicyclic compound 88 was synthesized from commercial 
available cycloheptene 87. Silver perchlorate was then used to carry out the electrocyclic 
ring-opening of 88 to the trans-allylic cation, which was captured with tetraethylene glycol 
affording (E)-bromocyclooctene 89. The 
1
H NMR spectrum of 89 clearly shows a signal at 
6.18 ppm characteristic of the vinylic proton. Cyclooctyne PEG 90 was obtained in dry      
i-PrOH at rt using t-BuOK as the base (Scheme 3.9). 
13
C NMR spectrum of 90 shows the 
characteristic C≡C signals at 100.5 and 92.8 ppm. Mesylation of cyclooctyne PEG 90 with 
MsCl in dry CH2Cl2 followed by a substitution reaction with potassium thioacetate in dry 
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DMF afford thioester 92, which was subject to reduction with LiAlH4 affording the 
correspondent  thiol 93 (Scheme 3.9).   
 
 
Scheme 3.9. reagents and conditions: a) CHBr3 (1.0 equiv.), t-BuOK (1.15 equiv.), dry pentane, 0ºC,    
6 h; b) tetraethylene glycol (30.0 equiv.) AgClO4 (3.0 equiv.), dry toluene, dry pyridine, 4 h, reflux, 54% 
(2 steps); c) t-BuOK (2.5 equiv.), dry i-PrOH, 60 h, rt, 84%; d) MsCl (1.2 equiv.), Et3N (1.5 equiv.), dry 
CH2Cl2, 0ºC-rt, 3 h; e) potassium thioacetate (2.1 equiv.), dry DMF, rt, 2h, 74% (over 2 steps); f) LiAlH4 
(5.0 equiv.), dry THF, 0ºC, 15 min. 
Compound 65 was first selectively bromoacetylated
99
 at the primary hydroxyl group, to 
give intermediate 78 (55 %). Treatment of the latter with the crude thiol 93 in dry DMF 
afforded compound 94 (77 %) (Scheme 3.10). The 
1
H NMR spectrum of 94 shows a signal 
at  3.35 ppm corresponding to C=OCH2S, while 
13
C NMR spectrum of 94 shows the 
characteristic C≡C signals at 100.2 and 93.1 ppm, and the OCO signal at 170.6 ppm.  
 
 
Scheme 3.10. reagents and conditions: a) bromoacetyl bromide (1.3 equiv.), sym-collidine (1.4 equiv.), dry 
DMF, -45ºC, 40 min., 55%; b) CsCO3 (1.1 equiv.), thiol 93 (1.5 equiv.), rt, 40 min., 77%. 
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3.1.3.5 Generation of liposomes 
In collaboration with Dr. S. Mourtas from the group of Professor S. Antimisiaris of the 
Laboratory of Pharmaceutical Technology, University of Patras, Greece (UPAT), 
functionalized liposomes were obtained by simply reacting the liposome bearing the azido-
PEG-lipid 95 and the glycofused tricyclic-PEG-cyclooctyne derivative 94 in PBS 
buffer/DMSO.  
 
 
Figure 3.20: Azido-PEG-lipid and glycofused tryciclic-PEG-cyclooctyne. 
Liposome preparation 
The thin film method was used for multilamellar liposome (MLV-range from 500 to 
10,000 nm) preparation. Probe sonication was used in order to prepare unilamellar small 
liposomes (SUV) approximately 50-100 nm. Calcein encapsulated liposomes were 
prepared in order to measure liposome integrity, control liposomes without 94 or 94 
decorated liposomes. Liposome dispersions were purified from non-encapsulated calcein 
by column chromatography.  
For the case of liposomes with lipid-peg-N3 95, the latter was incorporated in liposome 
membrane in 5% and 20% (half of the azido groups should be on the outer surface of 
liposomes and half inside) during thin film formation. This means that final liposomes will 
have 2.5% or 10% of lipids with an azide group available to react with cyclooctyne 
moieties. It was found that reaction of 94 with SUV liposomes 96 (Scheme 3.11) results in 
moderate yields with available N3-groups. 
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Scheme 3.11. reagents and conditions: a) PBS pH=7.4, 32ºC, 48h, 58%. 
In this synthesis different reaction conditions, especially different lipid ratios were 
considered and the reaction was monitored at different times. The lipid concentration is 
measured by the Stewart method and shows the total lipid concentration of the prepared 
liposomes (Stewart method measures mostly phospholipids). 
Time of reaction Lipid concentration 
6h 2.5 mg/mL 
6h 10 mg/mL 
24h 2.5 mg/mL 
24h 10 mg/mL 
48h 2.5 mg/mL 
48h 10 mg/mL 
The reaction product was identified using ESI-MS, while the liposome reaction efficiency 
was monitored using 
1
H-NMR on decorated liposomes 97. After purification by dialysis to 
remove all unreacted ligand, liposomes were dissolved in methanol and a selected peek 
integrated. In particular we were interested in evaluating the percentage of azido group 
reaction. To do this we identified a peek belonging to the azido linker which integration we 
set equal to 1, and quantified the reaction integrating the formation of the new peak, which 
was correlated to the proton signal from the glycofused tricyclic (Figure 3.21)  
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Figure 3.21: 
1
H NMR quantification of azido group reaction with glycofused tricyclic derivative 94. 
Best results correspond to 58% azido conversion at 48 h 10 mg/mL lipid concentration 
(Figure 3.22). 
 
Figure 3.22: Quantification of azido group reaction with glycofused tricyclic derivative 94.. 
Liposome compositions 
(96 Before click reaction):  
1,2-dipalmitoyl-sn-glycero-3-
phosphocholine/Cholesterol DPPC/Chol (1:1)   
Lipid-Peg1000-OMe (4 mol%)  
Lipid-Peg-N3 (5 mol%) 
(97 After click reaction):  
DPPC/Chol (1:1)   
Lipid-Peg1000-OMe (4 mol%)  
Lipid-Peg-N3 96 (2.5 mol % not reacted)  
Lipid-97 (2.5 mol %) 
Liposome control: 
DPPC/Chol (1:1) 
Lipid-Peg1000-OMe (9 mol%) 
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Liposome characterization 
Decorated (2.5%) liposomes 97 were characterized by dynamic light scattering (DLS) 
(Malvern Nano-ZS, Malvern Instrument, UK) at 25
ο
C at 175
ο
 angle for size distribution, 
polydispersity index (PdI) and zeta-potential (Table 3.3). According to these findings, the 
mean diameter of the decorated (2.5%) liposomes 97 during storage at 4ºC was stable at 
least for a period of 7 days. Some evidence of liposome aggregation was seen after 16 days 
of storage (PdI≈0.35). However, bath sonication for a few minutes (1-5 min) of liposome 
97, leads to their complete disaggregation (PdI≈0.17). 
Table 3.3: Characterization of decorated liposome 97 [DPPC/Chol (1:1) + 4% 
DSPE-PEG1000-OMe + 2,5% 95 + 2,5% 97]. 
storage 
period 
(days) 
Liposome 
treatment 
Diameter 
(nm) 
PdI 
z-potential 
(mV) 
0 - 153.9 ± 0.4 0.22 -2.64 ± 0.064 
1 - 157.3 ± 1.8 0.31 -2.54 ± 0.044 
7 - 148.8 ± 2.2 0.24 -2.37 ± 0.141 
16 - 155.6 ± 1.8 0.35 -2.45 ± 0.021 
21 sonication 127.12± 0.17 0.17 -2.52 ± 0.034 
Calcein release from vesicles was used in order to measure SUV-liposome integrity. Thus 
liposomes 97 and the corresponding control liposomes (without 94) were incubated in 
presence of serum proteins (at 37
o
C for 48 h). The results are presented in Figure 3.23.  
 
Figure 3.23: Liposome integrity. 
As can be seen, although decorated liposomes 97 seem unstable during incubation at 37
o
C, 
these are very stable in presence of plasma proteins, even after 48 hours of incubation, 
indicating that these liposomes can be used for further in vivo experiments. 
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The use of DSPE-PEG2000-OMe instead of DSPE-PEG1000-OMe at the same percentage 
(8% in both cases), did not affect size stability even after prolonged storage according to 
the following results (Table 3.4). 
Table 3.4: Characterization of decorated liposome 97 [DPPC/Chol (1:1) + 
8% DSPE-PEG2000-OMe + 10% 95 + 10% 97]. 
Storage 
period 
(days) 
Liposome 
treatment 
Diameter 
(nm) 
PdI 
z-potential 
(mV) 
1 - 174.8 ± 0.07 0.199 -2.50 ± 0.034 
8 - 178.7 ± 0.141  0.213 -1.71 ± 0.454  
11 - 191.4 ± 1.202  0.268 -1.96 ± 0.134  
15 sonication 204.6 ± 1.626  0.309 -1.78 ± 0.346  
Some aggregation is seen at 15 days. Normally (like in Table 3.3) the liposomes will be 
disaggregated after a few probe sonication (1-5 min), but we will keep the experiment for 
15 more days and then sonicate.  
A novel, very simple method, was developed in order to covalently attach a tricyclic 
derivative 94 on liposome surfaces. Such attachment may increase the binding affinity for 
Aβ, due to multivalency, and/or allow the preparation of dual decorated NPs. The 
synthesized decorated nanoliposomes 97, demonstrated high size stability at 4
o
C and high 
integrity (retention of encapsulated calcein) at 37
o
C in the presence of plasma proteins, 
revealing either possible interactions of decorated nanoliposome 97 with plasma serum 
proteins, preventing the usual action of plasma proteins on nanoliposomes, or approach 
difficulties of proteins on the decorated 97 nanoliposome surface.  
3.1.3.6 Decorated liposomes NMR binding studies 
Previously were described STD-NMR interactions studies on glyco fused tricyclic 
derivatives, with or whithout functionalization with a lipophilic entitie. The same 
methodology has been applied herein to check the effect of decorated lipsome 97 on the 
Aβ(1-42) oligomer recognition process. In particular, the interaction studies with the Aβ(1-
42) were carried out using Water-Ligand Observed via Gradient Spectroscopy (Water-
LOGSY) experiment. In a Water-LOGSY experiment, the NMR resonance of the water is 
selectively excited and the magnetization is allowed to be transferred by NOE to all other 
protons. The water magnetization is transferred by NOE to the protein and from there to 
the ligand (spin-diffusion). In this experiment, the resonances of non-binding compounds 
Synthesis of new A-ligands useful in diagnosis of Alzheimer’s Disease 
78 
appear with opposite sign and tend to be weaker than those of the interacting ligand. The 
ligand is used in very large excess over the protein so that the protein is not observable in 
the NMR spectrum.
100,101
 
Water-LOGSY experiments were performed using ligand:peptide 20:1 mixtures dissolved 
in deuterated PBS, pH=7.4, 25°C. In the water-LOGSY experiments acquired in the 
presence of A, was observed the presence of tricyclic aromatic signals, which are absent 
in the corresponding spectra of the lyposome preparation alone, meaning that there is 
interaction between the tricycle on the liposome surface and A (Figure 3.25).  
 
Figure 3.24: Decorated liposomes 97, PBS, pH=7.4, 25ºC: 
1
H NMR spectrum (3); water-LOGSY NMR 
spectrum with 1.2 s mixing time (2); water-LOGSY NMR spectrum with 1.6 s mixing time (1). 
 
Figure 3.25: A1-42) 80 μM with decorated liposomes 97, PBS, pH=7.4, 25ºC: 1H NMR spectrum (3); 
water-LOGSY NMR spectrum with 1.2 s mixing time (2); water-LOGSY NMR spectrum with 1.6 s mixing 
time (1). 
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 Synthesis of glycofused tetracyclic derivatives 3.2.
The scope of this section is to develop synthetic procedures that will allow the generation 
of tetracyclic glucofused compounds. Many natural and synthetic compounds of biological 
interest bear a linear fused tetracyclic structure, part of which displays an aromatic 
character. Among them tetracyclines (TCs) and anthracyclines constitute two families of 
compounds that have found wide application in pharmaceutical field. Anthracyclines are 
glycoconjugated molecules that constitute a family of natural compounds in which the 
aglycon is characterized by a tetracyclic system with a skeleton of 7,8,9,10-
tetrahydrotetracene-5,12-quinone, the anthracyclinone.
102,103,104
 They differ in the aglycone 
and in a wide array of attached sugar residues. The high scientific and industrial interest in 
anthracyclines arise from their remarkable pharmaceutical properties. Their significant 
activity in the treatment of solid tumors, as well as acute mieloblastic leukemia, made them 
among the most widely used anticancer drugs and the most intensively studied natural 
products over the past 50 years.
103,105
 TCs are a group of structurally related antibiotics, 
discovered in the late 1940s. The basic chemical structure, which characterizes in general 
all TCs is represented by the naphthacene carboxamide nucleus, composed of four linear 
fused hexamerous rings A, B, C and D. Chemical modifications of natural structures and 
synthesis of new compounds produced a number of novel tetracyclines, including 
minocycline and doxycycline, which are the more common semi-synthetic clinical 
antibiotics.
106
 More recently the anti-amyloidogenic activity of TCs was described and 
curiously, these old class of antibiotics which was almost abandoned because of the 
development of resistant bacterial strains, are currently involved in more than 130 clinical 
trials, non-related to their antimicrobial activity.
106
  
This section will center on the development of synthetic methods for the generation of 
glycofused linear tetracyclic systems, analogues of the upper mentioned tetracyclic 
compounds that may find similar pharmacological applications. The introduction of the 
glycofused moiety has the purpose to improve physical-chemical properties, allowing for 
example the modulation of the solubility characteristics, as well as to constitute a 
derivatisable moiety that may allow the conjugation of the compound to other entities 
(NPs, contrast agents, other drugs, etc.) for the generation of novel diagnostic and/or 
therapeutic tools. 
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In particular, as described in the previous sections, being particularly interested in the 
identification of novel Aβ ligands, this section will focus on the synthesis of small 
molecules with a heteroaromatic polycyclic structure which resemble TCs (Figure 3.26). 
These compounds maintain the aromatic feature which is present in a wide range of small 
molecules able to interact with Aβ and which seems to be crucial for the binding 
ability,
67,86
 and at the same time, possess a glycofused entity which confers them ideal 
water solubility properties. 
 
 
Anthracyclines Tetracyclines 
 
 
 
Tetracycline Carbohydrate moiety (e.g. D-Glucose) 
  
 
Figure 3.26: Glycofused tetracyclic structure. 
The strategy it’s aimed to obtain new tetracyclic glycofused compounds starting from new 
glycidic scaffolds (6 and 10) that could be used in a tandem Michael-Dieckmann reaction 
(Scheme 3.12).  
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 Synthesis of a new sugar scaffolds to be employed in tandem Michael-Dieckmann 
reactions or in DA reactions to synthesize new tetracyclic derivatives. 
 
 
Scheme 3.12 
 
3.2.1. Synthesis of the glycofused bicyclic scafffold 6a and 6b  
The synthesis of a suitable Michael acceptor such as 6a according to the retrosynthetic 
analysis is depicted in Scheme 3.13. Methyl -D-glucopyranoside 98 is conveniently 
protected in position 4 and 6 as a p-methoxybenzylidene acetal 99. Orthogonally protection 
of compound 99 with benzyl bromide and selective opening of the p-methoxybenzylidene 
affords compound 101.
107
 Swern oxidation of the free hydroxyl group of 101 leads to 
ketone 102.
108
 Alkylation with allyl magnesium bromide affords compound 103, with a 
60% yield (over 2 steps), the absolute configuration was determined by NMR experiments.  
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Scheme 3.13. reagents and conditions: a) anisaldehyde dimethylacetal (1.2 equiv.), CSA (0.01 equiv.), dry 
DMF, 60ºC, 2 h, 75%; b) BnBr (3.0 equiv.), NaH (3.0 equiv.), dry DMF, rt, 1 h, 96%; c) NaCNBH3            
(5.0 equiv.), TFA (10.0 equiv.), 3Ǻ MS, dry DMF, rt, 12 h, 87%; d) (COCl)2 (4.0 equiv.), dry DMSO      
(8.0 equiv.), dry Et3N (10.0 equiv.), -78ºC, 2 h; e) allylmagnesium bromide 1M Et2O (3.0 equiv.), dry THF, 
-78ºC, 3 h, 60% (over 2 steps); f) CAN (5.0 equiv.), H2O, CH3CN, rt, 20 min., 72%; g) i. (COCl)2 (4.0 
equiv.), dry DMSO (8.0 equiv.), dry Et3N (10.0 equiv.), -78ºC, 2 h; ii. vinylmagnesium bromide 1M THF 
(12.0 equiv.), dry THF,-78ºC, 4 h, 45% (over two steps); h) Hoveyda-Grubbs catalyst 2
nd
 generation (5% 
weight), dry CH2Cl2, 40ºC, 1 h, 89%; i)  MnO2 activated (7.0 equiv.), EtOAc, reflux, 2 h, 91%. 
 
1
H NMR spectrum of compound 103 (Figure 3.27) clearly shows a signal between 5.84 - 
5.57 ppm characteristic of the allylic proton H-2’, which couples with H-3’ at 4.86 ppm, 
and H-1a’ and H-1b’ at 2.66 and 2.34 ppm, corresponding all of them to the allylic 
system. H-1 signal appears at 4.75ppm as a doublet with J = 3.4 Hz, indicating that H-1 
being couple only with H-2. From 2D-COSY, H-2 couples with H-3 at 4.ppm. 
The 2D-NOESY spectrum of compound 103 is shown in Figure 3.28, where a weak NOE 
effect can be observed between H-3 and H-1’, and absence of a NOE effect between H-2 
and H-1’. 
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Figure 3.27: 
1
H NMR spectrum (400 MHz, CDCl3) of compound 103. 
 
 
 
Figure 3.28: 2D-NOESY spectrum (400 MHz, CDCl3) of compound 103. 
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The stereoselectivity of this reaction can be ascribed to the formation of a Cram chelated 
intermediate in which the magnesium ion coordinates the carbonyl group and the benzylic 
oxygen. This has been explained for similar systems by chelation of the magnesium atom 
of the Grignard reagent with the C-4 carbonyl oxygen and the C-3 oxygen atom. The 
chelated oxo sugar assumes a 
4
C1 conformation (Figure 3.29), and equatorial attack of the 
nucleophile dominates over the sterically hindered axial attack.
109
 
Compound 104 was obtained by selective deprotection of primary hydroxyl group of 103 
using cerium (IV) ammonium nitrate (CAN).
110
 Swern oxidation of the alcohol 104 led to 
the formation of an aldehyde, which upon treatment with vinylmagnesium bromide in THF 
at -78°C afforded allylic alcohol 105 as a single diastereomer, which could be isolated in 
45% yield (over 2 steps). Ring closing metathesis (RCM) of diene 105 using Hoveyda-
Grubbs catalyst 2
nd
 generation afforded compound 106. The 
1
H NMR spectrum of the 
bicyclic product 106, isolated in 89% yield, was used to establish the stereochemistry of 
the new chiral center formed in the Grignard reaction used to produce 105. The 
observation of a vicinal coupling between H-7 and H-7a (J = 8.5 Hz), confirmed the 
antiperiplanar orientation of these two protons. Finally oxidation of allylic alchohol 106 
affords ,-unsaturated ketone 6a in 91% yield. 13C NMR spectrum of 6a shows the 
characteristic C=O signal at 193.6 ppm. 
1
H NMR spectrum of compound 106 (Figure 3.30) shows a doublet for proton H-7a at       
 3.61 ppm with a J = 8.5Hz, due to the coupling with H-7 and indicating their trans-
diaxial relationship. Proton H-3 appear at  3.71 ppm as a doublet with a J = 9.5 Hz, 
indicating the expected trans-diaxial orientation with respect to H-2. The signal 
corresponding to H-2 appear at  3.92 ppm as a double doublet with J = 9.5, 3.5 Hz. The 
presence of only two olefinic protons H-6 and H-5 between  5.70 - 5.58 ppm confirmed 
the formation of the expected cyclized product. The allylic protons H-4appear at  2.38 and 
2.08 ppm respectively 
 
Figure 3.29: Cram chelate model for compound 102. 
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Figure 3.30: 
1
H NMR spectrum (400 MHz, CDCl3) of compound 106. 
The synthesis of compound 6b (Scheme 3.14) took advantage of the already know 
aldehyde 110 that was prepared from the known ketone 102 via a sliglithly modified 
literature procedure. This transformation requires Wittig methylenation of 102 to give 
olefin 107 and hydroboration using BH3•Me2S to afford a separable mixture in 4:3 ratio, 
corresponding to the boron placed on the less substituted carbon and the other bearing the 
boron atom placed on the more substituted carbon. A more hindred borane like 9-BBN, 
which could favourable the formation of the desired product was tried; unfortunately 9-
BBN didn’t react with olefin 107. This could be due to steric hindrance of the substrate. 
The resulting alkylborane was treated with hydrogen peroxide in the second step. This 
process replaces the B-C bonds with HO-C bonds, affording compound 108 in 49% yield. 
Oxidation of compound 108 affords the corresponding aldehyde 110 in 98% yield, which 
upon treatment with vinylmagnesium bromide in THF at -78°C afforded alcohol 111 as 
single diastereomer, which could be isolated in 84% yield. 
 
Scheme 3.14. reagents and conditions: a) methyl phenylphosphonium bromide (7.0 equiv.), BuLi (6.5 
equiv.), dry THF, -78ºC, 12 h, 80%; b) BH3•Me2S (1.25 equiv.), NaOH, H2O2 30%, dry THF, rt, 12 h, 49%; 
c) (COCl)2 (4.0 equiv.), dry DMSO (8.0 equiv.), dry Et3N (10.0 equiv.), dry CH2Cl2, -78ºC, 2 h, 98%; (cont.) 
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Scheme 3.14. (cont.) reagents and conditions: d) vinylmagnesium bromide 1M THF (2.5 equiv.), dry THF,         
-78ºC, 90 min., 84%; e) TESCl (1.5 equiv.), imidazole (2.0 equiv.), dry DMF, 60ºC, 1 h, 85%; f) DDQ (1.4 
equiv.), CH2Cl2/H20 (20:1), 0ºC, 3 h, 87%; g) (COCl)2 (4.0 equiv.), dry DMSO (8.0 equiv.), dry Et3N (10.0 
equiv.), dry CH2Cl2, -78ºC, 2 h; h) vinylmagnesium bromide 1M THF (2.5 equiv.), dry THF, -78ºC, 90 min., 
69% (over 2 steps); i) Hoveyda-Grubbs catalyst 2
nd
 generation (5% weight), dry CH2Cl2, 40ºC, 2 h, 84%;     
j) MnO2 activated (7.0 equiv.), EtOAc, reflux, 2 h, 70%. 
Protection of the allyl alcohol 111 with TESCl followed by selectively removal of p-
methoxybenzyl protection group using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), 
results in primary alcohol 113 that was then smoothly oxidized under Swern conditions 
leading to aldehyde 114. Treatment of 114 with vinylmagnesium bromide gave rise to the 
allylic alcohol 115, as a single diastereomer, in 69% (over 2 steps) yield. RCM of diene 
115 using Hoveyda-Grubbs catalyst 2
nd
 generation afforded compound 116, isolated in 
84% yield, that was oxidized with MnO2 to give de desired product 6b in 70% yield.  
The 
1
H NMR spectrum (Figure 3.31) of the bicyclic product 116 and the corresponding 
2D-NOESY (Figure 3.32) were used to establish the stereochemistry of the new 
stereocenters formed in the Grignard reactions used to produce 111 and 115. The 
observation of a small vicinal coupling in 
1
H NMR between H-7 and H-7a confirmed the 
cis orientation of these two protons.  
The double doublet corresponding to proton H-2 at 3.71 ppm (J = 9.1, 3.7 Hz) has a NOE 
cross-peak found in the 2D-NOESY experiment with a double doublet matching to proton 
H-4 at 4.39 ppm (J = 6.3 Hz), which allow to determining the right stereochemistry of 
that assymetric carbon as being the one depicted in Figure 3.31. Another evidence is the 
absence of cross-peaks between proton H-4 and proton H-3 3.94 ppm. 
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Figure 3.31: 
1
H NMR spectrum (400 MHz, CDCl3), T=19ºC, of compound 116. 
 
 
Figure 3.32: 2D-NOESY spectrum (400 MHz, CDCl3), T=25ºC, of compound 116. 
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3.2.2. Synthesis of glycofused bicyclic scafffold 10a and 10b 
The synthesis of scaffold 10a starts from α-allyl-C-glucoside 117 which can be easily 
obtained by a Sakurai reaction
111
 from methyl -D-glucopyranoside 98. Benzylation of 
117, followed by selective debenzilation of C-2 hydroxyl group using a well established 
iodocyclization reaction followed by reductive elimination (I2, then Zn and AcOH) 
afforded derivative 120.
112
 This selective deprotection was exploited for the introduction of 
a second double bond (Scheme 3.15). Oxidation of alcohol 120 afforded the corresponding 
ketone 121, which was subject to a Grignard reaction with allylmagnesium bromide in 
toluene:CH2Cl2 (2:1)
113
 affording a separable mixture of tertiary alchohols 122a and 122b 
(68:32 ratio, 85%), in favor of the D-manno configured isomer 122a, (the absolute 
configuration was determined by NMR experiments). RCM of 122a using a second-
generation Grubb’s catalyst (5% weight) at 40°C in CH2Cl2 afforded the expected cyclized 
product 123 in 88% yield. The presence of only two olefinic protons at  5.53 ppm and  
5.49 ppm as two broad singlets for these two protons in its 
1
H NMR spectrum confirmed 
the formation of the expected cyclized product. Debenzylation of 123 with BCl3 at -78ºC in 
CH2Cl2 produce bicyclic product 124, which was then acetylated affording compound 125 
in 80% yield. Allylic oxidation of 125 was achieved using commercially available 
manganese(III) acetate dihydrate as the catalyst and TBHP as the cooxidant at room 
temperature.
114
 3Å molecular sieves were added to remove the trace amount of water. 
After 48 h the ,-unsaturated compound 10a was obtained in 52% yield. 13C NMR 
spectrum of 10a shows the characteristic C=O signal at 196.4 ppm. 
The major diene 122a has the allyl group at C-2 equatorially oriented. Its 
1
H NMR 
spectrum showed a clean doublet at  3.60 with J = 7.8 Hz, indicating that proton H-3 
couples only with H-4 and thus must be trans-diaxial to each other. Proton H-1a’’ 
appeared as a double doublet at  2.74 ppm with J = 14.6, 5.6 Hz, and proton H-2’’ 
appeared as a multiplet at  6.12–5.68 ppm. The 2D-NOESY spectrum for the derivative 
122a (Figure 3.33) showed a cross-peak between H-3 and H-1a’’, H-1b’’, and of H-1a’ and 
H-1b’. Also evident is the absence of a cross-peak between proton H-4 and protons H-1a’’ 
and H-1b’’. Likewise, the structure of the minor compound 122b was established on the 
basis of its spectral data. 
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Scheme 3.15. reagents and conditions: a) BTSTFA (3.0 equiv.), AllSi(CH3)3 (2.0 equiv.), TMSOTf (0.5 
equiv.), dry CH3CN, 60ºC–rt, 12 h, 75%; b) BnBr (5.0 equiv.), NaH 60% (5.0 equiv.), dry DMF, rt, 12 h, 
80%; c) I2 (5.0 equiv.), dry CH2Cl2, rt, 90 min.; d) Zn (10.0 equiv.), AcOH glacial (2.0 equiv.), 
Et2O:MeOH (1:1), 3 h, rt, 74% (over 2 steps); e) (COCl)2 (4.0 equiv.), dry DMSO (8.0 equiv.), dry Et3N 
(10.0 equiv.), dry CH2Cl2, -78ºC, 2 h, 89%; f) allylmagnesium bromide 1M Et2O (2.5 equiv.), dry 
toluene:CH2Cl2 (2:1), -78ºC, 3 h, 85%; g) Hoveyda-Grubbs catalyst 2
nd
 generation (5% weight), dry 
CH2Cl2, 40ºC, 90 min., 88%; h) BCl3 (12.0 equiv.), dry CH2Cl2, -78ºC–rt, 12 h, 71%; i) Ac2O (10.0 
equiv.), DMAP (cat.), dry Py, rt, 80%; j) t-BuOOH 6.0M decane (5.2 equiv.), Mn3(OAc)9·2H2O (0.1 
equiv.), 3Ǻ MS, dry EtOAc, 48 h, 52%. 
 
Figure 3.33: 2D-NOESY (400 MHz, CDCl3) of compound 122a. 
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For the synthesis of Michael acceptor 10b (Scheme 3.16), O-methyl--D-glucopyranoside 
was transformed into compound 107 according to know procedures.
115
 Dihydroxylation of 
107 with OsO4/N-methylmorpholine N-oxide (NMO) led exclusively to -face attack 
furnishing derivative 126.
116
 Protection of the free hydroxyl groups with acetone 
dimethylacetal affords compound 127 in 77% yield (over 2 steps). Selective cleavage of 
PMB group, provides compound 128 which was oxidized to the corresponding aldehyde 
129, and subject to a Grignard reaction with vinylmagnesium bromide in THF affording 
allylic alchohol 130, in 80% yield (over 2 steps), as a single diastereoisomer. 
1
H NMR 
spectrum showed a clean doublet at  3.44 ppm with J = 4.3 Hz indicating that proton H-5 
couples only with H-6 and thus must be on the same side. Allyl alcholol 130 was 
subsequently benzylated with PMBBr affording the derivative 131 in 80% yield (Scheme 
3.16). Cleavage of isopropylidene group forms compound 132 in quantitative yield. To 
achieve the final bicyclic product 10b it will be necessary to oxidize the primary alcohol of 
compound 132, followed by alkylation of the corresponding aldehyde with 
vinylmagnesium bromide to the resultant allylic alcohol. RCM of 133 followed by allylic 
oxidation with MnO2 will originate the desired product 10b. 
 
Scheme 3.16. reagents and conditions: a) OsO4 0.076 M in t-BuOH (0.05 equiv.), NMO (2.1 equiv.), 
H2O:THF (0.5:1.5), rt, 90 min.; b) 2,2-dimethoxypropane (4.0 equiv.), CSA (0.1 equiv.), dry Et3N (4.0 
equiv.), dry CH3CN, rt, 20 min., 77% (over 2 steps); c) CAN (5.0 equiv.), H2O, CH3CN, rt, 20 min., 82%; d) 
Dess-Martin (1.5 equiv.), CH2Cl2, rt, 30 min.; e) vinylmagnesium bromide 1M THF (2.5 equiv.), dry THF,   
-78ºC, 1 h, 80% (over 2 steps); f) PMBBr (1.2 equiv.), NaH (1.2 equiv.), dry DMF, 60ºC, 1 h, 80% ; g) 
AcOH 60%, THF, 60ºC, 6 h, 100%. 
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The 2D-NOESY spectrum of product 127 was used to establish the correct stereochemistry 
of the dihydroxylation reaction of compound 107. A cross-peak between H-2 and H-1’a, 
and between H-1’b and H-6b (Figure 3.34) confirmed the introduction of the C-4 OH from 
the α face. 
 
Figure 3.34: 2D-NOESY spectrum (400 MHz, CDCl3) of compound 127. 
Within this section were developed three different synthetic procedures for the synthesis of 
bicyclic glycofused scaffolds 6a, 6b and 10a. In relation to compound 10b, we weren’t 
able to reach the desired scaffold due to fact of having reached the end of time for this PhD 
project. Bicyclic glycofused compounds 6a, 6b and 10a were synthesized in a 
straightforward manner (Figure 3.35). These compounds will be used to synthesize the 
corresponding tetracyclic derivatives, taking advantage of the ,-unsaturated ketones, that 
can be used as Michael acceptors for the Michael-Dieckmann annulation or as dienophiles 
for the DA reaction. 
 
Figure 3.35: Synthesized glycofused bicyclic compounds 6a, 6b, 10a. 
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3.2.3. Synthesis of the Michael donors 
The condensation of o-toluate anions (e.g. precursor 5) with various Michael acceptors 
(e.g. compound 6a) represents an useful and well established protocol for the synthesis of 
polycyclic natural products. An absolute requirement for the toluate is the presence of a 
substituent (usually OR) at the R
2
 position (Scheme 3.17).  
 
Scheme 3.17 
Without it, rapid dimerization of the anion (X=R
2
=H) takes place. The scope and 
limitations of this attractive annulation were established by the pioneering research of 
Hauser, Staunton, and Weinreb.
107,117,118
 Additional methoxy groups were tolerated (e.g., 
R
1
=R
2
= OMe, X=H) and the ester could be varied (R=Me, Et, Ph).
119
 
Herein is described the synthesis of two analogs for precursor 5. The first precursor, 
compound 137 (Scheme 3.18), was prepared from the commercially available nitro 
compound 134 in five steps. Therefore, compound 135 was transformed to phenol 136 via 
hydrogenation followed by diazotization.
120
 Compound 136 was then treated with 
diazomethane in ether to yield the corresponding methyl ester 137.
121,122
 It is noteworthy 
that the phenolic hydroxyl group remains unaffected during the etherification with 
diazomethane, which is probably due to strong intramolecular hydrogen bonding. Phenol 
137 was then protected with Boc anhydride to provide methyl ether 138.
123
 Compound 
138, on bromination with N-bromosuccinimide (NBS) in the presence of a catalytic 
amount of 2,2’-azobisisobutyronitrile (AIBN) yielded 139 in 62% yield. 
 
Scheme 3.18. reagents and conditions: a) Pd/C, H2, MeOH, rt, 12 h; b) NaNO2 (1.1 equiv.), 10% H2SO4 in 
water, -5ºC to 70ºC, 2 h, 81% (over 2 steps); c) CH2N2/diethyl ether, 0ºC, 2 h, 96%; (cont.)  
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Scheme 3.18 (cont.) reagents and conditions: d) Boc2O (1.02 equiv.), DMAP (0.05 equiv.), hexane, rt, 2 
h, 75%; e) NBS (1.1 equiv.), AIBN (cat.), CCl4, 2.5h, 62%. 
The second o-toluate anion precursor 143 was synthesized as depicted in Scheme 3.19 in 3 
steps, starting from 2,3-dimethylanisole.
124,125
 Commercial available 2,3-dimethylanisole 
140 was selectively oxidized to the corresponding aldehyde 141 by copper(II) sulfate 
pentahydrate and potassium peroxydisulfate, followed by oxidation to the corresponding 
carboxylic acid 142 using sulfamic acid in water/THF. Subsequent esterification afford 
phenyl ester 143 in 54% overall yield. 
 
Scheme 3.19. reagents and conditions: a) CuSO4·5H2O (1.02 equiv.), K2S2O8 (3.18 equiv.), CH3CN/H2O 
(1:1), 75ºC, 1 h, 85%; b) H2NSO3H (1.34 equiv.), NaClO4 (1.3 equiv.), H2O/THF (2:1), rt, 1 h, 70%; c) 
(COCl)2 (4.0 equiv.), PhOH (2.0 equiv.), DMAP (2.0 equiv.), dry DMF, dry CH2Cl2, rt, 24 h, 91%. 
3.2.4. Synthesis of benzocyclobutenol precursor  
Benzocyclobutenols are important in natural product syntheses since undergo ring opening 
to the reactive ortho-quinodimethanes (oQDMS) 8 which readily undergo inter- and 
intramolecular DA reactions. oQDMs have been extensively studied over the last 40 years 
in order to design intra- and intermolecular DA reactions for synthesizing target complex 
molecules, including steroids, alkaloids, and anthracyclines.
126-129
 As cis-dienes, oQDMs 
have a remarkable DA reactivity and are often used as building blocks in the syntheses of 
cyclic organic compounds. 
Here is describe the synthesis of benzocyclobutenol 147, present in literature (Scheme 
3.20).
130
 Epoxide 145 was prepared by reaction of sulfur ylide, generated from the 
corresponding sulfonium salt with 2’-bromoacetophenone 144. Epoxide 145 was then 
converted in intermediate benzocyclobutenol 146, using MgBr2•Et2O and BuLi at -78ºC in 
dry THF. Finally protection of the secondary hydroxyl group in compound 146 as silyl 
ether, give the desired product 147 in 54% yield. 
Synthesis of new A-ligands useful in diagnosis of Alzheimer’s Disease 
94 
 
Scheme 3.20. reagents and conditions: a) trimethylsulfoxonium  iodide (1.3 equiv.), NaH (1.3 equiv.), dry 
DMSO, 48 h, rt, 86%; b) MgBr2•Et2O (2.0 equiv.), BuLi 1.6M (1.1 equiv.), dry THF, -78ºC, 60%; c) 
TESOTf (1.3 equiv.), dry Et3N (1.5 equiv.), dry CH2Cl2, rt, 30 min. 54%. 
The 2D-NOESY spectrum of product 147 (Figure 3.36) shows the respective cross-peak 
between CH-OR and CH3. 
 
Figure 3.36: 2D-NOESY spectrum (400 MHz, CDCl3) of compound 147. 
3.2.5. Michael-Dieckmann reaction approach 
Michael-Dieckmann cyclization reaction
121,127,128
 of compound 139, which will form the o-
toluate anion once reated with a strong base as BuLi, with the Michael acceptor 6a 
provided the formation of compound 148 instead of the desired glycofused tetracyclic, as 
depicted in Scheme 3.21.  
 
Scheme 3.21. reagents and conditions: a) 139 (3.0 equiv.), BuLi 1.6 M (8.0 equiv.), dry THF, -78ºC-rt, 12 
h, 52%. 
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This might be due to the fact that the methyl ester present in the aromatic ring of 
compound 139 is not a good leaving group and also to the fact that compound 6a has a 
hydroxyl group in anti-periplanar position to the proton in  to a carbonyl group which 
favors the elimination product. 
1
H NMR spectrum of compound 148 (Figure 3.37) shows a 
doublet at 4.8 ppm (J = 2.3 Hz) characteristic of anomeric proton H-1, which couples 
with H-2, a double doublet at 3.82ppm (J = 8.0, 2.3 Hz). 
From 2D-COSY, H-3 appears at 4.24ppm as a doublet (J = 8.0 Hz) coupling only with 
H-2. H-10a appears at 2.55 ppm as a double doublet (J = 16.1, 2.6 Hz) and the other H-
10a at 2.2 ppm also as a double doublet (J = 16.1, 11.4 Hz), both coupling each other 
and with H-4a at 2.38 ppm, that appears as a broad multiplet. H-5 potons appear between 
2.82.4 ppm as a multiplet due to the coupling with only H-4a. The H-7 appears at 
7.22 ppm, H-8 at 7.1 ppm as a doublet (J = 8.0 Hz) and H-6 at 7.2 ppm also as a 
doublet (J = 7.6 Hz). 
13
C NMR spectrum cleary shows a peak at 192.9 ppm 
corresponding to the carbonyl group of the ,-unsaturated ketone moiety and at 166.7 
ppm belonging to the carbonyl carbon of the ester group.  
 
Figure 3.37: 
1
H NMR spectrum (400 MHz, CDCl3), T=19ºC, of compound 148. 
This constrains lead to the development of a new synthetic route for the Michael acceptor 
6b as showed in Scheme 3.14, as well as for the o-tuloate anion precursor (Scheme 3.19). 
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The tandem Michael-Dieckmann was carried out by the deprotonation of 143 with LDA in 
the presence of lithium bromide in THF at -78 °C followed by the addition of enone 6b, 
yielding the crude intermediate 149 (not optimized). Unfortunely, it was not manageable to 
purify this product and perform an acurate characterization.  
 
Scheme 3.22. reagents and conditions: a) i-Pr2NH (3 equiv.), BuLi 1.6 M (2.8 equiv.), 143 (3.1 equiv.), dry 
THF, -78ºC, 12 h. 
Nevertheless 
1
H NMR spectrum for the crude product shows a clean triplet at  4.21 ppm 
with J = 6.2 Hz indicating that proton H-4 couples with other two protons, H-4a and H-3a. 
Protons H-5 appeared as a broad signal between  2.38-2.27 ppm and from 2D-COSY it 
only couples with H-4a.  
3.2.. Diels-Alder reaction approach 
The Diels-Alder reaction is considered to be one of the most powerful and reliable 
synthetic strategy to achieve structural and stereochemical complexity. This is testiﬁed to 
by its many applications in total synthesis.
131
 It occupies a position of particular 
importance in the resource of the synthetic organic chemist providing the possibility to 
generate six-membered-rings with high regio- and stereoselectivity, leading to the creation 
of four continuous stereogenic centers in one synthetic operation.
132
 
The reaction is stereospecifically syn (suprafacial) for both the diene and dienophile, endo- 
products are stereoselectively preferred over exo isomers and 1,2-disubstituted products are 
regioselectively preferred over 1,3-disubstituted isomers.
132,133
 
Herein is described the synthesis for the dienophile 155 (Scheme 3.23). Taking advantage 
of previously synthesized compound 6a, an improvement of the overall yield was done by 
methylation of the tertiary hydroxyl group of compound 103, affording compound 150 in 
92% yield. Selective deprotection of primary hydroxyl group of 150 using CAN, afforded 
compound 151 in 82% yield. Selective oxidation of the primary hydroxyl group of 
compound 151 with Dess-Martin leds to aldehyde 152. Alkylation with vinylmagnesium 
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bromide afforded compound 153, with an yield of 94% in a separable mixture of 
diastereomers (R:S 62:38) (the absolute configuration was determined by NMR 
experiments). This mixture was subject to RCM using Hoveyda-Grubbs catalyst 2
nd
 
generation affording compounds 154, which where oxidized to produce the ,-
unsaturated ketone 155 in 95% yield. These changes resulted in an improvement in the 
overall yield from 10% up to 22%. 
1
H NMR spectrum showed the presence of only two 
olefinic protons H-5 [ 6.68 ppm (ddd, J = 10.1, 5.9, 2.1 Hz)] and H-6 [6.06 ppm (dd,     
J = 10.1, 3.1 Hz)].
13
C NMR spectrum of 155 shows the characteristic C=O signal at 
193.8 ppm confirming the formation of the expected product.  
 
Scheme 3.23. reagents and conditions: a) MeI (1.2 equiv.), NaH (2.0), dry DMF, rt, 2 h, 92%; b) CAN, H2O, 
CH3CN, rt, 20 min., 82%; c) Dess-Martin, CH2Cl2, rt, 1 h, 89%; d) vinylmagnesium bromide 1M THF (2.5 
equiv.), dry THF, -78ºC, 1 h, 94%; e) Hoveyda-Grubbs catalyst 2
nd
 generation (5% weight), dry CH2Cl2, 
40ºC, 2 h, 97%; f) MnO2 activated (7.0 equiv.), EtOAc, reflux, 2 h, 95%. 
Benzocyclobutenol 147 in 1,2-dichlorobenzene at 160ºC generates intermediate oQDM 
156, which readily undergo DA reaction with dienophile 155, producing glycofused 
tetracyclic compound 157 in 74% yield, and traceless amount of the other diastereomer. 
 
Scheme 3.24. reagents and condtions: 1,2-dichlorobenzene, 160ºC, 90 min., 74%. 
The stereochemistry of the new stereocenters for compound 157 formed in the DA reaction 
was determined by 
1
H NMR and 2D-NOESY spectrum. 
1
H NMR spectrum showed H-10a 
at  3.21 ppm as a broad triplet with J = 8.2 Hz. The 2D-NOESY experiment (Figure 3.38) 
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of the tetracyclic compound 157 showed a cross-peak between H-5 and H-4a, H-5 and H-
10a, and H-5 and H-10, thus all these protons are on the same side. Absence of a cross-
peak between H-10a and H-11a is consistent with the anti-conformation of these protons. 
Finally 
13
C NMR spectrum of 157 shows the characteristic C=O signal at 203.3 ppm.  
 
Figure 3.38: 2D-NOESY (400 MHz, CDCl3) of compound 157. 
Silyl ether cleavage from glycofused tetracyclic 157, revealed to be tricky (Scheme 3.25). 
The deprotection of silyl ethers is usually carried out with tetrabutylammonium ﬂuoride 
(TBAF), aqueous acid, aqueous HF–CH3CN or various Lewis acids. Many other methods 
have also been reported including catalytic transfer hydrogenation using Pd as catalyst, 
reductive cleavage by diisobutylaluminium hydride (DIBAL-H) and oxidative cleavage by 
DDQ. 
134,135
 Tetracyclic 157 possesses a leaving group (R-OMe) in anti-periplanar position 
to a hydrogen in -position to a carbonyl group. Thus using basic conditions will engage 
the formation of elimination products, which were confirmed using TBAF in dry THF that 
formed a separable mixture of two elimination products (Scheme 3.25 c)). Thus, the 
cleavage of this silyl ether must be done in neutral conditions. Two procedures were tried, 
one using a solution of H2O:THF:AcOH and TBAF, and the other using NaIO4 in 
THF:H2O, both procedures revealed not be effective (Scheme 3.25 a) and b)). The last 
procedure that was tried was the catalytic transfer hydrogenolysis using Pd as catalyst.
136
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This procedure led to the cleavage of benzyl ethers, but unfortunately triethylsilyl ether 
remained untouched (Scheme 3.25 d)). 
 
 
Scheme 3.25: reagents and conditions: a) H2O:HOAc:THF (3:5:11), TBAF 1M in THF (0.8 equiv.), rt, 2 h; 
b) NaIO4 (6.0 equiv.), THF:H2O (4:1); c) TBAF 1.0M in THF (1.1 equiv.), dry THF, 5ºC, 1 h, 75% (overall 
yield); d) Pd/C (10%), H2, EtOAc:MeOH (1:9), AcOH, rt, 24h. 
Within this section were described different procedures to accomplish the formation of 
glycofused tetracyclic structures. Michael-Dieckmann annulation gave promising results 
that will be improved for the subsequent synthesis of the desired products. Concerning DA 
approach, it was synthesized a glycofused tetracyclic structure 157, unfortunatley 
deprotection of group OTES revealed to be complicated. Protective group manipulation of 
diene 147 will be attempt. It was also synthesized promising glycofused bicyclic structures 
6a, 6b and 10a that could be used for the synthesis of natural compounds.  
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4. Conclusions and future perspectives 
 
 
 
 
 Conclusions 4.1.
This very last section summarises the scientiﬁc results of the research done in the 
framework of this PhD dissertation. At the same time provides some outlooks for further 
continuation of this research.  
Glycofused tricyclic compounds 
Synthesis of a small library of glycofused tricyclic compounds was accomplished and their 
interaction with amyloid-beta peptide (A(1-42) evaluated by saturation transfer 
difference - nuclear magnetic resonance (STD-NMR) experiments. Several NMR of 
compounds 61-70 appeared in the STD spectra recorded in the presence of Aβ oligomers, 
showing their ability to recognize and bind Aβ(1-42) , with the notable exception of 
compound 62, whose signals are absent. In agreement with the STD results, all 2D 
transferred nuclear Overhauser effect spectroscopy (tr-NOESY) spectra of compounds 61-
70 acquired in the presence of Aβ(1-42) showed the key change, from positive to negative, 
of the corresponding cross-peak signs, except for compound 62. According to the STD 
relative intensities, the region of the ligand mainly involved in the interaction with Aβ(1-
42) (the binding epitope) is the aromatic ring, while protons of the saccharide portion 
showed the least intense STD signals. These evidences explain why the stereochemistry of 
sugar carbons does not influence the binding affinity, while the polarity of the aromatic 
substituents, as previously stated, plays a crucial role in the interaction. 
Fluorescent derivative 73 was synthesized, in order to perform blood brain barrier (BBB) 
passage studies. Fluorescency measurements carried out with this compound indicate that 
its favorable physical–chemical properties, in terms of balanced hydrophylicity/ 
lipophylicity, allow this compound to permeate through the BBB, most probably exploiting 
a diffusion mechanism, and to stain amyloid plaques.   
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STD spectra of nanoliposomes functionalised with our Aβ ligands also clearly demonstrate 
their ability to recognize and bind Aβ(1-42). 
These properties, taken together, suggest that these compounds could be very promising 
candidates for possible future applications both in the therapy and in the diagnosis of 
Alzheimer’s disease (AD). 
Glycofused tetracyclic compounds 
Three new glycofused bicyclic scaffolds were synthesised. Bicycle 6a was obtain in nine 
steps starting from methyl -D-glucopyranoside in 10% overall yield. Bicyclic compounds 
6b and 10a were obtain in thirteen and in ten steps respectively, in 10% and 5.2% overall 
yield. For the synthesis of tetracyclic compounds, bicyclic structures 6a and 6b reactivity 
was explored in a tandem Michael-Dieckmann reaction with o-toluates 139 and 143. 
Structure 6a revealed not to be a promising structure when reacted with compound 139. 
The synthesis of a tetracyclic structure wasn’t achieved possibly mainly due to the fact that 
the methyl ester present in the aromatic ring of compound 139 is not a good leaving group 
and also to the fact that compound 6a has a hydroxyl group in anti-periplanar position to 
the proton in  to a carbonyl group which favors the elimination product. Structure 6b 
which doesn’t possess the problems of compound 6a, demonstrated to be propitious as 
Michael acceptor, when reacted with compound 143. Even if wasn’t manageable to purify 
the product and do a more accurate characterization, this positive preliminary results 
encourage to continuing exploring this approach. The second method exploited to 
synthesize glycofused tetracyclic structures considered the Diels-Alder reaction of bicyclic 
compound 6a with oQDM precursor 147. This approach led to the synthesis of the first 
tetracyclic derivative 157 in 74% yield. Silyl ether cleavage revealed to be delicate and 
neutral conditions were tried, but unfortunately removal of TES group wasn’t 
accomplished. Reactivity of bicyclic structure 10a as well as 10b will also be exploit in a 
near future. 
In summary, this work generated a library of glucofused tricyclic structures able to interact 
with A and led to the development of a promising lead structure. It was also established 
synthetic procedures to achieve a tetracyclic glycofused structure. This study did not 
allowed yet to draw deﬁnitive conclusions; however a synthesis of tetracyclic structure was 
accomplished. Since these linear fused tetracyclic structures have found wide application 
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in pharmaceutical field, we envisioned the synthesis of antitumor compounds taking 
advantage of the bicyclic structures synthesized before. 
 Future perspectives 4.2.
4.2.1. Anthracyclines glycofused derivatives 
Anthracyclines are an important class of antitumor agents with significant biological 
activities. Anthracyclines are DNA intercalating agents.
137
 Anthracycline antibiotics are 
among the most potent antitumor agents, with proven clinical effectiveness against 
leukemias, lymphomas, breast carcinomas, and sarcomas. However, their therapeutic 
efficacy is limited due to a number of undesirable side effects. The toxic effects of therapy 
with anthracyclines include nausea and vomiting, alopecia totalis (especially for 
doxorubicin) and myelosuppression. The most serious effect of multiple anthracycline 
administration is myocardial degeneration, causing congestive cardiac failure which has 
limited the therapeutic potential of these drugs.
138
 These side effects could be modulated 
by changing the aglycone moiety of the anthracycline by a tetracyclic glycofused structure 
(Figure 4.1). 
  
Figure 4.1: Anthracyclines vs glycofused tetracyclic derivatives. 
Among the strategies for assembling the tetracyclic skeleton of the aglycone, a particularly 
effective and versatile approach is based on the coupling of its AB and CD ring 
segments.
138
 The retrosynthetic analysis is proposed in Scheme 4.1.  
 
Scheme 4.1 
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The target molecule 164 could be made using a Hauser annulation between compound 165 
and compound 166. The originally proposed mechanism is depicted in Scheme 4.2,
139
 
being the first step deprotonation of phthalide 165. The subsequent anion 167 undergoes 
Michael addition with acceptor 168, forms carbanion 169 which undergoes intramolecular 
Dieckmann cyclization on the lactone carbonyl group to give 170. Collapse of the 
intermediate 170 through expulsion of benzenesulfinate ion results in formation of 
annulated product 171. Base-promoted tautomerization of 172 finally gives naphthoquinol 
173. The isobenzofuranone 165 is a synthetic equivalent of 1,4-dipolar synthon 174. 
 
Scheme 4.2 
4.2.2. Quinoxalines glycofused derivatives 
Quinoxalines have shown a broad spectrum of biological activities such as antibacterial, 
antiviral, herbicidal and anti-inﬂammatory activity, thus they are an important class of 
nitrogen-containing heterocycles and useful intermediates in organic synthesis. Recently 
some of these types of molecules have been reported as candidates for the treatment of 
cancer and disorders associated with angiogenesis functions.
140-144
 
Herein is described the synthesis of a possible antitumoral quinoxaline derivative with a 
glycofused tetracyclic structure that we developed in parallel with the previously described 
compounds. Starting from derivative 175 it’s possible to obtain compound 181 (Scheme 
4.3). Benzylation of the tertiary alcohol of compound 176 followed by dihydroxylation 
afforded compound 177 as mixture of diastereomers, which were oxidized to the 
corresponding 1,2-diketone 178. Reaction of crude 1,2-diketone 178 with 1,2-
diaminobenzene produce 179 in 71% (over 2 steps) and 180 in 10% yield. 
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Scheme 4.3. reagents and conditions: a) NaH (1.2 equiv.), BnBr (1.2 equiv.), dry DMF, rt, 3 h, 94%; b) 
OsO4 0.076M in t-BuOH (0.05 equiv.), NMO (2.1 equiv.), H2O:acetone (1:1), rt, 2 h, 96%; c) triflic 
anhydride (2.0 equiv.), dry DMSO (4.0 equiv.), dry Et3N (8.0 eq), dry CH2Cl2, -78ºC, 3 h; d) 1,2-diamino-
benzene (1.2 equiv.), dry THF, rt, 3 h, 81% (overall yield over 2 steps), 179 in71%. 
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5. Experimental section 
 
 
 
 
 General remarks 5.1.
All solvents were dried with molecular sieves for at least 24 h prior to use. Thin layer 
chromatography (TLC) was performed on silica gel 60 F254 plates (Merck) with detection 
using UV light when possible, or by charring with a solution of concd. H2SO4/EtOH/H2O 
(5:45:45) or a solution of (NH4)6Mo7O24 (21 g), Ce(SO4)2 (1 g), concd. H2SO4 (31 mL) in 
water (500 mL). Flash column chromatography was performed on silica gel 230-400 mesh 
(Merck). 
1
H and 
13
C NMR spectra were recorded at 25 °C unless otherwise stated, with a 
Varian Mercury 400 (400 MHz for 
1
H and 100.1 MHz for 
13
C) Bruker Avance 300 (300.13 
MHz for 
1
H and 75.47 MHz for 
13
C) and Bruker Avance 500 (500.13 MHz for 
1
H and 
125.77 MHz for 
13
C). Chemical shift assignments, reported in ppm, are referenced to the 
corresponding solvent peaks. HRMS were recorded on a QSTAR elite LC/MS/MS system 
with a nanospray ion source. Optical rotations were measured at room temperature using 
an Atago Polax-2L polarimeter and are reported in units of 10
-1
 deg·cm
2
·g
-1
. 
 Molecular mechanics and molecular dynamics calculations  5.2.
Molecular mechanics (MM) and molecular dynamics (MD) studies were conducted with 
MacroModel 9.8.207
145
 implemented in the 9.1.207 version of the Maestro suite,
146
 using 
MM3* force field.
147
 The starting coordinates for dynamics calculations were those 
obtained after energy minimization of the structures, followed by conformational search. In 
particular, a systematic variation of the torsional degrees of freedom of the molecules 
permitted different starting structures to be constructed that were further minimized to 
provide the corresponding local minima. For each compound the conformer with the 
lowest energy was considered. Simulations were carried out over 5 ns at 298 K with a 0.25 
fs time step and a 20 ps equilibration step; 100 structures were sampled and minimized for 
further analysis. The continuum GB/SA solvent model
148
 was employed and the general 
Synthesis of new A-ligands useful in diagnosis of Alzheimer’s Disease 
112 
PRCG (Polak–Ribiere Conjugate Gradient) method for energy minimization was used. An 
extended cut-off was applied and the SHAKE procedure for bonds was not selected. 
 Peptide synthesis and purification 5.3.
Procedure 
Aβ(1-42) was prepared by solid-phase peptide synthesis on a 433A synthesizer (Applied 
Biosystems) using Fmoc-protected L-amino acid derivatives, NOVASYN-TGA resin on a 
0.1 mM scale 
149
. Peptide was cleaved from the resin as previously described
150
 and 
purified by reverse phase HPLC on a semi-preparative C4 column (Waters) using 
water:acetonitrile gradient elution. Peptide identity was confirmed by MALDI-TOF 
analysis (model Reflex III, Bruker). Peptide purity was always above 95%. 
 NMR spectroscopy binding studies 5.4.
NMR experiments were recorded on  a Varian 400 MHz Mercury. A batch of Aβ(1-42)  
was selected that contained pre-amyloidogenic seeds highly toxic to N2a cells. 
Immediately before use, lyophilized Aβ(1-42)  was dissolved in 10 mM NaOD in D2O at a 
concentration of 160 μM, then diluted 1:1 with 10 mM phosphate buffer saline (PBS), 
pH=7.4 containing 100 mM NaCl (PBS) and one of the tested compounds. Compounds 61-
70, 73 and 74 were dissolved in 10 mM NaOD in D2O and then diluted in PBS, pH=7.4, 
sonicated for 1 h and added to the peptide solution. The pH of each sample was verified 
with a Microelectrode (Mettler Toledo) for 5 mm NMR tubes and adjusted with NaOD or 
DCl. All pH values were corrected for isotope effect. Basic sequences were employed for, 
2D-NOESY and STD experiments. For STD, a train of Gaussian-shaped pulses each of 50 
ms was employed to saturate selectively the protein envelope; the total saturation time of 
the protein envelope was adjusted by the number of shaped pulses and was varied between 
3 s and 0.3 s. 
5.4.1. Liposome binding studies 
A batch of lyposomes functionalized with tricyclic derivative 97 [DPPC/Chol (1:1) + 4% 
peg-2000 + 20% lipid-N3 - Clicked (10% on surface)] was diluted 1:1 with H2O and 10% 
D2O, at pH=7.4. 
1
H NMR (128 transients) and water-LOGSY (2048 transients, 1.2 s and 
1.6 s mixing time) experiments were acquired at 298 K on a Bruker Advance 600 (600 
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MHz for 
1
H and 150 MHz for 
13
C) instrument, equipped with a triple resonance cryo-
probe. The same experiments were acquired diluting the lyposome preparation with a 
solution of pre-dissolved A1-42), whose final concentration in the NMR tube was         
80 μM. 
 Sections staining 5.5.
Brain tissue from Tg CRND8 mice encoding a double mutant form of amyloid precursor 
protein 695 (KM670/671NL + V717F) under the control of the PrP gene promoter (Chishti 
et al., 2001) were dissected and were fixed in Carnoy’s and embedded in paraffin.151  
Procedures involving animals and their care were conducted in conformity with the 
institutional guidelines that are in compliance with italian (D.L. No. 116, G.U. Suppl. 40, 
Feb. 18, 1992, Circolare No. 8, G.U., 14 Luglio 1994) and international laws and policies 
(EEC Council Directive 86/609, OJ L 358, 1 Dec.12, 1987; NIH Guide for the Care and 
use of Laboratory Animals, U.S. National Research Council, 1996). All efforts were made 
to minimize the number of animals used and their suffering. 
Seven-micrometer-thick serial sections of paraffin-embedded blocks from the temporal 
cortex were mounted on gelatin coated microscope slides and used for staining. Paraffin 
sections were subjected to two incubations of 5 min. in xylene, an incubation of 10 min. 
each in 100%, 96%, 70% EtOH for the complete dewaxing and two successive incubations 
of 5 min. in water. Tissue sections were covered with a solution of thioflavine T (ThT)      
(3 μM) or of compound 73 (6 μM) dissolved in water. After 30 min. of incubation, the 
sections were washed 3 times for 5 min. in water and 5 min. each in 70%, 96%, 100% 
EtOH. The sections were then incubated 5 min. in xylene before adding the coverslip. 
Sections were visualized by fluorescent fluoromicroscope M-3204CCCD (OlympusBX61) 
equipped with the filters FITC (Ex 488 nm) for detecting ThT and DAPI (Ex. 405 nm) for 
detecting the tested compounds. 
 Transport experiments 5..
Trans-endothelial-electrical resistances (TEER) were measured by EVOMX meter, STX2 
electrode (World Precision Instruments, Sarasota, Florida). Fluorescence measurements 
were done using a Cary Eclipse spectrofluorimeter (Varian Inc., Palo Alto, California). The 
radioactivity assay were achieved by means of a Tri-Carb 2200 CA Liquid Scintillation 
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Analyzer (Packard Instrument Co. Inc., Rockville, MD).The differences were evaluated for 
statistical significance using Student's t-test. 
For transport experiments across a cell monolayer, hCMEC/D3 were seeded in a 12-well 
Transwell® inserts coated with type I collagen. Cell suspensions (0.5 mL) containing     
2.0•105 cells were added to the upper (donor) chamber, which was inserted into the lower 
(acceptor) chamber containing the culture medium (1.0 mL). A cell monolayer was usually 
formed 14 days after seeding judged by three criteria: (1) the cells formed a confluent 
monolayer without visible spaces between cells under a light microscope; (2) the height of 
the culture medium in the upper chamber had to be at least 2 mm higher than that in the 
lower chamber for at least 24 h; and (3) a constant TEER (trans-endothelial-electrical 
resistance) value, measured using an EVOM Endohm chamber. Wells were used when 
TEER value was higher than 50 Ω∙cm2. Trans-endothelial permeability coefficient (PE) 
was calculated as reported by Bickel U.
152
 
After adding the test substance to the donor compartment, repeated samples are taken from 
the donor compartment over the desired time course. The concentration measured in these 
samples and the known volumes of the compartments (Vdonor and Vacceptor) are used to 
calculate the incremental clearance volumes ∆VCl for each time point: 
∆VCl  =    C acceptor ∙ V acceptor / C donor 
As long as the concentration in the acceptor compartment is small and ∆VCl increases in 
linear manner, the slope of the line can be interpreted as the PS product for unidirectional 
transfer. With the known exchange surface, S, (filter area) the permeability may be 
obtained as P = PS/S. Finally, a correction needs to be made for the permeability of the 
cell-free filter: 
1/Pendothel = 1/Ptotall – 1(Pfilter) 
With Pendothel being equal to PE. 
After adding the test substance to the upper compartment, samples were taken from the 
lower compartment at different times (0, 60, 180 min) for liquid scintillation counting (C14 
sucrose) and for fluorescence assays (compound 73). At the end of the experiments, TEER 
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and [
14
C]sucrose PE were re-determined in order to prove no occurrence of adverse effects 
on tight junction function due to sample application. 
 Liposome 5.7.
5.7.1. Nanoliposome preparation 
Glycofused tricyclic-PEG-cyclooctyne derivative 95 was added to liposomes in presence 
of DMSO, and the reaction was gently stirred for 24 h at 25–27°C under continuous flow 
of N2. Any aggregates that may have been formed during the reaction were disaggregated 
by gentle bath sonication (∼2–5 min.) and the resulting mixture was placed in a 10.000 
MW cutoff dialysis tubing (Servapore, Serva) and dialyzed against PBS buffer overnight. 
The vesicle dispersion was further purified by column chromatography (Sephadex G50). 
Quantification of 95 in final liposomal dispersion 98 after liposomal click reaction was 
achieved by HPLC analysis of a specific quantity of freeze-dried liposomal dispersion and 
integration of the corresponding peak HPLC was performed with a Lichrosphere 100     
RP-18 (5 μm) column; eluted with a CHCl3/MeOH (9:1) + 0.08% TFA mobile phase at a         
1 mL/min flow rate, by a Shimatzu, LC-20AB Prominence Liquid Chromatography 
System. 
5.7.2. Characterization of nanoliposome 
5.7.2.1 Size, polydispersity and ζ-potential 
The size, polydispersity and ζ-potential of the liposome were determined using a NanoZeta 
series particle sizer and ζ-potential analyzer (Malvern). The size and polydispersity 
measurements were performed at 25ºC. Liposomes, prepared in 10 mM PBS,                  
150 mM NaCl, 1 mM EDTA, pH=7.4, were diluted at 0.25 mM total lipid concentration. 
The particle size was assessed by dynamic laser light scattering with a 652 nm laser beam. 
Particle size and polydispersity index were obtained from the intensity autocorrelation 
function of the light scattered at a fixed angle of 173° (conditions which avoid errors due to 
back-scattering). The ζ-potential was measured at 25ºC. Each measurement was performed 
on freshly prepared liposome samples. For some of the liposome types prepared, vesicle 
stability was measured when the liposomes were dispersed in buffer (at various lipid 
concentrations) and stored at 4ºC, by following their size, polydispersity index and            
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ζ-potential (which were measured by dynamic laser light scattering as described above) for 
periods of 3–30 days.  
5.7.2.2 Nanoliposome integrity studies 
The integrity of vesicles with lipid membrane compositions similar to those used for 
surface decoration by the click chemistry methodology was evaluated in order to establish 
the optimum conditions for the reaction. Integrity of DPPC/Chol (1:1) liposomes were 
evaluated under the conditions and in the presence of the solutions required for the click 
reaction to take place. For this, the latency (%) of calcein in the vesicles was measured at 
various time points during incubation of liposomes at 25º or 37ºC, in presence of reaction 
media. Lipid/reaction compound ratios of 1:1 and 1:2 mol/mol were used. The lipid 
concentration in the incubated dispersions was always constant at 1 mM, and, calcein was 
initially encapsulated in the vesicles at a quenched concentration (100 mM). For % calcein 
latency calculation, samples from the liposomes (20 μL) were diluted with 4 mL buffer,    
pH=7.40, and fluorescence intensity (FI) was measured (EX 470 nm, EM 520 nm), before 
and after addition of triton X-100 at a final concentration of 1% v/v (that ensures liposome 
disruption and release of all encapsulated dye). Percent latency (% latency) was calculated 
from: 
          
             
        
     
Where: FBT and FAT are calcein fluorescence intensities before and after the addition of triton X-
100, respectively. 
After establishing the conditions at which the liposomes remain stable, and carrying out the 
click chemistry reaction for decoration of the vesicle surface as described above, the 
vesicles produced were studied for their integrity during incubation in absence and in 
presence of serum proteins. For this, liposomes that encapsulated calcein, were prepared as 
described above and subjected to the click reaction for glycofused tricyclic-PEG-
cyclooctyne derivative 95 attached to their surface. They were subsequently incubated in 
absence or presence of serum proteins (80% v/v) and their integrity was evaluated during 
their incubation at 37ºC for 24 or 48 h. 
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 Synthesis  5.8.
5.8.1. General synthetic strategy for protected compounds 51-60 
 
Scheme 5.1 
A mixture containing the appropriate o-hydroxybenzaldehyde (42-48) (2.5 equiv.), 
trimethylorthoformate (2.5 equiv.) and scandium triflate (3% mol) in CH2Cl2 is stirred at rt 
for 20 min. The mixture is then cooled at 0°C and the appropriate tri-O-benzyl glycal (49-
50) is added. The reaction is then left stirring at rt for 30 min. The reaction is then diluted 
with CH2Cl2, washed with water, dried over Na2SO4, filtrated and the solvent is removed 
under reduced pressure. The crude is purified by flash chromatography [(eluent 
toluene/AcOEt (9.75:0.25)] to afford pure compounds 51-60. 
Compound 51: yield 59%, C5 R/S 92/8  
(5R)  
 
1
H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 7.6 Hz, 1H, H-6), 7.37 – 7.22 (m, 15H, Ar-H), 
7.23 – 7.15 (m, 1H, H-8), 6.99 (t, J = 7.6 Hz, 1H, H-7), 6.83 (d, J = 8.1 Hz, 1H, H-9), 5.66 
(d, J = 2.9 Hz, 1H, H-10a), 4.96 (d, J = 11.4 Hz, 1H, CH2Ph), 4.77 (d, J = 4.3 Hz, 1H, H-
5), 4.62 – 4.31 (m, 5H, CH2Ph), 4.18 (t, J = 6.4 Hz, 1H, H-2), 3.79 (bs, 1H, H-3), 3.68 – 
3.63 (m, 1H, H-4), 3.63 – 3.59 (m, 2H, CH2O), 3.58 (s, 3H, OMe), 3.36 – 3.26 (m, 1H, H-
4a);
 13
C NMR (101 MHz, CDCl3) δ 152.2, 139.0, 138.8, 138.2, 129.1, 128.6, 128.4, 128.4, 
128.4, 128.1, 128.0, 127.9, 127.7, 127.5, 126.2, 122.4, 121.3, 115.5, 97.7, 76.2, 75.6, 75.1, 
73.9, 73.7, 72.7, 71.71, 69.1, 57.1, 34.7. [α]D
20
= +5.3 (c=1, CHCl3). MS: m/z calcd for    
[M + Na]
+ 
= 575, [M + K]
+ 
= 591; found [M + Na]
+ 
= 575, [M + K]
+ 
= 591.
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1
H NMR (400 MHz, CDCl3) δ 7.39 – 7.24 (m, 13H, Ar-H), 7.24 – 7.20 (m, 1H, H-6), 7.18 
(dd, J = 7.0, 2.2 Hz, 2H, Ar-H), 7.07 (d, J = 7.4 Hz, 1H, H-8), 6.95 – 6.79 (m, 2H, H-7, H-
9), 5.71 (d, J = 3.2 Hz, 1H, H-10a), 4.92 (d, J = 11.5 Hz, 1H, CH2Ph), 4.64 – 4.44 (m, 5H, 
CH2Ph), 4.40 (d, J = 2.1 Hz, 1H, H-5), 4.23 – 4.19 (m, 1H, H-2), 3.98 (bs, 1H, H-3), 3.72 – 
3.64 (m, 2H, CH2O), 3.37 (s, 3H, OMe), 3.32 (dd, J = 11.8, 2.4 Hz, 1H, H-4), 3.06 – 2.98 
(m, 1H, H-4a). 
13
C NMR (101 MHz, CDCl3) δ 153.8, 138.7, 138.0, 137.7, 131.2, 130.3, 
128.6, 128.6, 128.5, 128.2, 128.2, 128.0, 128.0, 127.8, 127.8, 120.8, 118.5, 116.9, 95.0, 
75.1, 74.7, 74.7, 73.7, 71.6, 71.5, 71.5, 68.9, 56.3, 37.7, 29.9. [α]D
20
= +8.7 (c=1, CHCl3). 
MS: m/z calcd for [M + Na]
+ 
= 575, [M + K]
+ 
= 591; found [M + Na]
+ 
= 575, [M + K]
+ 
= 
591. 
Compound 52: yield 40%, C5 R/S 100/0
 
 
1
H NMR (400 MHz, CDCl3) δ 8.43 (dd, J = 2.7, 1.1 Hz, 1H, H-6), 8.08 (dd, J = 9.0, 2.7 
Hz, 1H, H-8), 7.43 – 7.17 (m, 15H, Ar-H), 6.87 (d, J = 9.0 Hz, 1H, H-9), 5.73 (d, J = 2.9 
Hz, 1H, H-10a), 4.96 (d, J = 11.3 Hz, 1H, CH2Ph), 4.74 (d, J = 4.3 Hz, 1H, H-5), 4.64 – 
4.36 (m, 5H, CH2Ph), 4.11 (t, J = 6.4 Hz, 1H, H-2), 3.86 (bs, 1H, H-3), 3.64 (dd, J = 9.2, 
5.8 Hz, 2H, CH2O), 3.59 (d, J = 7.4 Hz, 3H, OMe), 3.50 (dd, J = 11.1, 2.5 Hz, 1H, H-4), 
3.41 – 3.32 (m, 1H, H-4a). 13C NMR (101 MHz, CDCl3) δ 157.5, 142.3, 138.7, 138.0, 
137.9, 128.6, 128.5, 128.4, 128.4, 128.2, 128.1, 128.1, 127.9, 127.8, 125.3, 123.3, 123.2, 
116.2, 98.8, 75.2, 75.2, 74.6, 73.8, 73.0, 72.3, 72.1, 68.9, 57.1, 33.9.[α]D
20
= -4.5 (c=1, 
CHCl3). MS: m/z calcd for [M + H]
+ 
= 598, [M + Na]
+ 
= 620, [M + K]
+ 
= 636; found [M + 
H]
+ 
= 598, [M + Na]
+ 
= 620, [M + K]
+ 
= 636. 
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Compound 53: yield 35%, C5 R/S 100/0
 
 
1
H NMR (400 MHz, CDCl3) δ 7.52 – 7.25 (m, 20H, Ar-H), 7.23 (d, J = 2.6 Hz, 1H, H-6), 
6.86 (dd, J = 8.8, 2.6 Hz, 1H, H-8), 6.78 (d, J = 8.8 Hz, 1H, H-9), 5.64 (d, J = 2.9 Hz, 1H,      
H-10a), 5.10 – 4.95 (m, 3H, CH2Ph), 4.76 (d, J = 4.4 Hz, 1H, H-5), 4.64-4.34 (m, 5H,    
CH2Ph), 4.20 (t, J = 6.5 Hz, 1H, H-2), 3.83 (bs, 1H, H-3), 3.67 (dd, J = 11.1, 2.6 Hz, 1H, 
H-4), 3.65 – 3.61 (m, 2H, CH2O), 3.58 (s, 3H, OMe), 3.36 – 3.25 (m, 1H, H-4a).
 13
C NMR 
(101 MHz, CDCl3) δ 149.9, 139.0, 138.9, 138.1, 130.5, 129.6, 128.6, 128.4, 128.4, 128.3, 
128.1, 127.9, 127.9, 127.7, 127.5, 126.5, 121.9, 115.3, 97.62, 76.3, 75.6, 75.1, 73.9, 73.7, 
72.6, 71.6, 69.1, 57.1, 34.7, 20.9. [α]D
20
= -5.5 (c=1, CHCl3); MS: m/z calcd for [M + Na]
+ 
= 681 [M + K]
+ 
= 697; found [M + Na]
+ 
= 682, [M + K]
+ 
= 697
 
Compound 54: yield 73%, C5 R/S 85/15 
(5R)  
 
1
H NMR (400 MHz, CDCl3) δ 7.37 – 7.21 (m, 15H, Ar-H), 7.11 (d, J = 0.9 Hz, 1H, H-6), 
6.76 – 6.75 (AB, J = 8.6 Hz, 2H, H-8, H-9), 5.61 (d, J = 2.9 Hz, 1H, H-10a), 4.96 (d, J = 
11.4 Hz, 1H, CH2Ph), 4.74 (d, J = 4.4 Hz, 1H, H-5), 4.60-4.36 (m, 5H, CH2Ph), 4.18 (t, J = 
6.4 Hz, 1H, H-2), 3.83 – 3.78 (m, 4H, ArOMe and H-3), 3.66 (dd, J = 11.1, 2.6 Hz, 1H, H-
4), 3.65 – 3.61 (m, 2H, CH2O), 3.57 (s, 3H, OMe), 3.33 – 3.24 (m, 1H, H-4a).
 13
C NMR 
(101 MHz, CDCl3) δ 154.3, 146.1, 139.0, 138.9, 138.1, 128.6, 128.4, 128.4, 128.3, 128.1, 
127.9, 127.9, 127.7, 127.5, 123.1, 116.3, 115.1, 110.8, 97.6, 76.2, 75.7, 75.1, 73.9, 73.7, 
72.7, 71.6, 69.1, 57.0, 56.0, 34.7. [α]D
20
= +7.1 (c=1, CHCl3); MS: m/z calcd for [M + K]
+ 
= 
621; found [M + K]
+ 
= 622.  
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1
H NMR (400 MHz, CDCl3) δ 7.39 – 7.15 (m, 15H, Ar-H), 6.84 – 6.76 (m, 2H, H-8 and H-
9), 6.58 (bs, 1H, H-6), 5.64 (d, J = 3.1 Hz, 1H, H-10a), 4.91 (d, J = 11.5 Hz, 1H, CH2Ph), 
4.66 – 4.40 (m, 5H, CH2Ph), 4.35 (d, J = 2.0 Hz, 1H, H-5), 4.26 – 4.17 (m, 1H, H-2), 4.00 
(bs, 1H, H-3), 3.76 (s, 3H, ArOMe), 3.70 – 3.63 (m, 2H, CH2O), 3.40 (s, 3H, OMe), 3.34 
(dd, J = 11.8, 2.3 Hz, 1H, H-4), 3.03 – 2.94 (m, 1H, H-4a). 13C NMR (101 MHz, CDCl3) δ 
153.6, 147.6, 138.7, 138.1, 137.7, 128.6, 128.5, 128.4, 128.4, 128.2, 128.2, 128.0, 128.03, 
127.9, 127.8, 127.8, 127.7, 127.5, 119.0, 117.6, 116.6, 115.2, 99.1, 94.8, 74.9, 74.8, 73.7, 
71.60, 71.4, 71.4, 70.6, 70.0, 69.8, 68.9, 56.5, 55.9, 37.6. [α]D
20
= +6.6 (c=1, CHCl3); MS: 
m/z calcd for [M + K]
+ 
= 621; found [M + K]
+ 
= 622 
Compound 55: yield 91%, C5 R/S 95/5 
(5R)  
 
1
H NMR (400 MHz, CDCl3) 7.31 – 7.21 (m, 16H, Ar-H, H-6), 6.99 (dd, J = 8.2, 0.9Hz, 
1H, H-8), 6.72 (d, J = 8.2 Hz, 1H, H-9), 5.61 (d, J = 2.9 Hz, 1H, H-10a), 4.96 (d, J = 11.4 
Hz, 1H, CH2Ph), 4.74 (d, J = 4.5 Hz, 1H, H-5), 4.62 – 4.33 (m, 5H, CH2Ph), 4.18 (t, J = 
6.4 Hz, 1H, H-2), 3.80 (bs, 1H, H-3), 3.66 (dd, J = 11.2, 2.6 Hz, 1H, H-4), 3.61 (dd, J = 
6.3, 4.1 Hz, 2H, CH2O), 3.57 (s, 3H, OMe), 3.33 – 3.23 (m, 1H, H-4a), 2.31 (s, 3H, Me).
 
13
C NMR (101 MHz, CDCl3) δ 149.9, 139.0, 138.9, 138.1, 130.5, 129.6, 128.6, 128.4, 
128.4, 128.3, 128.1, 127.9, 127.7, 127.5, 126.5, 121.9, 115.3, 97.6, 76.9, 76.3, 75.6, 75.1, 
73.9, 73.71, 72.69, 71.6, 69.1, 57.1, 34.7, 20.9. [α]D
20
= -5.2 (c=1, CHCl3); MS: m/z calcd 
for [M + H]
+ 
= 567, [M + Na]
+ 
= 589, [M + K]
+ 
= 605; found [M + H]
+ 
= 568,                   
[M + Na]
+ 
= 590, [M + K]
+ 
= 606.   
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1
H NMR (400 MHz, CDCl3) δ 7.40 – 7.13 (m, 15H, Ar-H), 7.01 (dd, J = 8.3, 1.7 Hz, 1H, 
H-8), 6.82 (s, 1H, H-6), 6.75 (d, J = 8.3 Hz, 1H, H-9), 5.66 (d, J = 3.2 Hz, 1H, H-10a), 
4.92 (d, J = 11.5 Hz, 1H, CH2Ph), 4.65 – 4.42 (m, 5H, CH2Ph), 4.34 (d, J = 2.0 Hz, 1H,   
H-5), 4.26 – 4.17 (m, 1H, H-2), 3.98 (bs, 1H, H-3), 3.72 – 3.63 (m, 2H, CH2O), 3.38 (s, 
3H, ArOMe), 3.36 – 3.29 (dd, J = 11.8, 2.4 Hz, 1H, H-4), 3.06 – 2.93 (m, 1H, H-4a), 2.26 
(s, 3H, Me). 
13
C NMR (101 MHz, CDCl3) δ 151.5, 138.8, 138.1, 137.7, 131.3, 131.0, 
129.9, 128.6, 128.6, 128.5, 128.4, 128.2, 128.2, 128.0, 127.9, 127.8, 118.1, 116.6, 94.8, 
75.0, 74.8, 74.8, 73.7, 71.5, 71.4, 71.3, 68.9, 56.4, 37.6, 29.9, 20.7. [α]D
20
= -2.1 (c=1, 
CHCl3); MS: m/z calcd for [M + H]
+ 
= 567, [M + Na]
+ 
= 589, [M + K]
+ 
= 605;            
found [M + H]
+ 
= 568, [M + Na]
+ 
= 590, [M + K]
+ 
= 601.   
Compound 56: yield 64%, C5 R/S 53/47 
(5R)  
 
1
H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 8.6 Hz, 1H, H-6), 7.37 – 7.21 (m, 15H, Ar-H), 
6.56 (dd, J = 8.6, 2.4 Hz, 1H, H-7), 6.39 (d, J = 2.4 Hz, 1H, H-9), 5.62 (d, J = 2.8 Hz, 1H,        
H-10a), 4.96 (d, J = 11.4 Hz, 1H, CH2Ph), 4.71 (d, J = 4.4 Hz, 1H, H-5), 4.60-4.35 (m, 5H, 
CH2Ph), 4.19 (t, J = 6.4 Hz, 1H, H-2), 3.80 (bs, 1H, H-3), 3.78 (s, 3H, ArOMe), 3.66 (dd, J 
= 11.1, 2.4 Hz, 1H, H-4), 3.60 (t, J = 6.3 Hz, 2H, CH2O), 3.55 (s, 3H, OMe), 3.31 – 3.24 
(m, 1H, H-4a).
 13
C NMR (101 MHz, CDCl3) δ 160.5, 153.1, 139.0, 138.9, 138.1, 128.6, 
128.4, 128.4, 128.1, 127.9, 127.7, 127.5, 127.1, 114.7, 107.8, 100.7, 97.9, 76.0, 75.6, 75.2, 
74.1, 73.7, 72.8, 71.8, 69.2, 56.9, 55.5, 34.9, 29.9. [α]D
20
= -2.2 (c=1, CHCl3); MS: m/z 
calcd for [M + Na]
+ 
= 605, [M + K]
+ 
= 621; found [M + Na]
+ 
= 606, [M + K]
+ 
= 621.  
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1
H NMR (400 MHz, CDCl3) δ 7.39 – 7.16 (m, 15H, Ar-H), 6.97 (d, J = 8.4 Hz, 1H, H-6), 
6.47 (dd, J = 8.4, 2.4 Hz, 1H, H-7), 6.43 (d, J = 2.4 Hz, 1H, H-9), 5.71 (d, J = 3.2 Hz, 1H, 
H-10a), 4.97 – 4.87 (d, J = 11.4 Hz, 1H, CH2Ph), 4.65 – 4.43 (m, 5H, CH2Ph), 4.37 (d, J = 
2.1 Hz, 1H, H-5), 4.19 (t, J = 6.5 Hz, 1H, H-2), 3.98 (bs, 1H, H-3), 3.77 (s, 3H, ArOMe), 
3.70 – 3.63 (m, 2H, CH2O), 3.35 (s, 3H, OMe), 3.32 (d, J = 2.4 Hz, 1H, H-4), 3.05 – 2.95 
(m, 1H, H-4a). 
13
C NMR (101 MHz, CDCl3) δ 161.4, 155.0, 138.8, 138.1, 137.8, 131.9, 
128.6, 128.6, 128.5, 128.2, 128.2, 128.0, 128.0, 127.8, 111.1, 108.0, 101.4, 95.17, 75.3, 
74.7, 74.3, 73.8, 71.7, 71.6, 71.6, 69.0, 56.1, 55.5, 37.8, 29.9. [α]D
20
= -4.6 (c=1, CHCl3). 
MS: m/z calcd for [M + Na]
+ 
= 605, [M + K]
+ 
= 621; found [M + Na]
+ 
= 606, [M + K]
+ 
= 
622.  
Compound 57: yield 45%, C5 R/S 100/0 
 
1
H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 7.8 Hz, 1H, H-6), 7.37 – 7.20 (m, 15H, Ar-H), 
6.81 (d, J = 7.8 Hz, 1H, H-7), 6.66 (s, 1H, H-9), 5.63 (d, J = 2.8 Hz, 1H, H-10a), 4.97 (d,   
J = 11.4 Hz, 1H, CH2Ph), 4.74 (bd, J = 4.2 Hz, 1H, H-5), 4.62 – 4.34 (m, 5H, CH2Ph), 4.19 
(t, J = 6.3 Hz, 1H, H-2), 3.81 (bs, 1H, H-3), 3.69 – 3.59 (m, 3H, H-4 and CH2O), 3.56 (s, 
3H, OMe), 3.34 – 3.21 (m, 1H, H-4a), 2.31 (s, 3H, Me). 13C NMR (101 MHz, CDCl3) δ 
152.1, 139.2, 139.07, 139.0, 138.2, 128.6, 128.4, 128.4, 128.4, 128.1, 127.9, 127.9, 127.7, 
127.5, 126.1, 122.3, 119.5, 116.0, 97.7, 76.2, 75.7, 75.2, 74.0, 73.7, 72.8, 71.7, 69.2, 57.0, 
34.8, 21.4. [α]D
20
= -6.2 (c=1, CHCl3). MS: m/z calcd for [M + K]
+ 
= 605; found [ [M + K]
+ 
= 605. 
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Compound 58: yield 66%, C5 R/S 100/0 
 
1
H NMR (400 MHz, CDCl3) δ 7.43 – 7.18 (m, 14H, Ar-H and H-6), 7.09 (dd, J = 6.7, 2.7 
Hz, 2H, Ar-H), 6.99 (d, J = 8.5 Hz, 1H, H-8), 6.72 (d, J = 8.5 Hz, 1H, H-9), 5.60 (d, J = 
3.0 Hz, 1H, H-10a), 4.82 (d, J = 10.7 Hz, 1H, CH2Ph), 4.74 (d, J = 4.4 Hz, 1H, H-5), 4.71 
– 4.44 (m, 5H, CH2Ph), 4.07 (bd, J = 9.9 Hz, 1H, H-2), 3.86 – 3.79 (m, 2H, CH2O), 3.74 
(bs, 1H, H-3), 3.72 – 3.65 (m, 1H, H-4), 3.55 (s, 3H, OMe), 2.83 (ddd, J = 10.5, 4.4, 3.2 
Hz, 1H, H-4a), 2.30 (s, 3H, Me).
 13
C NMR (101 MHz, CDCl3) δ 149.8, 139.1, 138.4, 
138.1, 130.7, 129.7, 128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 127.55, 126.48, 121.8, 
115.5, 97.1, 78.5, 78.5, 76.4, 75.6, 74.9, 73.7, 72.5, 68.6, 57.3, 40.1, 20.9. [α]D
20
= +3.7 
(c=1, CHCl3). MS: m/z calcd for  [M + Na]
+ 
= 589, [M + K]
+ 
= 605; found [M + Na]
+ 
= 
589,     [M + K]
+ 
= 605.  
 Compound 59: yield 37%, C5 R/S 100/0 
 
1
H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.6 Hz, 1H, H-6), 7.38 – 7.19 (m, 10H, Ar-H), 
7.15 – 7.05 (m, 2H, Ar), 6.56 (dd, J = 8.6, 2.3 Hz, 1H, H-7), 6.40 (t, J = 2.3 Hz, 1H, H-9), 
5.61 (d, J = 2.8 Hz, 1H, H-10a), 4.83 (d, J = 10.6 Hz, 1H, CH2Ph), 4.72 (d, J = 4.4 Hz, 1H, 
H-5), 4.70-4.44 (m, 5H, CH2Ph), 4.08 (d, J = 10.0 Hz, 1H, H-2), 3.88 – 3.73 (m, 3H, H-3 
and CH2O), 3.79 (s, 3H, OMe), 3.73 – 3.65 (m, 1H, H-4), 3.52 (s, 3H, OMe), 2.89 – 2.75 
(m, 1H, H-4a).
 13
C NMR (101 MHz, CDCl3) δ 160.7, 152.9, 139.1, 138.4, 138.1, 128.6, 
128.6, 128.4, 128.2, 128.2, 128.0, 127.9, 127.9, 127.6, 127.2, 114.6, 108.1, 100.8, 97.5, 
78.5, 78.4, 76.1, 75.6, 74.9, 73.7, 72.7, 68.6, 57.2, 55.5, 40.2. [α]D
20
= +11.6 (c=1, CHCl3). 
MS: m/z calcd for [M + Na]
+ 
= 605, [M + K]
+ 
= 621; found [M + Na]
+ 
= 606,                   
[M + K]
+ 
= 621.  
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Compound 60: yield 21%, C5 R/S 100/0 
 
1
H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 7.8 Hz, 1H, H-6), 7.39 – 7.18 (m, 13H, Ar-H), 
7.14 – 7.03 (m, 2H, Ar), 6.80 (d, J = 7.8 Hz, 1H, H-7), 6.65 (bs, 1H, H-9), 5.62 (d, J = 2.7 
Hz, 1H, H-10a), 4.82 (d, J = 10.6 Hz, 1H, CH2Ph), 4.74 (d, J = 3.8 Hz, 1H, H-5), 4.72 – 
4.39 (m, 5H, CH2Ph), 4.07 (d, J = 10.0 Hz, 1H, H-2), 3.89 – 3.72 (m, 3H, H-3 and CH2O), 
3.68 (t, J = 9.7 Hz, 1H, H-4), 3.53 (s, 3H, OMe), 2.87 – 2.78 (m, 1H, H-4a), 2.30 (s, 3H, 
Me).
 13
C NMR (101 MHz, CDCl3) δ 151.9, 139.7, 139.1, 138.4, 138.2, 128.6, 128.6, 128.4, 
128.2, 128.0, 127.9, 127.9, 127.6, 126.1, 122.4, 119.3, 116.2, 97.2, 78.5, 76.9, 76.3, 75.6, 
74.9, 73.8, 72.6, 68.7, 57.3, 40.2, 21.3. [α]D
20
= +8.3 (c=1, CHCl3). MS: m/z calcd for       
[M + Na]
+ 
= 589, [M + K]
+ 
= 605; found [M + Na]
+ 
= 590, [M + K]
+ 
= 605.  
 
5.8.2. General synthetic strategy for compounds 61-70  
 
Scheme 5.2. 
 
To a 6 mM solution of the protected compound in AcOEt/MeOH 1:1, previously degassed, 
Pd(OH)2 5% mol is added and the reaction mixture is stirred under H2 atmosphere for      
45 min.-1.5 h. Then the catalyst is removed by filtration and the solvent evaporated under 
reduced pressure to afford pure compounds 61-70.   
Compound 61: yield 97% 
 
1
H NMR (400 MHz, CD3OD) δ 7.45 (d, J = 7.7 Hz, 1H, H-6), 7.18 (t, J = 7.7 Hz, 1H, H-
8), 6.95 (t, J = 7.7 Hz, 1H, H-7), 6.78 (d, J = 7.7 Hz, 1H, H-9), 5.62 (d, J = 3.1 Hz, 1H, H-
10a), 4.91 (d, J = 2.4 Hz, 1H, H-5), 3.99 (t, J = 6.0 Hz, 1H, H-2), 3.83 – 3.78 (m, 2H, H-3 
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and H-4), 3.80 – 3.74 (m, 2H, CH2O), 3.69 (s, 3H, OMe), 3.00 – 2.92 (m, 1H, H-4a).
 13
C 
NMR (101 MHz, CD3OD) δ 156.3, 132.9, 130.0, 125.3, 124.8, 119.2, 100.6, 81.5, 76.6, 
71.5, 71.2, 65.5, 61.6, 38.4. [α]D
20
= -7.6 (c=1, CHCl3); MS: m/z calcd for [M + Na]
+ 
= 305, 
[M + K]
+ 
= 321; found [M + Na]
+ 
= 305, [M + K]
+ 
= 321.
 
Compound 62: yield 94% 
 
1
H NMR (400 MHz, CD3OD) δ 6.89 (s, 1H, H-6), 6.65-6.55 (m, 2H,  H-8 and H-9), 5.52 
(d, J = 3.0 Hz, 1H, H-10a), 4.83 (d, J = 4.9 Hz, 1H, H-5), 3.98 (t, J = 5.8 Hz, 1H, H-2), 
3.87 – 3.78 (m, 2H, H-3 and H-4), 3.79 – 3.73 (m, 1H, CH2O), 3.67 (s, 3H, OMe), 2.96 – 
2.85 (m, 1H, H4a).
 13
C NMR (101 MHz, CD3OD) δ 149.1, 144.7, 125.6, 121.0, 119.6, 
118.6, 117.3, 114.5, 100.3, 81.7, 80.9, 76.5, 71.5, 71.4, 65.5, 61.7, 38.7. [α]D
20
= +13.3 
(c=1, CHCl3).  MS: m/z calcd for [M + H]
+ 
= 298 [M + Na]
+ 
= 320, [M + K]
+ 
= 336; found 
[M + H]
+ 
= 298, [M + Na]
+ 
= 320, [M + K]
+ 
= 336. 
Compound 63: yield 100% 
 
1
H NMR (400 MHz, CD3OD) δ 6.88 (bs, 1H, H-6), 6.64 – 4.59 (m, 2H, H-8 and H-9), 5.54 
(d, J = 2.8 Hz, 1H, H-10a), 4.84 (d, J = 4.8 Hz, 1H, H-5), 3.98 (t, J = 5.9 Hz, 1H, H-2), 
3.84 (d, J = 2.7 Hz, 1H, H-4), 3.81 (bs, 1H, H-3), 3.76 (dd, J = 5.9, 2.3 Hz, 2H, CH2O), 
3.68 (s, 3H, OMe), 2.98 – 2.84 (m, 1H, H-4a). 13C NMR (101 MHz, CD3OD) δ 155.3, 
149.1, 125.9, 119.8, 119.7, 116.1, 116.0, 100.4, 81.6, 76.5, 71.5, 71.3, 65.5, 61.6, 38.6. 
[α]D
20
= +11.1 (c=1, CHCl3); MS: m/z calcd for [M + Na]
+ 
= 321; found [M + Na]
+ 
= 321  
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Compound 64: yield 96% 
 
1
H NMR (400 MHz, CD3OD) δ 7.00 (d, J = 2.2 Hz, 1H, H-6), 6.77 (dd, J = 8.9, 2.2 Hz, 
1H, H-8), 6.71 (d, J = 8.9 Hz, 1H, H-9), 5.57 (d, J = 3.0 Hz, 1H, H-10a), 4.87 (bs, 1H, H-
5), 3.98 (t, J = 6.0 Hz, 1H, H-2), 3.83 – 3.79 (m, 2H, H-3 and H-4), 3.76 (dd, J = 6.1, 3.0 
Hz, 2H, CH2O), 3.74 (s, 3H, OMe), 3.68 (s, 3H, OMe), 2.98 – 2.89 (m, 1H, H-4a).
 13
C 
NMR (101 MHz, CD3OD) δ 158.3, 150.1, 125.9, 119.9, 118.9, 114.6, 100.5, 81.5, 76.6, 
71.6, 71.2, 65.5, 61.5, 58.8, 38.4. [α]D
20
= +8.9 (c=1, CHCl3); MS: m/z calcd for [M + Na]
+ 
= 335; found [M + Na]
+ 
= 335. 
Compound 65: yield 95% 
 
1
H NMR (400 MHz, CD3OD) δ 7.24 (bs, 1H, H-6), 6.98 (d, J = 8.2 Hz, 1H, H-8), 6.66 (d, 
J = 8.2 Hz, 1H, H-9), 5.57 (d, J = 3.0 Hz, 1H, H-10a), 4.86 (1H, H-5, under the H2O 
signal), 3.98 (t, J = 6.0 Hz, 1H, H-2), 3.83 – 3.78 (m, 2H, H-3 and H-4), 3.77 (dd, J = 6.0, 
2.9 Hz, 2H, CH2O), 3.68 (s, 3H, OMe), 2.96 – 2.89 (m, 1H, H-4a), 2.26 (s, 3H, Me).
 13
C 
NMR (101 MHz, CD3OD) δ 150.1, 130.2, 129.5, 126.3, 120.9, 115.1, 96.6, 77.6, 72.6, 
67.6, 67.4, 61.6, 57.7, 34.59, 19.5. [α]D
20
= +13.3 (c=1, CHCl3); MS: m/z calcd for [M + 
Na]
+ 
= 319, [M + K]
+ 
= 335; found [M + Na]
+ 
= 319, [M + K]
+ 
= 335. 
 Compound 66: yield 97% 
 
1
H NMR (400 MHz, CD3OD) δ 7.32 (d, J = 8.6 Hz, 1H, H-6), 6.54 (dd, J = 8.6, 2.4 Hz, 
1H, H-7), 6.35 (d, J = 2.4 Hz, 1H, H-9), 5.58 (d, J = 3.0 Hz, 1H, H-10a), 4.84 (d, J = 4.9 
Hz, 1H, H-5), 4.00 (t, J = 6.0 Hz, 1H, H-2), 3.86 – 3.79 (m, 2H, H-3 and H-4), 3.77 (dd, J 
= 6.0, 3.3 Hz, 2H, CH2O), 3.74 (s, 3H, OMe), 3.67 (s, 3H, OMe), 2.96-2.86 (m, 1H, H-4a).
 
13
C NMR (101 MHz, CD3OD) δ 160.9, 153.2, 126.9, 113.5, 107.3, 100.4, 96.9, 77.5, 72.8, 
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67.6, 67.2, 61.6, 57.6, 54.5, 34.6. [α]D
20
= -7.6 (c=1, CHCl3); MS: m/z calcd for  [M + Na]
+ 
= 335, [M + K]
+ 
= 351; found [M + Na]
+ 
= 335, [M + K]
+ 
= 351.  
Compound 67: yield 97% 
 
1
H NMR (400 MHz, CD3OD) δ 7.29 (d, J = 7.8 Hz, 1H, H-6), 6.76 (d, J = 7.8 Hz, 1H,      
H-7), 6.60 (bs, 1H, H-9), 5.57 (d, J = 3.0 Hz, 1H, H-10a), 4.85 (d, J = 4.7 Hz, 1H, H-5), 
3.98 (t, J = 5.9 Hz, 1H, H-3), 3.83 – 3.73 (m, 4H, CH2O, H-2, H-4), 3.67 (s, 3H, OMe), 
2.96 – 2.85 (m, 1H, H-4a), 2.25 (s, 3H, Me).13C NMR (101 MHz, CD3OD) δ 156.1, 143.2, 
133.2, 129.6, 125.6, 122.2, 119.7, 100.6, 81.5, 76.6, 71.2, 65.6, 61.6, 38.5, 23.9. [α]D
20
= 
+8.3 (c=1, CHCl3); MS: m/z calcd for [M + Na]
+ 
= 319; found [M + Na]
+ 
= 319. 
Compound 68: yield 98% 
 
1
H NMR (400 MHz, CD3OD) δ 7.12 (bs, 1H, H-6), 6.85 (d, J = 8.3 Hz, 1H, H-8), 6.54 (d, 
J = 8.3 Hz, 1H, H-9), 5.38 (d, J = 2.9 Hz, 1H, H-10a), 4.86 (1H, H-5, under the H2O 
signal), 3.75 – 3.59 (m, 3H, CH2O and H-2), 3.53 (bs, 4H, H-3 and OMe), 3.34 (t, J = 8.9 
Hz, 1H, H-4), 2.50 – 2.40 (m, 1H, H-4a), 2.13 (s, 3H, Me). 13C NMR (101 MHz, CD3OD) 
δ 150.0, 130.3, 129.5, 126.4, 121.1, 115.1, 96.3, 77.5, 73.8, 70.3, 70.1, 61.2, 57.5, 40.0, 
19.5. [α]D
20
= +13,3 (c=1, CHCl3); MS: m/z calcd for  [M + K]
+ 
= 335.1; found [M + K]
+ 
= 
335.3.    
 Compound 69: yield 97% 
 
1
H NMR (400 MHz, CD3OD) δ 7.33 (d, J = 8.6 Hz, 1H, H-6), 6.54 (dd, J = 8.6, 2.4 Hz, 
1H, H-7), 6.36 (d, J = 2.4 Hz, 1H, H-9), 5.51 (d, J = 2.9 Hz, 1H, H-10a), 4.83 (d,                
J = 4.9 Hz, 1H, H-5), 4.00 (t, 1H, J = 6.0Hz, H-2), 3.87 – 3.66 (m, 6H, CH2O and H-4 and 
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OMe), 3.66 (d, J = 6.3 Hz, 3H, OMe), 3.48 (t, J = 9.2 Hz, 1H, H-3), 2.57 (ddd, J = 10.3, 
4.9, 3.1 Hz, 1H, H-4a).
 13
C NMR (101 MHz, CD3OD) δ 160.9, 153.1, 127.1, 113.7, 107.4, 
100.4, 96.6, 77.4, 73.9, 70.2, 70.0, 61.2, 57.3, 54.5, 40.1. [α]D
20
= +11.6 (c=1, CHCl3); MS: 
m/z calcd for  [M + Na]
+ 
= 335, [M + K]
+ 
= 351; found [M + Na]
+ 
= 336, [M + K]
+ 
= 352. 
 
Compound 70: yield 98% 
 
1
H NMR (400 MHz, CD3OD) δ 7.31 (d, J = 7.8 Hz, 1H, H-6), 6.78 (d, J = 7.8 Hz, 1H, H-
7), 6.62 (bs, 1H, H-9), 5.52 (d, J = 3.0 Hz, 1H, H-10a), 4.85 (d, J = 4.8 Hz, 1H, H-5), 3.85 
(dd, J = 13.7, 4.4 Hz, 1H, CH2O), 3.76 (m, 2H, CH2O and H-2), 3.68 – 3.62 (m, 4H, H4 
and OMe), 3.48 (t, J = 9.7 Hz, 1H, H-3), 2.58 (ddd, J = 9.7, 4.8, 3.0 Hz, 1H, H-4a), 2.27 (s, 
3H, Me).
 13
C NMR (101 MHz, CD3OD) δ 152.1, 139.3, 126.1, 121.8, 118.5, 115.6, 96.4, 
77.5, 73.8, 70.3, 70.0, 61.2, 57.4, 40.0, 19.9. [α]D
20
= -7.8 (c=1, CHCl3); MS: m/z calcd for  
[M + Na]
+ 
= 319, [M + K]
+ 
= 335; found [M + Na]
+ 
= 319.4, [M + K]
+ 
= 335. 
 
5.8.3. Synthetic strategy for fluorescent compounds 71-74 
Compound 78 
 
Scheme 5.3 
To a solution of compound 65 (90 mg, 0.303 mmol) and 2,4,6-trimethylpyridine (0.424 
mmol, 56 L) in dry DMF (1.68 mL) with stirring at -45ºC a solution of bromoacetyl 
bromide (0.394 mmol, 34 L) in dry toluene (200 L) was added. Stirring was continued 
for 40 min. at -45ºC, and the mixture was allowed to warm to room temperature. Toluene 
(12 mL) was added, and the solid filtered off, and the filtrate concentrated. The residue was 
purified by flash chromatography [toluene/EtOAc (7:3) and EtOAc], affording 54% (68 
mg) of a white solid.
 1
H NMR (400 MHz, CDCl3) δ 7.22 (bs, 1H, H-6), 7.02 (d, J = 8.2 Hz, 
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1H, H-8), 6.74 (d, J = 8.2 Hz, 1H, H-9), 5.55 (d, J = 3.0 Hz, 1H, H-10a), 4.81 (d, J = 4.7 
Hz, 1H, H-5), 4.49 – 4.50 (m, 1H, CH2O), 4.28 (t, J = 6.0 Hz, 1H, H-2), 4.04 – 3.95 (m, 
1H, H-4), 3.95 – 3.84 (m, 3H, CH2Br and H-3), 3.73 (s, 3H, OCH3), 2.98 – 2.82 (m, 1H, H-
4a), 2.30 (s, 3H, CH3).
13
C NMR (101 MHz, CD3OD) δ 171.7, 153.7, 134.3, 133.5, 130.4, 
125.0, 119.1, 100.2, 81.3, 75.2, 74.1, 73.9, 68.8, 61.41, 52.39, 52.2, 51.9, 51.7, 51.5, 51.3, 
51.1, 43.8, 29.2, 23.5.  
Compound 71 
 
Scheme 5.4 
A solution of 4-trifluoromethyl-7-hydroxycoumarin (41 mg, 0.18 mmol) in dry DMF (2 
mL) was added to a stirred solution of compound 78 (50 mg, 0.12 mmol) in dry DMF         
(1 mL). To the reaction mixture was added CsCO3 (43 mg, 0.13 mmol) and the resulting 
solution was stirred at rt for 1 h, after which was poured into a solution of CH2Cl2-H2O. 
The organic phase was washed with 1 M NaOH solution (1 mL) and aqueous layer was 
washed with CH2Cl2 (5 mL). The combined organic layers were dried and concentrated 
under reduce pressure. The crude product was purified by flash chromatography 
[toluene/EtOAc (6:4)], affording 37% (25 mg) of a white powder. 
1
H NMR (400 MHz, 
DMSO) δ 7.61 (d, J = 9.0 Hz, 1H, H-5´), 7.25 – 7.12 (m, 2H, H-8´,H-6), 7.09 (dd, J = 9.0, 
2.3 Hz, 1H, H-6´), 6.95 (d, J = 8.4 Hz, 1H, H-8), 6.86 (s, 1H, H-3´), 6.63 (d, J = 8.4 Hz, 
1H, H-9), 5.57 (d, J = 2.5 Hz, 1H, H-10a), 5.03 (s, 2H, -OCOCH2-), 4.82 (d, J = 4.7 Hz, 
1H, H-5), 4.39 – 4.26 (m, 1H, CH2), 4.30 – 4.2 (m, 2H, CH2, H-3), 4.10 – 3.98 (m, 1H, H-
2), 3.62 – 3.54 (m, 1H, H-4), 3.53 (s, 3H, OCH3), 2.90 – 2.76 (m, 1H, H-4a), 2.21 (s, 3H, 
CH3). 
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Compound 79 
 
Scheme 5.5 
A solution of compound 65 (482 mg, 1.63 mmol) in dry pyridine (3.3 mL) was cooled to 
0ºC in an ice bath with stirring. A solution of p-toluenesulfonyl chloride (574 mg, 3 mmol) 
in dry pyridine (3.8 mL) was then added dropwise and stirring was continued at rt until the 
reaction seemed completed by TLC. After 12h, the solvent was then removed in vacuum to 
afford a crude product which was purified by flash chromatography, [petroleum ether/ 
EtOAc (5:5)], yielding 98% (719 mg) of a white powder. 
1
H NMR (400 MHz, CDCl3) δ 
7.83 (d, J = 8.1 Hz, 2H, OTs), 7.34 (d, J = 8.1 Hz, 2H, OTs), 7.19 (bs, 1H, H-6), 7.01 (d, J 
= 8.3 Hz, 1H, H-8), 6.71 (d, J = 8.3 Hz, 1H, H-9), 5.46 (d, J = 2.8 Hz, 1H, H-10a), 4.76 (d, 
J = 5.0 Hz, 1H, H-5), 4.39 - 4.21 (m, 2H, CH2O), 3.94 (m, 2H, H-4 and H-2), 3.83 (s, 1H, 
H-3), 3.69 (s, 3H, OMe), 2.82 (m, 1H, H-4a), 2.44 (s, 3H, Me), 2.29 (s, 3H, CH3).
13
C NMR 
(101 MHz, CDCl3) δ 149.6, 145.1, 133.1, 131.1, 130.5, 130.1, 128.3, 126.7, 120.0, 116.1, 
95.9, 78.5, 77.5, 77.2, 76.9, 69.5, 68.9, 66.9, 66.6, 59.6, 34.7, 21.8, 20.8. [α]D
20
= +4,1 (c=1, 
CH3CH2OH); MS: m/z calcd for  [M + Na]
+ 
= 474; found [M + Na]
+ 
= 473. 
Compound 80 
 
Scheme 5.6 
To a solution of compound 79 (100 mg, 0.22 mmol) in dry DMF (1 mL), a solution of 
NaN3 (101 mg, 1.55 mmol) in dry DMF (0.5 mL) was added and stirring was continued at 
100ºC for 12 h. Upon cooling to rt, the colorless precipitate was filtrate ad the solvent was 
evaporated to dryness. The crude product was purified by flash chromatography, 
[petroleum ether/EtOAc (6:4)] affording 60% (42 mg) of a white powder. 
1
H NMR (400 
MHz, CDCl3) δ 7.22 (bs, 1H, H-6), 7.02 (d, J = 8.1 Hz, 1H, H-8), 6.75 (d, J = 8.1 Hz, 1H, 
H-9), 5.56 (d, J = 2.7 Hz, 1H, H-10a), 4.80 (d, J = 5.0 Hz, 1H, H-5), 4.16 (t, J = 5.9 Hz, 
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1H, H-2), 3.98 (d, J = 2.9 Hz, 1H, H-4), 3.83 (s, 1H, H-3), 3.72 (s, 3H, OCH3), 3.71 – 3.66 
(m, 1H, CH2O), 3.51 (dd, J = 12.7, 5.9 Hz, 1H, CH2O), 2.93-2.84 (m, 1H, H-4a), 2.30 (s, 
3H, CH3). 
13
C NMR (101 MHz, CDCl3) δ 149.7, 131.1, 130.5, 126.7, 120.1, 116.1, 96.1, 
78.5, 77.5, 77.2, 76.9, 70.6, 67.3, 67.2, 59.7, 51.5, 34.6, 20.9. [α]D
20
= -10.3 (c=1, 
CH3CH2OH); MS: m/z calcd for [M + Na]
+ 
= 344; found [M + Na]
+ 
= 344. 
Compound 81  
 
Scheme 5.7 
To a solution of compound 80 (30 mg, 0.093 mmol) in MeOH (6 mL) was added Lindlar 
catalyst (5%), and the mixture was hydrogenated at 1 atm and rt for 30 min. Filtration and 
concentration gave amine 81 in a quantitative yield. 
1
H NMR (400 MHz, CD3OD) δ 7.23 
(d, J = 2.4 Hz, 1H, H-6), 6.98 (d, J = 8.1 Hz, 1H, H-9), 6.64 (dd, J = 8.2, 2.4 Hz, 1H, H-8), 
5.59 (d, J = 3.0 Hz, 1H, H-10a), 4.86 (d, J = 5.0 Hz, 1H, H-5), 3.97 – 3.90 (m, 1H, H-2), 
3.88 – 3.77 (m, 1H, H-4), 3.74 (dd, J = 9.7, 5.3 Hz, 1H, H-3), 3.68 (s, 3H, OMe), 3.06 – 
3.00 (m, 1H, CH2O), 2.97 – 2.90 (m, 1H, H-4a), 2.87 (dd, J = 13.3, 4.7 Hz, 1H, CH2O), 
2.29 – 2.23 (m, 3H, CH3). 
Compound 82 
 
Scheme 5.8 
Working in anhydrous conditions: Compound 81 (30 mg, 0.093 mmol),                              
7-hydroxycoumarin-4-acetic acid (24.6 mg, 0.112 mmol) and HBTU (53.1 mg, 0.14 mmol) 
were dissolved in dry DMF (1.3 mL). To this reaction mixture DIPEA (48 µL, 0.28 mmol) 
was added at rt and after 10 min. DIC (0.14 mmol, 22 µL) was added at 0ºC. The final 
reaction mixture was stirred at room temperature until the reaction seemed completed by 
TLC. After 12 h, the solvent was then removed in vacuum to afford a crude product, which 
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was purified by flash chromatography, [CHCl3/MeOH (9.5:0.5)], yielding 43% (20 mg) of 
a white solid. 
1
H NMR (400 MHz, CD3OD) δ 7.59 (d, J = 8.8 Hz, 1H, H-5‘), 7.23 (bs, 1H, 
H-6), 6.97 (d, J = 7.5 Hz, 1H, H-8), 6.76 (d, J = 8.8 Hz, 1H, H-6‘), 6.68 – 6.58 (m, 2H, H-9 
and H-8‘), 6.16 (bs, 1H, H-3‘), 5.54 (d, J = 2.8 Hz, 1H, H-10a), 4.85 (d, J = 4.9 Hz, 1H, H-
5), 4.02 (m, 1H, H-2), 3.81-3.71 (m, 3H, H-4 and CH2C=O), 3.67 (bs, 4H, OCH3 and H-3), 
3.57 (dd, J = 13.8, 4.5 Hz, 1H, CH2O), 3.44 (dd, J = 13.5, 8.5 Hz, 1H, CH2O), 2.90 – 2.84 
(m, 1H, H-4a), 2.26 (s, 3H, CH3).
13
C NMR (101 MHz, CD3OD) δ 170.4, 162.9, 156.0, 
150.0, 130.2, 129.6, 126.3, 126.2, 120.9, 115.2, 114.7, 110.7, 110.4, 102.9, 96.6, 77.6, 
70.5, 68.1, 67.1, 67.0, 57.6, 48.4, 48.2, 48.0, 47.8, 47.6, 47.4, 47.2, 40.7, 34.4, 29.6, 19.6. 
[α]D
20
= +16.6 (c=1, CH3CH2OH); MS: m/z calcd for [M + Na]
+ 
= 521; found                    
[M + Na]
+ 
= 520. 
Compound 82 
 
Scheme 5.9 
To a solution of compound 67 (500 mg, 1.69 mmol) in dry CH3CN (8.0 mL), acetone 
dimethylacetal (6.76 mmol, 0.4 mL) and CSA (1% mmol) were added under argon. The 
reaction mixture remained under magnetic stirring for 45 min. at room temperature, after 
which was added Et3N to neutralize the CSA. The reaction was then concentrated under 
reduce pressure and the crude product purified by flash chromatography, [petroleum 
ether/EtOAc (6:4)] affording 60% (336 mg) of a yellow solid. 
1
H NMR (400 MHz, 
CD3OD) 7.30 (d, J = 7.9 Hz, 1H, H-6), 6.78 (d, J = 7.9 Hz, 1H, H-7), 6.63 (bs, 1H, H-9), 
5.52 (d, J = 3.8 Hz, 1H, H-10), 4.68 (d, J = 5.2 Hz, 1H, H-5), 4.32 – 4.29 (m, 1H, H-2), 
4.15 (dd, J = 5.6, 2.4 Hz, 1H, H-3), 4.12 – 4.06 (m, 1H, H-4), 3.80 (dd, J = 6.1, 3.5 Hz, 2H, 
CH2O), 3.54 (s, 3H, OCH3), 2.79 – 2.66 (m, 1H, H-4a), 2.26 (s, 3H, Ar CH3), 1.53 (s, 3H, 
CH3), 1.29 (s, 3H, CH3). 
13
C NMR (101 MHz, CD3OD) δ 152.1, 139.1, 127.0, 121.8, 
118.7, 115.8, 108.6, 95.5, 75.2, 71.4, 70.8, 69.4, 61.4, 55.9, 48.2, 48.0, 47.7, 47.5, 47.3, 
47.1, 46.9, 37.6, 26.9, 24.8, 19.7. MS: m/z calcd for [M + Na]
+ 
= 359; found [M + Na]
+ 
= 
359. 
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Compound 84 
 
Scheme 5.10 
To a 60 % suspension of sodium hydride in oil (75 mg, 2,67 mmol) an argon atmosphere 
dry DMF (10 mL) was added. The suspension was cooled to 0ºC with stirring and a 
solution of compound 83 (300 mg, 0.89 mmol) in dry DMF (3 ml) and compound 84      
(570 mg, 1.79 mmol) in dry DMF (3 mL) were added. The mixture was stirred at 70ºC for 
12 h. After cooling to 0ºC, the reaction was quenched by slowly addition of MeOH (4 mL) 
and stirred for more 20 min. The reaction mixture was diluted with EtOAc, and washed 
with water, dried (Na2SO4) and concentrated. The residue was purified by flash 
chromatography, [petroleum ether/EtOAc (3:7)], yielding 75% of a brownish oil. MS: m/z 
calcd for [M + Na]
+ 
= 516; found [M + Na]
+ 
= 516. 
Compound 85 
 
Scheme 5.11 
To a solution of compoud 84 (100 mg, 0.22 mmol) in CH3CN:H2O (10:2) (10 mL),            
p-toluenesulfonic acid (0.42 mg, 0.002 mmol) was added. The final reaction mixture was 
stirred at room temperature until the reaction seemed completed by TLC. After 30 min., 
Et3N is added and the solvent was then removed in vacuum to afford a crude product 
which was purified by flash chromatography, [petroleum ether/EtOAc (2:8)], yielding 90% 
of a brownish oil. 
1
H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 7.7 Hz, 1H, H-6), 6.79 (d, J = 
7.7 Hz, 1H, H-7), 6.65 (bs, 1H, H-9), 5.57 (d, J = 2.8 Hz, 1H, H-10a), 4.79 (s, 3H, OCH3), 
4.19 (t, J = 5.4 Hz, 1H, H-2), 4.01 – 3.90 (m, 2H, H-3, H-4), 3.83 (dd, J = 9.0, 5.7 Hz, 2H, 
H-1’’), 3.77 – 3.57 (m, 13H, triethyleneglycol, CH3O), 3.40 (t, J = 5.0 Hz, 2H, H-7’’), 2.94 
(dd, J = 11.5, 2.8 Hz, 2H, H-4a), 2.29 (s, 3H, CH3). 
13
C NMR (101 MHz, CDCl3) δ 151.71, 
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139.79, 126.07, 122.23, 117.45, 116.30, 96.15, 78.29, 78.29, 77.33, 77.33, 77.01, 77.01, 
76.69, 76.69, 70.63, 70.42, 70.02, 67.37, 67.12, 59.27, 50.66, 34.58, 29.69.
 
Compound 86 
 
Scheme 5.12 
To a solution of compound 85 (80 mg, 0.20 mmol) in CHCl3:MeOH (1:1) (5 mL) was 
added Lindlar catalyst (5%), and the mixture was hydrogenated at 1 atm and rt for 1h. 
Filtration and concentration gave amine 86 in 90% yield as a yellow oil. 
1
H NMR           
(400 MHz, CDCl3) δ 7.29 (d, J = 7.8 Hz, 1H, H-6), 6.78 (d, J = 7.7 Hz, 1H, H-7), 6.64 (bs, 
1H, H-9), 5.57 (d, J = 2.2 Hz, 1H, H-10a), 4.78 (d, J = 4.4 Hz, 1H, H-5), 4.17 (t, J = 5.6 
Hz, 1H, CH2PEG), 4.00 – 3.58 (m, 15H, H-2, H-3, H-4, CH2O, 5 CH2PEG, CH3O), 3.54 (t,    
J = 4.7 Hz, 2H, CH2PEG), 3.05 – 2.94 (m, 1H, H-4a), 2.88 (bs, 2H, CH2PEG), 2.28 (s, 3H, 
CH3). 
13
C NMR (101 MHz, CDCl3) δ 149.18, 137.10, 123.49, 119.60, 115.04, 113.67, 
93.76, 75.59, 74.76, 74.45, 74.13, 69.93, 68.25, 67.99, 67.93, 67.92, 67.75, 67.57, 64.57, 
64.28, 56.63, 38.73, 32.05, 18.59. MS: m/z calcd for [M + H]
+ 
= 429; found [M + H]
+ 
= 
4289 
Compound 73 
 
Scheme 5.13 
Working in anhydrous conditions, compound 86 (50 mg, 0.13 mmol), 7-hydroxycoumarin-
4-acetic acid (31 mg, 0.16 mmol) and HBTU (68.26 mg, 0.20 mmol) were dissolved in dry 
DMF (2 mL). To this reaction mixture DIPEA (0.39 mmol, 67 µL) was added at rt and 
after 10 min. DIC (0.20 mmol, 31 µL) was added at 0ºC. The final reaction mixture was 
stirred at room temperature until the reaction seemed completed by TLC. After 12 h, the 
solvent was then removed in vacuum to afford a crude product which was purified by flash 
chromatography, CH2Cl2/acetone (5:5), yielding 20% (15 mg) of a brown color solid.
 1
H 
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NMR (400 MHz, CD3OD) δ 7.61 (d, J = 9.0 Hz, 1H, H-5’), 7.28 (d, J = 8.0 Hz, 1H, H-6), 
6.80 (dd, J = 9.0, 2.1 Hz, 1H, H-6’), 6.75 (d, J = 8.0 Hz, 1H, H-7), 6.70 (d, J = 2.1 Hz, 1H, 
H-8’), 6.56 (s, 1H, H-3’), 6.19 (bs, 1H, H-9), 5.54 (d, J = 3.0 Hz, 1H, H-10a), 4.10 (t, J = 
5.7 Hz, 1H, CH2PEG ), 4.86 (1H, H-5, under H2O signal), 3.85 – 3.48 (m, 18H, H-9’, H-2. 
H-3, H-4, 4 CH2PEG, OCH3, CH2O), 3.43 – 3.38 (m, 2H, CH2PEG), 2.97 – 2.83 (m, 1H, H-
4a), 2.24 (s, 3H, CH3). 
13
C NMR (101 MHz, CD3OD) δ 169.56, 162.02, 161.61, 155.36, 
151.85, 151.24, 139.06, 126.13, 125.72, 121.57, 118.06, 115.39, 112.97, 111.71, 111.59, 
102.21, 96.44, 77.34, 70.81, 70.39, 70.30, 70.17, 70.09, 69.85, 68.94, 67.39, 66.91, 57.44, 
48.21, 47.99, 47.78, 47.57, 47.35, 47.14, 46.93, 39.37, 38.78, 34.30, 19.77. MS: m/z calcd 
for    [M + H]
+ 
= 629; found [M + Na]
+ 
= 629.
 
Compound 74 
 
Scheme 5.14 
To a vigorously stirring suspension of compound 86 (72 mg, 0.27 mmol) in 1:1                  
t-BuOH/H2O, copper(II) sulfate pentahydrate (9 mg, 0.035 mmol) and sodium ascorbate 
(14 mg, 0.069 mmol) were added. The reaction mixture was stirred for 10 min at room 
temperture and then compound 76 (110 mg, 0.23 mmol) was added. The suspension was 
stirred vigorously at rt for 12 h. At this time TLC indicated completion of the reaction. 
Distilled water was added, and the aqueous layer was extracted with CH2Cl2. The 
combined extracts were dried, filtered and evaporated to afford a brownish oily solid. The 
product was then purified using column chromatography using CHCl3 as eluant, which 
afforded the expected compound 74 as a brownish solid in 55% yield.
1
H NMR (400 MHz, 
CD3OD) δ 8.26 (s, 1H, H-10’), 7.65 (dd, J = 9.0, 1.8 Hz, 1H, H-5’), 7.25 (d, J = 7.8 Hz, 
1H, H-6), 7.14 (d, J = 2.5 Hz, 1H, H-8’), 7.07 (dd, J = 9.0, 2.5 Hz, 1H, H-6’), 6.72 (d,        
J = 7.8 Hz, 1H, H-7), 6.68 (s, 1H, H-3’), 6.47 (bs, 1H, H-9), 5.52 (d, J = 3.0 Hz, 1H, H-
10a), 5.32 (s, 2H, H-9’), 4.80 (d, J = 4.8 Hz, 1H, H-5), 4.67 – 4.57 (m, 2H, H-6’’), 4.08 (t, 
J = 5.9 Hz, 1H, H-2’’), 3.95 – 3.87 (m, 2H, H-7’’), 3.79 – 3.52 (m, 15H, H-3’’,H-4’’, H-
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5’’, H-1’’, H-2, H-3, H-4, OCH3), 2.95 – 2.85 (m, 1H, H-4a), 2.22 (s, 3H, ArCH3).
13
C 
NMR (400 MHz, CD3OD) δ 162.3, 156.2, 151.8, 142.2, 139.0, 125.9, 125.7, 125.5, 121.8, 
112.2, 115.4, 113.6, 107.0, 102.2, 96.4, 76.3, 70.9, 70.5, 70.3, 70.4, 70.1, 70.0, 68.8, 67.4, 
66.9, 66.9, 61.6, 61.6, 57.4, 50.1, 34.3, 19.7. 
19
F NMR (400 MHz, CD3OD) δ -62.2                 
MS: m/z calcd for [M + H]
+ 
= 722; found [M + H]
+ 
= 722 
 
5.8.4. Synthetic strategy for tricyclic derivative 93 for the assembly of 
liposomes 
Compound 88 
Acording to literature procedure:
98
 
 
Scheme 5.15 
A stirred suspension of cis-cycloheptene 87 (1.92 g, 20.0 mmol) and potassium t-butoxide 
(2.58 g, 23.0 mmol) in anhydrous pentane (50 mL) was cooled to 0 °C. A solution of 
bromoform (1.75 mL, 20.0 mmol) in anhydrous pentane (50 mL) was added dropwise over 
a period of 6 h at 0 °C under argon. After complete addition the resulting brown mixture 
was warmed to room temperature and stirred overnight. After addition of water (200 mL 
and neutralization with conc. HCl, the aqueous layer was extracted with pentane (3 x 30 
mL). The combined organic layers were washed with water (3 x 30 mL) and dried over 
Na2SO4. Evaporation of the solvent under high vacuum gave crude product 88 as brown 
oil. 
1
H NMR (400 MHz, CDCl3) δ 2.33–2.21 (m, 2H, H-2a, H-6a), 1.94–1.78 (m, 3H, H-
3a, H-4a, H-5a), 1.76–1.66 (m, 2H, H-1, H-7), 1.43–1.31 (m, 2H, H-3b, H-5b), 1.24–1.09 
(m, 3H, H-2b, H-4b, H-6b).
13
C NMR (101 MHz, CDCl3) δ 40.9, 34.9, 32.4, 29.1, 28.2.  
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Compound 89 
Acording to literature procedure:
98
 
 
Scheme 5.16 
Tetraethyleneglycol (24 mL, 139 mmol) and AgClO4 (5.7 g, 139 mmol) dissolved in dry 
toluene (12 mL) were added to a solution of 88 (2.48 g, 9.25 mmol) in a mixture of dry 
toluene (5 mL) and dry pyridine (6.6 mL). The reaction was refluxed in the dark for 4 h 
and the solvent was evaporated. Then, brine (200 mL) was added, the insoluble silver salts 
were removed by filtration, and the aqueous phase was extracted with Et2O (7x100 mL). 
The combined organic layer was washed with brine (140 mL) and H2O (140 mL), dried 
(Na2SO4), and concentrated. The crude product was purified by flash chromatography 
[(petroleum ether/ EtOAc 3:7)] to give 89 in 54% yield (over two steps) as yellow pailed 
oil. 
1
H NMR (400 MHz, CDCl3) δ 6.18 (dd, J = 11.8, 4.1 Hz, 1H, CH=CBr), 3.92 (dd, J = 
10.4, 4.9 Hz, 1H, CHOpropargyl), 3.79 – 3.64 (m, 13H, CH2PEG), 3.64 – 3.57 (m, 2H, 
CH2PEG), 3.57 – 3.40 (m, 1H, CH2PEG), 2.73 (qd, J = 11.8, 5.5 Hz, 1H, CH2ring), 2.35 – 2.14 
(m, 2H, CH2ring), 2.10 – 1.95 (m, H, CH2ring), 1.96 – 1.80 (m, 2H, CH2ring), 1.80 – 1.63 (m, 
1H, CH2ring), 1.48 (dq, J = 11.5, 5.0 Hz, 1H, CH2ring), 1.36 – 1.19 (m, 1H, CH2ring), 0.88 – 
0.69 (m, 1H, CH2ring). 
13
C NMR (101 MHz, CDCl3) δ 131.8, 85.5, 76.9, 72.8, 70.8, 70.8, 
70.6, 70.5, 68.2, 68.1, 61.9, 39.7, 28.3, 26.6.
 
 
Compound 90 
Acording to literature procedure:
98
 
 
Scheme 5.17 
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KO
t
Bu (1.066 g, 9.5 mmol) was added to a solution of 89 (1.45 g, 3.8 mmol) in a mixture 
of dry i-PrOH (29 mL)/ dry pyridine (4 mL). After 60 h of stirring at rt, the reaction was 
neutralized with 5% HCl and partitioned between CH2Cl2 and H2O. Then, the aqueous 
layer was extracted with CH2Cl2 (7 x 30 mL), dried (Na2SO4), and concentrated under 
vacuum to give a crude product that was purified by column chromatography [gradient 
from petroleum ether/EtOAc 4:6 to EtOAc] to give 90 (1.337 g, 84%) as a yellow oil. 
1
H 
NMR (400 MHz, CDCl3) δ 4.26 – 4.11 (m, 1H, CHOpropargyl), 3.76 – 3.54 (m, 15H, 
CH2PEG), 3.53 – 3.42 (m, 1H, CH2PEG), 2.94 (br s, 1H, OH), 2.29 – 2.18 (m, 1H, CH2ring), 
2.19 – 2.04 (m, 2H, CH2ring), 2.03 – 1.85 (m, 2H, CH2ring), 1.85 – 1.73 (m, 2H, CH2ring), 
1.71 – 1.52 (m, 2H, CH2ring), 1.46 –1.33 (m, 1H, CH2ring). 
13
C NMR (101 MHz, CDCl3) δ 
100.5, 92.8, 73.0, 73.0, 70.8, 70.7, 70.6, 70.5, 70.3, 68.6, 61.8, 42.3, 34.4, 29.9, 26.5, 20.9. 
Compound 91 
 
Scheme 5.18 
To a solution of alcohol 90 (540 mg, 1.80 mmol) and dry triethylamine (0.376 mL, 2.70 
mmol) in dry CH2Cl2 (8.5 mL), kept to 0ºC, was added mesyl chloride (0.167 mL, 2.16 
mmol). The reaction was maintained at 0ºC during the first hour, followed by warming to 
room temperature, under vigorous stirring and argon atmosphere for 3 h. At the end of this 
time the solution was extracted with CH2Cl2 and the combined organic extracts were 
washed with a 10% aqueous HCl, brine, dried over sodium sulfate and evaporated. The 
obtained residue was used without further purification 
Compound 92 
 
Scheme 5.19 
Potassium thioacetate (393 mg, 3.44  mmol) was added to a stirred mixture of compound 
91 (620 mg, 1.64 mmol) in dry DMF (8 mL). The resulting mixture was stirred at rt for      
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2 h. After removal of solvent under vacuum, the residue was purified by flash column 
chromatography on silica gel [(petroleum ether/ EtOAc 6:4)] to give compound 92 as an 
yellow oil (473 mg, 74% over 2 steps). 
1
H NMR (400 MHz, CDCl3) δ 4.20 (dd, J = 7.0, 
5.3 Hz, 1H CHOpropargyl), 3.75 – 3.55 (m, 13H, CH2PEG), 3.53 – 3.45 (m, 1H, CH2PEG), 3.07 
(t, J = 6.4 Hz, 2H, SCH2PEG), 2.32 (s, 3H, CH3), 2.30 – 2.05 (m, 3H CH2ring), 2.00 – 1.86 
(m, 2H, CH2ring), 1.86 – 1.74 (m, 2H, CH2ring), 1.72 – 1.51 (m, 2H, CH2ring), 1.50 – 1.31 (m, 
1H, CH2ring). 
Compound 93 
 
Scheme 5.20 
To a stirred solution of the thioacetate 92 (50 mg, 0.14 mmol) in anhydrous THF (1.5 ml) 
at 0 °C was added LiAlH4 (26 mg, 0.7 mmol) under an Ar atmosphere. The mixture was 
stirred at 0 °C for 15 min. Then, water was added and the aqueous phase was extracted 
with CH2Cl2. The combined organic layer was dried (Na2SO4), and concentrated under 
reduce pressure to give the crude thiol 93 as yellow oil. MS: m/z calcd for [M + H]
+ 
=317.46, [M + Na]
+ 
=339.46, [M + K]
+ 
=355; found [M + H]
+ 
= 318, [M + Na]
+ 
=339,      
[M + K]
+ 
=355. 
Compound 94 
 
Scheme 5.21 
A solution of the crude thiol 93 (74 mg, 0.24 mmol) in dry DMF (1 mL) was added to a 
solution of compound 78 (65 mg, 0.16 mmol) in dry DMF (1.0 mL). To the mixture was 
added CsCO3 (57 mg, 0.176 mmol) and the resultant solution was stirred at room 
temperature for 40 min., after which was poured into CH2Cl2-H2O mixture. The aqueous 
phase was extracted with CH2Cl2 (3 x 5 mL), and the combined organic layers were dried 
over Na2SO4 and concentrated under reduce pressure. The residue was purified by flash 
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chromatography [(toluene/EtOAc 7:3)] affording 94 (80 mg, 77%) as yellow pailed solid. 
1
H NMR (400 MHz, CDCl3) δ 7.21 (bs, 1H, H-6), 7.01 (dd, J = 7.9, 1.0 Hz, 1H, H-8), 6.72 
(d, J = 7.9 Hz, 1H, H-9), 5.54 (d, J = 2.7 Hz, 1H, H-10a), 4.80 (d, J = 5.0 Hz, 1H, H-4a), 
4.54 – 4.36 (m, 2H, H-1‘‘), 4.33 – 4.18 (m, 2H, H-2, CHpropargyl), 4.00 (d, J = 3.0 Hz, 1H, 
H-4), 3.88 (bs, 1H, H-3), 3.83 – 3.57 (m, 16H, CH2PEG, OCH3), 3.57 – 3.45 (m, 1H, 
CH2PEG), 3.35 (s, 2H, SCH2CO), 3.00 – 2.78 (m, 3H, H-5, SCH2PEG), 2.31 (s, 3H, CH3), 
2.26 – 2.06 (m, 3H, CH2ring), 2.04 – 1.88 (m, 2H, CH2ring), 1.90 – 1.74 (m, 2H, CH2ring), 
1.74 – 1.53 (m, 2H, CH2ring), 1.50 – 1.34 (m, 1H, CH2ring).
13
C NMR (101 MHz, CDCl3) δ 
170.6, 158.7, 149.7, 131.0, 130.5, 126.7, 120.1, 116.1, 100.2, 96.1, 93.1, 78.5, 72.9, 70.8, 
70.6, 70.6, 69.7, 68.7, 67.1, 67.1, 64.6, 59.7, 46.3, 42.5, 34.7, 34.5, 34.1, 32.1, 29.1, 26.6, 
20.1, 20.9.  
 
5.8.5. Synthetic strategy for compound 6a 
Compound 99 
Acording to literature procedure:
153
 
 
Scheme 5.22 
Methyl α-D-glucopyranoside 98 (10 g, 51.5 mmol) and anisaldehyde dimethylacetal (9.63 
mL, 56.6 mmol) are dissolved in dry DMF (40 mL). Camphorsulfonic acid (CSA)       
(0.01 equiv.) is added and the flask is attached to a rotary evaporator, rotated, evacuated, 
and lowered into a water bath at approximately 60ºC to remove the methanol, which is 
formed during the reaction. After 1 h, all the DMF is removed by evaporation. Then a 
solution of sodium hydrogen carbonate (1 g in 50 mL of water) is added to the residue, and 
the mixture is heated at 100ºC until the product is finely dispersed. The mixture is cooled 
to room temperature, and the product filtered off, washed thoroughly with water, and dried. 
1
H NMR (400 MHz, DMSO) δ 7.34 (d, J = 8.4 Hz, 2H, Ar-H), 6.89 (d, J = 8.4 Hz, 2H, Ar-
H), 5.48 (s, 1H, H-1’), 5.19 (s, 1H, OH), 5.03 (s, 1H, OH), 4.60 (d, J = 3.2 Hz, 1H, H-1), 
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4.12 (dd, J = 9.9, 4.4 Hz, 1H, H-6), 3.72 (s, 3H, OMe), 3.64 (t, J = 9.9 Hz, 1H, H-6), 3.59 – 
3.50 (m, 2H, H-5, H-3), 3.37 – 3.26 (m, 5H, OCH3, H-2, H-4). 
13
C NMR (101 MHz, 
DMSO) δ 164.9, 135.6, 133.1, 118.7, 106.2, 105.9, 86.7, 77.8, 75.3, 73.6, 67.8, 60.5, 60.2, 
45.6, 45.3, 45.1, 44.9, 44.7, 44.5, 44.3. 
Compound 100 
Acording to literature procedure:
153
 
 
Scheme 5.23 
A stirred solution of 99 (10 g, 0.032 mol) in anhydrous DMF (100 mL) under argon at 0 ºC 
was treated with of NaH (60% in mineral oil, 3.8 g, 0.096 mol). After 15 min. at room 
temperature, the mixture was treated dropwise and rapidly with BnBr (0.096 mol, 11 mL) 
and then allowed to stand for 1 h at rt. The mixture was diluted with EtOAc (40 mL), and 
washed with saturated NaHCO3 solution (70 mL). The aqueous phase was back-extracted 
with EtOAc (3 x 30 mL), and all the organic fractions were combined, washed with brine, 
and dried over anhydrous Na2SO4. The residue was recrystallize from toluene to give 100 
(15.2 g, 96% yield) as a white solid. 
13
C NMR (101 MHz, CDCl3) δ 159.4, 139.0, 138.2, 
130.2, 129.5, 128.8, 128.7, 128.4, 128.2, 128.2, 128.1, 128.0, 113.9, 98.4, 81.6, 79.7, 77.5, 
77.2, 76.9, 75.6, 73.4, 73.4, 71.0, 70.0, 69.3, 55.4. 
Compound 101  
Acording to literature procedure:
153
 
 
Scheme 5.24 
A solution at 0ºC of trifluoroacetic acid (100 mmol, 7.40 mL) in dry DMF (40 mL) was 
added dropwise to a stirred solution containing compound 101 (5 g, 10 mol), NaCNBH3 
(3.142 g, 50 mmol) and 3Ǻ MS in dry DMF (50 mL). After 12h at rt the mixture was 
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filtered through celite and powered into ice-cold saturated NaHCO3. The aqueous phase 
was repeatedly extracted with EtOAc (3 x 30 mL). The combined extracts were washed 
with saturated aqueous NaHCO3 (100 mL), dried over Na2SO4, filtered and concentrated 
under reduce pressure. The residue was purified by flash chromatography [(petroleum 
ether/ EtOAc 8:2)] do give 87% as green pale oil. 
1
H NMR (400 MHz, CDCl3) δ 7.42 – 
7.19 (m, 12H, Ar-H), 6.85 (d, J = 8.7 Hz, 2H, Ar-H), 4.99 (d, J = 11.8 Hz, 1H, CH2Ph), 
4.77 (d, J = 12.3 Hz, 1H, CH2Ph), 4.73 (d, J = 11.8 Hz, 1H, CH2Ph), 4.65 (d, J = 12.3 Hz, 
1H, CH2Ph), 4.62 (d, J = 3.5 Hz, 1H, H-1), 4.51 (d, J = 11.8 Hz, 1H, CH2Ph), 4.46 (d, J = 
11.8 Hz, 1H, CH2Ph), 3.83 – 3.74 (m, 4H, ArOMe, H-4), 3.73 – 3.66 (m, 1H, H-5), 3.66 – 
3.60 (m, 2H, H-6), 3.62 – 3.56 (m, 1H, H-3), 3.52 (dd, J = 9.6, 3.5 Hz, 1H, H-2), 3.37 (s, 
3H, OMe). 
13
C NMR (101 MHz, CDCl3) δ 159.4, 139.0, 138.2, 130.2, 129.5, 128.8, 128.6, 
128.3, 128.2, 128.1, 128.0, 128.0, 113.9, 98.4, 81.6, 79.7, 77.5, 77.2, 76.9, 75.6, 73.4, 73.4, 
71.0, 70.0, 69.3, 55.4. 
Compound 102 
 
Scheme 5.25 
To a solution of (COCl)2 (46 mmol, 3.97 mL) in dry CH2Cl2 (92 mL) at -78ºC under argon 
atmosphere, a solution of anhydrous DMSO (92 mmol, 6.51 mL)  in dry CH2Cl2 (20 mL) 
was added dropwise, and the resulting solution was stirred for 30 min. To the reaction 
flask, a solution of compound 101 (5.693 g, 11.5 mmol) in dry CH2Cl2 (20 mL) was added 
dropwise at -78ºC. This final reaction mixture stayed under magnetic stirring for 1 h at       
-78ºC. Then dry Et3N (115 mmol, 13.91 mL) was added and the reaction stayed for more 
30 min. under magnetic stirring, and then allowed to warm up until 0ºC. A saturated 
solution of NH4Cl was added, and the reaction mixture was extracted with CH2Cl2 (x3). 
The organic extracts were dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude product was used without further purification. 
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Compound 103 
 
Scheme 5.26 
To a solution of 102 (2.03 g, 4.12 mmol) in dry THF (20 mL) at -78ºC under argon 
atmosphere, a solution of allylmagnesium bromide (1 M in Et2O) (8.24 mmol, 8.24 mL) 
was added dropwise. The resulting solution was stirred for 90 min. and then allowed to 
warm up until 0ºC. A saturated solution of NH4Cl (60 mL) was added, and the reaction 
mixture was extracted with CH2Cl2 (3 x 20 mL). The organic extracts were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by 
flash chromatography [(petroleum ether/ EtOAc 8.5:1.5)] do give 60% (over 2 steps) as 
green pale oil. 
1
H NMR (400 MHz, benzene-d6) δ 7.28 – 7.00 (m, 12H, Ar-H), 6.74 (d, J = 
8.5 Hz, 2H, Ar-H), 5.84 – 5.57 (m, 1H, H-2’), 5.03 (d,  J = 11.2 Hz, 1H, CH2Ph), 4.97 – 
4.86 (m, 2H, H-3), 4.75 (d, J = 3.4 Hz, 1H, H-1), 4.56 (d, J = 11.2 Hz, 1H, CH2Ph), 4.46 – 
4.29 (m, 4H, 2 CH2Ph), 4.16 – 4.06 (m, 2H, H-5, H-2), 4.04 – 3.95 (m, 2H, H-3, H-6), 3.88 
(dd, J = 10.6, 5.8 Hz, 1H, H-6), 3.23 (s, 3H, ArOMe), 3.20 (s, 3H, OMe), 2.66 (dd, J = 
14.0, 7.7 Hz, 1H, H-1’), 2.34 (dd, J = 14.0, 7.4 Hz, 1H, H-1’). 13C NMR (101 MHz, 
benzene-d6) δ 159.5, 139.2, 139.0, 133.3, 130.7, 129.3, 128.4, 128.3, 128.2, 128.1, 127.89, 
127.7, 127.6, 127.5, 118.5, 113.9, 98.0, 79.4, 77.1, 76.8, 75.3, 73.1, 72.3, 70.8, 69.4, 54.9, 
54.5, 40.6. 
Compound 104 
 
Scheme 5.27 
To a solution of compound 103 (1.317 g, 2.46 mmol) in CH3CN (100 mL) at 0ºC, a 
solution of CAN (6.743 g, 12.30 mmol) in water (30 mL) was added. The reaction mixture 
was stirred at room temperature for 20 min. and then diluted with CH2Cl2 (70 mL) and 
wash with water (2 x 100 mL). The combined organic phases were dried, concentrated and 
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purified by flash chromatography [(petroleum ether/ EtOAc 6:4)] do give 72% as green oil. 
1
H NMR (400 MHz, CDCl3) δ 7.44 – 7.23 (m, 10H, Ar-H), 5.66 (ddd, J = 18.2, 16.0, 7.5 
Hz, 1H, H-2’), 5.15 – 5.08 (m, 2H, H-3’), 5.06 (d, J = 11.0 Hz, 1H, CH2Ph), 4.76 (d, J = 
11.9 Hz, 1H, CH2Ph), 4.73 – 4.67 (m, 2H, H-1, CH2Ph), 4.64 (d, J = 11.9 Hz, 1H, CH2Ph), 
4.03 (dd, J = 12.0, 5.8 Hz, 1H, H-6), 3.94 (dd, J = 9.4, 3.5 Hz, 1H, H-2), 3.87 – 3.78 (m, 
2H, H-3, H-6), 3.74 – 3.68 (m, 1H, H-5), 3.39 (s, 3H, OCH3), 2.65 (dd, J = 14.3, 7.2 Hz, 
1H, H-1’), 2.30 (dd, J = 14.3, 7.7 Hz, 1H, H-1’).13C NMR (101 MHz, CDCl3) δ 138.3, 
138.2, 132.1, 128.7, 128.7, 128.4, 128.3, 128.2, 128.1, 119.6, 98.2, 78.7, 77.6, 77.2, 76.9, 
76.9, 76.8, 75.8, 73.4, 70.0, 61.3, 55.6, 40.3. 
Compound 105 
 
Scheme 5.28 
To a solution of (COCl)2 (0.48 mmol, 41 µL) in dry CH2Cl2 (92 mL) at -78ºC under argon 
atmosphere, a solution of anhydrous DMSO (0.96 mmol, 68 µL) in dry CH2Cl2 (0.75 mL) 
was added dropwise, and the resulting solution was stirred for 30 min. To the reaction 
flask, a solution of compound 104 (50 g, 0.12 mmol) in dry CH2Cl2 (0.75 mL) was added 
dropwise at -78ºC. This final reaction mixture stayed under magnetic stirring for 1 h at        
-78ºC. Then dry Et3N (1.2 mmol, 167 µL) was added and the reaction stayed for more      
30 min. under magnetic stirring, and then allowed to warm up until 0ºC. The solution was 
recooled to -78ºC and vinylmagnesium bromide 1 M in THF (1.44 mmol, 1.44 mL) was 
added dropwise and this final reaction mixture was stirred for 4h at -78ºC and then allowed 
to warm up until 0ºC. A saturated solution of NH4Cl was added (80 mL), and the reaction 
mixture was extracted with CH2Cl2 (3 x 30 mL). The organic extracts were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by 
flash chromatography [(petroleum ether/ EtOAc 8:2)] do give 45% as yellow pale oil.
 1
H 
NMR (400 MHz, CDCl3) δ 7.44 – 7.23 (m, 10H, Ar-H), 5.94 (ddd, J = 16.9, 10.4, 5.8 Hz, 
1H, H-2’’), 5.70-5.60 (m, H-2’), 5.32 (d, J = 16.9 Hz, 1H, H-3’’trans), 5.20 – 5.08 (m, 4H, 
H-3’’cis, H-3’, CH2Ph ), 5.06 (d, J = 10.9 Hz, 1H, CH2Ph), 4.75 (d, J = 12.0 Hz, 1H, 
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CH2Ph), 4.72 – 4.66 (m, 3H, H-1, H-1’’, CH2Ph), 4.62 (d, J = 12.0 Hz, 1H, CH2Ph), 3.94 
(dd, J = 9.5, 3.6 Hz, 1H, H-2), 3.81 (d, J = 9.5 Hz, 1H, H-3), 3.57 (bs, 1H, H-5), 3.32 (s, 
3H, OMe), 2.75 (dd, J = 14.3, 6.9 Hz, 1H, H-1’), 2.45 (dd, J = 14.4, 8.0 Hz, 1H, H-1’). 13C 
NMR (101 MHz, CDCl3) δ 138.2, 138.1, 132.0, 128.7, 128.7, 128.4, 128.3, 128.2, 128.1, 
119.7, 115.9, 98.2, 78.3, 77.9, 77.5, 77.2, 76.9, 76.7, 75.9, 73.4, 71.5, 70.9, 55.6, 40.4, 
32.1, 29.9, 29.9, 29.6, 14.3. 
Compound 106 
 
Scheme 5.29 
To a solution of 105 (60 mg, 0.136 mmol) in dry CH2Cl2 (5 mL), Hoveyda-Grubbs catalyst 
2
nd
 generation (5% weight), was added. The reaction mixture was stirred at 40ºC for 90 
min. The crude product was concentrated and purified by flash chromatography 
[(petroleum ether/ EtOAc 6:4)] to give 89% as brown pale oil. 
1
H NMR (400 MHz, 
CDCl3) δ 7.42 – 7.29 (m, 10H, Ar-H), 5.69 (d, J = 10.2 Hz, 1H, H-6), 5.64 – 5.57 (m, 1H, 
H-5), 5.00 (d, J = 11.0 Hz, 1H, CH2Ph), 4.78 (d, J = 12.1 Hz, 1H, CH2Ph), 4.73 (d, J = 3.5 
Hz, 1H, H-1), 4.70 – 4.62 (m, 2H, CH2Ph), 4.54 – 4.47 (m, 1H, H-7), 3.92 (dd, J = 9.5,    
3.5 Hz, 1H, H-2), 3.71 (d, J = 9.5 Hz, 1H, H-3), 3.61 (d, J = 8.5 Hz, 1H, H-7a), 3.41 (s, 
3H, OMe), 2.38 (dd, J = 18.4, 4.4 Hz, 1H, H-4), 2.12 – 2.03 (m, 1H, H-4). 
Compound 6a 
 
Scheme 5.30 
Compound 106 (86 mg, 0.2 mmol) and activated MnO2 (128 mg, 1.46 mmol) were slurried 
in EtOAc (2 mL), and the mixture was armed at reflux for 4 h. After consumption of the 
starting material, the reaction mixture was filtered hot though celite and the residual black 
solid was washed copiously with EtOAc (10 mL). The filtrate was concentrated in vacuum. 
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The crude product was purified by flash chromatography [(toulene/EtOAc 6:4)] to give 
91% as brown pale oil.
 1
H NMR (400 MHz, CDCl3) δ 7.42 – 7.25 (m, 10H, Ar-H), 6.66 
(ddd, J = 10.1, 5.6, 2.1 Hz, 1H, H-5), 6.07 (dd, J = 10.1, 2.8 Hz, 1H, H-6), 4.99 (d, J = 11.1 
Hz, 1H, CH2Ph), 4.79 (d, J = 3.4 Hz, 1H, H-1), 4.77 (d, J = 12.0 Hz, 1H, CH2Ph), 4.69 (d, 
J = 11.1 Hz, 1H, CH2Ph), 4.63 (d, J = 12 Hz, 1H, CH2Ph), 4.37 (s, 1H, H-5), 3.91 (dd, J = 
9.5, 3.4 Hz, 1H, H-2), 3.83 (d, J = 9.5 Hz, 1H, H-3), 3.40 (s, 3H, OMe), 2.67 (dd, J = 19.2, 
5.7 Hz, 1H, H-4a), 2.33 – 2.26 (m, 1H, H-4b). 13C NMR (101 MHz, CDCl3) δ 193.6, 
144.1, 138.0, 137.9, 128.7, 128.7, 128.5, 128.4, 128.3, 98.8, 98.7, 79.6, 77.6, 77.7, 77.3, 
77.0, 76.4, 76.0, 74.6, 73.6, 56.3, 56.3, 37.4, 29.9. 
 
5.8.. Synthetic strategy for compound 6b 
Compound 107 
 
Scheme 5.31 
To a suspension of methyltriphenylphosphonium bromide (10.6 g, 29.84 mmol) in dry 
THF (50 mL) was added n-BuLi 1.6 M solution in hexane (17.31 mL) at -78ºC with 
stirring under argon atmosphere. After being warmed to 0ºC for 30 min., the solution was 
recooled to -78ºC and treated with a solution of ketone 102 (2.1 g, 4.26 mmol) in dry THF 
(90 mL). The mixture was allowed to stir for 2 h until it warmed rt, poured in a saturated 
solution of NH4Cl (100 mL) and extracted with Et2O (3 x 30 mL). The organic extracts 
were dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash chromatography [(petroleum ether/ EtOAc 8.5:1.5)] do give 80% as 
yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 7.43 – 7.23 (m, 12H, Ar-H), 6.88 (d, J = 8.6 Hz, 
2H, Ar-H), 5.35 (bs, 1H, H-1’), 4.96 (s, 1H, H-1’), 4.85 (d, J = 12.2 Hz, 1H, CH2Ph), 4.80 
(d, J = 11.3 Hz, 1H, CH2Ph), 4.72 (d, J = 11.3 Hz, 1H, CH2Ph), 4.71 – 4.63 (m, 2H, H-1, 
CH2Ph), 4.58 – 4.48 (m, 2H, CH2Ph), 4.35 – 4.27 (m, 2H, H-5, H-3), 3.80 (s, 3H, OMe), 
3.76 (dd, J = 10.0, 4.9 Hz, 1H, H-6), 3.65 (dd, J = 10.0, 5.9 Hz, 1H, H-6), 3.48 (dd, J = 9.6, 
3.6 Hz, 1H, H-2), 3.43 (s, 3H, OMe). 
13
C NMR (101 MHz, CDCl3) δ 159.2, 142.6, 138.4, 
Experimental section 
147 
138.3, 129.9, 129.4, 128.3, 128.0, 127.7, 127.7, 127.5, 113.7, 107.7, 98.7, 81.5, 79.1, 77.3, 
77.0, 76.7, 73.8, 73.6, 73.1, 69.2, 67.7, 55.3, 55.2. 
Compound 108 
 
Scheme 5.32 
A solution of BH3•Me2S (7.3 mmol, 0.7 mL) was added dropwise to a solution of 107     
(2.9 g, 5.86 mmol) in dry THF (54 mL) at room temperature, under argon atmosphere and 
stirred for 90 min. The reaction mixture was cooled at 0ºC, aqueous NaOH 3 M (2.9 mL) 
and aqueous H2O2 (30%) (2.9 mL) were added dropwise subsequently. After 12 h, the 
reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (3 x 70 mL), 
dried over Na2SO4, filtered and concentrated under vacuum. The resulting residue was 
purified by flash chromatography [(petroleum ether/ EtOAc 7.5:2.5)] to give 49% as brown 
pale oil.
 
 
1
H NMR (400 MHz, CDCl3) δ 7.38 – 7.19 (m, 12H, Ar-H), 6.87 (d, J = 8.6 Hz, 
2H, Ar-H), 4.82 (d, J = 12.1 Hz, 1H, CH2Ph), 4.75 (d, J = 11.5 Hz, 1H, CH2Ph), 4.70 (d,           
J = 11.5 Hz, 1H, CH2Ph), 4.66 (d, J = 12.1 Hz, 1H, CH2Ph), 4.64 (d, J = 3.9 Hz, 1H, H-1), 
4.56 – 4.42 (m, 2H, CH2Ph), 4.09 – 4.01 (m, 2H, H-5, H-3), 3.94 (dd, J = 11.5, 5.5 Hz, 1H, 
H-6), 3.83 – 3.75 (m, 4H, ArOMe, H-6), 3.68 (dd, J = 10.2, 3.9 Hz, 1H, H-2), 3.61 – 3.54 
(m, 2H, H-1’), 3.37 (s, 3H, OMe), 2.34 (dd, J = 5.5, 1.9 Hz, 1H, H-4). 13C NMR (101 
MHz, CDCl3) δ 159.4, 138.1, 129.5, 129.4, 128.4, 128.3, 128.0, 127.6, 113.7, 98.8, 78.5, 
77.3, 77.0, 76.7, 76.5, 73.4, 73.0, 69.9, 67.9, 57.7, 55.2, 43.5. 
Compound 109 
 
Scheme 5.33 
Same experimental procedure used for compound 109. 
1
H NMR (400 MHz, CDCl3) δ 7.46 
– 7.17 (m, 12H, Ar-H), 6.87 (d, J = 8.6 Hz, 2H, Ar-H), 4.94 (d, J = 11.8 Hz, 1H, CH2Ph), 
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4.81 (d, J = 11.9 Hz, 1H, CH2Ph), 4.78 (d, J = 11.8 Hz, 1H, CH2Ph), 4.62 (d, J = 11.9 Hz, 
1H, CH2Ph), 4.59 (d, J = 3.8 Hz, 1H, H-1), 4.51 (d, J = 11.7 Hz, 1H, CH2Ph), 4.45 (d, J = 
11.7 Hz, 1H, CH2Ph), 3.88 (t, J = 6.1 Hz, 1H, H-5), 3.82 – 3.78 (m, 4H, H-3, ArOMe), 
3.68 (dd, J = 9.8, 6.1 Hz, 1H, H-6), 3.55 (dd, J = 9.8, 6.1 Hz, 1H, H-6), 3.46 – 3.36 (m, 4H, 
H-2, OMe), 1.18 (s, 3H, CH3). 
13
C NMR (101 MHz, CDCl3) δ 159.23, 139.17, 138.27, 
129.79, 129.29, 128.41, 128.39, 128.03, 127.81, 127.76, 127.56, 113.78, 98.01, 83.49, 
78.48, 77.37, 77.05, 76.73, 75.67, 74.32, 73.36, 73.23, 70.65, 68.61, 55.25, 55.10, 15.80. 
Compound 110 
 
Scheme 5.34 
To a solution of (COCl)2 (7.86 mmol, 0.7 mL) in dry CH2Cl2 (16 mL) at -78ºC under argon 
atmosphere, a solution of anhydrous DMSO (15.76 mmol, 1.1 mL)  in dry CH2Cl2 (6 mL) 
was added dropwise, and the resulting solution was stirred for 30 min. To the reaction 
flask, a solution of compound 108 (1 g, 1.97 mmol) in dry CH2Cl2 (10 mL) was added 
dropwise at -78ºC. This final reaction mixture stayed under magnetic stirring for 1 h at -
78ºC. The dry Et3N (19.7 mmol, 2.76 mL) was added and the reaction stayed for more 30 
min. under magnetic stirring, and then allowed to warm up until 0ºC. A saturated solution 
of NH4Cl (150 mL) was added, and the reaction mixture was extracted with CH2Cl2 (3 x 
50 mL). The organic extracts were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography [(petroleum ether/ 
EtOAc 7.5:2.5)] do give 98% as green pale oil. 
1
H NMR (400 MHz, CDCl3) δ 9.90 (d, J = 
5.3 Hz, 1H, CHO), 7.43 – 7.14 (m, 12H, Ar-H), 6.86 (d, J = 8.6 Hz, 2H, Ar-H), 4.85 (d, J 
= 12.1 Hz, 1H, CH2Ph), 4.78 (d, J = 3.8 Hz, 1H, H-1), 4.73 – 4.68 (m, 2H, CH2Ph), 4.63 
(d, J = 11.5 Hz, 1H, CH2Ph), 4.47 – 4.35 (m, 2H, CH2Ph), 4.17 – 4.05 (m, 2H, H-3, H-5), 
3.98 (dd, J = 10.0, 3.8 Hz, 1H, H-2), 3.80 (s, 3H, OMe), 3.56 (dd, J = 10.4, 4.2 Hz, 1H, H-
6), 3.47 (dd, J = 10.4, 5.0 Hz, 1H, H-6), 3.37 (s, 3H, OMe), 2.98 (ddd, J = 10.1, 5.3, 3.6 
Hz, 1H, H-4). 
13
C NMR (101 MHz, CDCl3) δ 197.3, 155.3, 134.1, 133.9, 125.5, 125.5, 
124.4, 124.4, 124.1, 123.9, 123.8, 123.7, 109.8, 95.1, 73.4, 73.0, 72.6, 72.5, 72.5, 69.6, 
69.3, 68.1, 65.8, 63.7, 51.5, 51.3, 50.6, 25.7. 
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Compound 111 
 
Scheme 5.35 
To a solution of 110 (720 mg, 1.42 mmol) in dry THF (30 mL) at -78ºC under argon 
atmosphere, a solution of vinylmagnesium bromide (1M in THF) (3.55 mmol, 3.6 mL) was 
added dropwise. The resulting solution was stirred for 90 min. and then allowed to warm 
up until 0ºC. A saturated solution of NH4Cl (100 mL) was added, and the reaction mixture 
was extracted with CH2Cl2 (3 x 35 mL). The organic extracts were dried over Na2SO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography [(petroleum ether/ EtOAc 7:3)] do give 84% as brown pale oil. 
1
H NMR 
(400 MHz, CDCl3) δ 7.41 – 7.12 (m, 12H, Ar-H), 6.97 – 6.78 (m, 2H, Ar-H), 6.02 (ddd, J 
= 17.2, 10.1, 7.5 Hz, 1H, H-2’), 5.22 (d, J = 17.2 Hz, 1H, H-3’trans), 5.08 – 5.02 (m, 1H, H-
3’cis), 4.79 (d, J = 12.1 Hz, 1H, CH2Ph), 4.74 – 4.62 (m, 4H, H-1, 3 CH2Ph), 4.53 – 4.48 
(m, 1H, H-1’), 4.48 – 4.41 (m, 2H, CH2Ph), 4.13 – 4.06 (m, 2H, H-3, H-5), 3.80 (s, 3H, 
OMe), 3.67 – 3.60 (m, 1H, H-6), 3.54 (dd, J = 10.2, 5.3 Hz, 1H, H-6), 3.38 (s, 3H, OMe), 
2.45 – 2.39 (m, 1H, H-4). 13C NMR (101 MHz, CDCl3) δ 159.2, 141.1, 141.1, 138.3, 138.2, 
137.9, 129.8, 129.7, 129.3, 129.3, 128.4, 128.4, 128.3, 128.1, 127.6, 127.5, 115.7, 113.8, 
98.5, 79.6, 78.9, 77.3, 77.0, 76.7, 75.7, 73.5, 73.4, 73.3, 73.0, 71.2, 68.9, 55.2, 55.2, 45.3, 
44.8. 
Compound 112 
 
Scheme 5.36 
To a solution of 111 (588 mg, 1.10 mmol) and imidazole (249 mg, 1.65 mmol) in dry DMF 
(7 mL) was added TESCl (1.65 mmol, 0.25 mL). The reaction mixture was heated at 60ºC 
for 90 min. and then allowed to cold until rt and a saturated aqueous solution of NaHCO3 
(40 mL) was added. The reaction mixture was extracted with EtOAc (3 x 15 mL) and the 
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organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. 
The residue was purified by flash chromatography [petroleum ether/ EtOAc (8:2)] do give 
85% as light green oil. 
1
H NMR (400 MHz, CDCl3) δ 7.46 – 7.16 (m, 12H, Ar-H), 6.86 (d, 
J = 8.6 Hz, 2H, Ar-H), 6.19 – 6.06 (m, 1H, H-2’), 5.08 (d, J = 17.2 Hz, 1H, H-3’trans), 4.94 
(d, J = 10.5 Hz, 1H, H-3’cis), 4.77 – 4.49 (m, 7H, H-1’, 5 CH2Ph, H-1), 4.42 (d, J = 11.6 
Hz, 1H, CH2Ph), 4.14 (d, J = 9.0 Hz, 1H, H-5), 4.04 – 3.97 (m, 2H, H-2, H-3), 3.89 – 3.81 
(m, 1H, H-6), 3.79 (s, 3H, ArOMe), 3.72 – 3.64 (m, 1H, H-6), 3.40 (s, 3H, OMe), 2.38 (bs, 
1H, H-4), 0.88 (t, J = 7.8 Hz, 9H, CH3CH2Si), 0.51 (q, J = 7.8 Hz, 6H, CH3CH2Si).
 13C 
NMR (101 MHz, CDCl3) δ 159.4, 141.5, 139.2, 138.9, 131.0, 129.5, 128.7, 128.6, 128.6, 
128.3, 128.0, 127.8, 127.7, 127.4, 116.1, 114.0, 77.8, 77.4, 77.1, 73.4, 73.1, 73.1, 72.7, 
55.6, 55.3, 7.3, 5.6, 5.3. 
Compound 113 
 
Scheme 5.37 
DDQ (300 mg, 1.31mmol) was added to an ice-cooled solution of 112 (609 mg, 0.94 
mmol) in H2O/CH2Cl2 (1:20) (42 mL), and the mixture was stirred for 2 h. The reaction 
mixture was then diluted with saturated aqueous solution of NaHCO3 (80 mL) and 
extracted with CH2Cl2 (3 x 15 mL). The extracts were washed with H2O (50 mL) and brine 
(50 mL), dried and concentrated under reduce pressure. The residue was purified by flash 
chromatography [(petroleum ether/ EtOAc (8:2)] do give 87% as green oil.
1
H NMR (400 
MHz, CDCl3) δ 7.45 – 7.21 (m, 10H, Ar-H), 6.26 – 6.06 (m, 1H, H-2’), 5.14 (d, J = 17.1 
Hz, 1H, H-3’trans), 4.98 (d, J = 8.7 Hz, 1H, H-3’cis), 4.82 – 4.67 (m, 4H, 3 CH2Ph, H-1’), 
4.61 (d, J = 12.2 Hz, 1H, CH2Ph), 4.55 (d, J = 3.4 Hz, 1H, H-1), 4.06 – 3.93 (m, 3H, H-2, 
H-3, H-5), 3.87 – 3.75 (m, 2H, H-6, H-6), 3.34 (s, 3H, OMe), 2.63 – 2.48 (m, 1H, H-4), 
0.97 – 0.87 (m, 9H, CH3CH2Si), 0.63 – 0.55 (m, 6H, CH3CH2Si). 
13
C NMR (101 MHz, 
CDCl3) δ 140.4, 138.7, 138.4, 128.3, 128.1, 128.2, 128.1, 127.7, 127.4, 127.3, 127.2, 
117.1, 98.7, 77.3, 77.1, 76.6, 74.2, 72.9, 72.93, 69.13, 62.7, 55.1, 55.1, 47.4, 29.6, 6.6, 4.6. 
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Compound 114 
 
Scheme 5.38 
To a solution of (COCl)2 (1.51 mmol, 0.13 mL) in dry CH2Cl2 (2 mL) at -78ºC under argon 
atmosphere, a solution of anhydrous DMSO (2.96 mmol, 0.2 mL) in dry CH2Cl2 (3 mL) 
was added dropwise, and the resulting solution was stirred for 30 min. To the reaction 
flask, a solution of compound 114 (200 mg, 0.37 mmol) in dry CH2Cl2 (4 mL) was added 
dropwise at -78ºC. This final reaction mixture stayed under magnetic stirring for 1 h at        
-78ºC. Then dry Et3N (3.7 mmol, 0.52 mL) was added and the reaction stayed for more 30 
min. under magnetic stirring, and then allowed to warm up until 0ºC. A saturated solution 
of NH4Cl (30 mL) was added, and the reaction mixture was extracted with CH2Cl2              
(3 x 10mL). The organic extracts were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue was used without further purification. 
Compound 115 
 
Scheme 5.39 
To a solution of 114 (380 mg, 0.72 mmol) in dry THF (18 mL) at -78ºC under argon 
atmosphere, a solution of vinylmagnesium bromide (1 M in THF) (1.8 mmol, 1.8 mL) was 
added dropwise. The resulting solution was stirred for 90 min. and then allowed to warm 
up until 0ºC. A saturated solution of NH4Cl (20 mL) was added, and the reaction mixture 
was extracted with CH2Cl2 (3 x 10 mL). The organic extracts were dried over Na2SO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography [petroleum ether/ EtOAc (8.5:1.5)] to give 69% (over 2 steps) as green 
pale oil. 
1
H NMR (400 MHz, CDCl3) δ 7.40 – 7.24 (m, 10H, Ar-H), 6.39 – 6.25 (m, 1H, H-
2’), 6.10 – 5.94 (m, 1H, H-2’’), 5.40 (d, J = 17.5 Hz, 1H, H-3’’trans), 5.18 (d, J = 10.4 Hz, 
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1H, H-3’’cis), 5.11 (d, J = 17.0 Hz, 1H, H-3’trans), 4.95 (d, J = 9.6 Hz, 1H, H-3’cis), 4.85 – 
4.68 (m, 4H, CH2Ph, H-1, H-1’), 4.58 (bd, J = 12.4 Hz, 2H, CH2Ph), 4.40 (s, 1H, H-1’’), 
4.13 – 4.03 (m, 1H, H-2), 4.03 – 3.93 (m, 1H, H-3), 3.79 (bs, 1H, H-5), 3.34 (s, 3H, OMe), 
2.46 (bs, 1H, H-4), 0.92 (t, J = 7.9 Hz, 9H, CH3CH2Si), 0.65 – 0.53 (m, 6H, CH3CH2Si). 
13
C NMR (101 MHz, CDCl3) δ 141.1, 138.3, 138.0, 136.5, 128.4, 128.3, 128.1, 127.7, 
127.7, 127.6, 117.5, 116.3, 99.1, 79.0, 77.3, 76.9, 76.6, 75.2, 73.4, 73.1, 72.8, 71.8, 71.7, 
55.6, 55.5, 45.5, 29.6, 6.7, 6.4. 
Compound 116 
 
Scheme 5.40 
To a solution of 115 (50 mg, 0.09 mmol) in dry CH2Cl2 (4 mL), Hoveyda-Grubbs catalyst 
2
nd
 generation (5% weight), was added. The reaction mixture was stirred at 40ºC for 2 h. 
The crude product was concentrated and purified by flash chromatography [(petroleum 
ether/ EtOAc 8:2)] to give 84% as brown pale oil. 
1
H NMR (400 MHz, CDCl3) δ 7.44 – 
7.17 (m, 10H, Ar-H), 5.88 – 5.71 (m, 2H, H-6, H-5), 4.89 (d, J = 12.6 Hz, 1H, CH2Ph), 
4.80 (d, J = 12.6 Hz, 1H, CH2Ph), 4.75 (d, J = 12.7 Hz, 1H, CH2Ph), 4.65 – 4.56 (m, 2H, 
CH2Ph, H-1), 4.39 (d, J = 6.3 Hz, 1H, H-4), 4.10 – 4.05 (m, 1H, H-7), 4.00 – 3.90 (m, 2H, 
H-7a, H-3), 3.71 (dd, J = 9.1, 3.7 Hz, 1H, H-2), 3.38 (s, 3H, OMe), 2.62 – 2.49 (m, 1H, H-
3a), 0.98 – 0.84 (m, 9H, 3 CH3CH2Si), 0.64 – 0.52 (m, 6H, 2 CH3CH2Si). 
Compound 6b 
 
Scheme 5.41 
Compound 116 (10 mg, 0.019 mmol) and MnO2 (12 mg, 0.132 mmol) were slurried in 
EtOAc (2 mL), and the mixture was armed at reflux for 2h. After consumption of the 
starting material, the reaction mixture was filtered hot though celite and the residual black 
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solid was washed copiously with EtOAc (10 mL). The filtrate was concentrated in vacuum. 
The crude product was purified by flash chromatography [(petroleum ether/ EtOAc 
8.5:1.5)] to give 70% as brown pale oil. 
1
H NMR (400 MHz, DMSO) δ 7.38 – 7.24 (m, 
8H, Ar-H), 7.13 (d, J = 6.9 Hz, 2H, Ar-H), 6.62 (dd, J = 9.8, 3.0 Hz, 1H, H-5), 5.89 (d, J = 
9.8 Hz, 1H, H-6), 4.72 (d, J = 11.6 Hz, 2H, CH2Ph, H-1), 4.61 – 4.47 (m, 3H, 2 CH2Ph, H-
4), 4.33 (bd, J = 12.5 Hz, 1H, CH2Ph), 3.80 – 3.74 (m, 1H, H-3), 3.72 – 3.67 (m, 1H, H-2), 
3.43 (s, 3H, OMe), 2.66 (bs, 1H, H-3a), 0.85 (t, J = 7.9 Hz, 9H, CH3CH2Si), 0.51 (q, J = 
7.9 Hz, 6H, CH3CH2Si). 
13
C NMR (101 MHz, DMSO) δ 139.1, 138.3, 128.6, 128.5, 128.1, 
127.9, 127.9, 127.7, 96.9, 76.0, 73.7, 73.1, 71.2, 56.9, 43.3, 40.5, 40.3, 40.1, 39.9, 39.7, 
39.5, 39.2, 7.0, 4.5. 
 
5.8.7. Synthetic strategy for compound 10a 
Compound 117 
Acording to literature procedure:
78
 
 
Scheme 5.42 
To a suspension of methyl α-D-glucopyranoside 98 (2.00 g, 0.01 mol) in acetonitrile (2.0 
mL), bis(trimethylsilyl)trifluoroacetamide (BTSFA) (8.20 mL, 0.031 mol) was added and 
the resulting mixture heated at reflux for 1 h (the mixture became clear and uniform). 
Allyltrimethylsilane (2.40 mL, 0.015 mol), followed by trimethylsilyl trifluorome-
thanesulfonate (0.92 mL, 5.00 mmol), was then added at 0 °C and the reaction mixture 
stirred for 18 h at room temp. After this time, the mixture was poured (CAUTION!) into 
ice-cold water and stirred for 3 h, prior to being neutralized (pH=7) with IRN78 resin, 
filtered through Celite and the filtrate concentrated under reduced pressure. The residue 
was purified by flash column chromatography over silica gel (EtOAc/MeOH, 15:1) 
affording 75 % of 117 as a powder solid. 
1
H NMR (400 MHz, CD3OD) δ 5.74 (ddt,             
J = 17.1, 10.1, 6.9, 1H, H-2’), 4.98 (dd, J = 17.1, 1.5, 1H, H-3’trans), 4.91 (d, J = 10.1, 1H, 
H-3’cis), 3.85 – 3.77 (m, 1H, H-1), 3.60 (dd, J = 11.7, 2.4, 1H, H-2), 3.48 (ddd, J = 15.1, 
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10.5, 5.4, 2H, H-6, H-4), 3.40 (t, J = 8.9, 1H, H-3), 3.35 – 3.28 (m, 1H, H-5), 3.19 – 3.12 
(m, 1H, H-6), 2.41 – 2.22 (m, 2H, H-1’).  
 
Compound 118 
Acording to literature procedure:
154
 
 
Scheme 5.43 
A stirred solution of 117 (10 g, 0.032 mol) in anhydrous DMF (100 mL) under argon at     
0 ºC was treated with NaH 60% in mineral oil (3.8 g, 0.096 mol). After 15 min. at room 
temperature, the mixture was treated dropwise and rapidly with BnBr (0.096 mol, 11 mL) 
and then allowed to stand for 1 h at rt. The mixture was diluted with EtOAc (80 mL), and 
washed with saturated NaHCO3 solution (3 x 50mL). The aqueous phase was back-
extracted with EtOAc (2 x 40 mL), and all the organic fractions were combined, washed 
with brine, and dried over anhydrous Na2SO4. The residue was purified by flash 
chromatography [petroleum ether/EtOAc (9:1)] affording 118 (80% yield) as colorless oil. 
NMR (300 MHz, CDCl3) δ 7.27-7.39 (m, 18H, Ar-H), 7.14-7.18 (m, 2H, Ar-H), 5.86 (ddt, 
1H, J = 6.6, 10.2, 17.1 Hz, H-2’), 5.08-5.18 (m, 2H, H-3’), 4.96 – 4.87 (m, 2H, CH2Ph), 
4.75 – 4.70 (m, 2H,CH2Ph), 4.68 – 4.60 (m, 2H, CH2Ph), 4.58 – 4.53 (m, 2H, CH2Ph), 4.17 
(m, 1H, H-1), 3.61-3.87 (m, 6H, H-2, H-3, H-4, H-4, H-6), 2.47-2.61 (m, 2H, H-1’). 
Compound 119 
Acording to literature procedure: 
154
 
 
Scheme 5.44 
To a solution of 118 (512 mg, 0.9 mmol) in dry CH2Cl2 (5 mL) was added iodine (2.3 g,     
9 mmol) at rt. After 90 min. the reaction mixture was diluted with EtOAc, aqueous 
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Na2S2O3 was added, and the mixture was stirred till the organic layer became colourless. 
Crude compound 119 was used without furder purification. 
Compound 120 
Acording to literature procedure: 
154
 
 
Scheme 5.45 
Product 119 (477 mg, 0.79 mmol) was dissolved in a 1:1 mixture of Et2O-MeOH (4 mL), 
and powdered zinc (519 mg, 7.9 mmol) and glacial acetic acid (90 L, 1.58 mmol) were 
sequentially added. The suspension was stirred overnight and then filtered over a Celite 
pad. The filtrate was evaporated and then diluted with EtOAc (20 mL) and washed with 
HCl (5%) (10mL) and H2O (10 mL), dried over Na2SO4, and purified by flash 
chromatography using [petroleum ether/EtOAc (8:2)] to give 120 (348mg, 74% yield over 
2 steps) as colourless oil. 
1
H NMR (400 MHz, CDCl3) δ 7.46 – 7.10 (m, 15H, Ar-H), 5.98 
– 5.66 (m, 1H, H-2’), 5.13 (broad dd, J = 16.8, 3.2 Hz, 1H, H-3’trans), 5.07 (broad dd, J = 
10.2, 3.2 Hz, 1H, H-3’cis), 4.71 – 4.46 (m, 6H, 3 CH2Ph), 4.08 – 4.02 (m, 1H, H-5), 3.97 – 
3.90 (m, 1H, H-1), 3.82 (dd, J = 10.0, 5.7 Hz, 1H, H-4), 3.75 (t, J = 5.7 Hz, 1H, H-3), 3.72 
– 3.60 (m, 3H, H-2, H-6a, H-6b), 2.91 (broad s, 1H, OH), 2.54 – 2.28 (m, 2H, H-1’). 
Compound 121 
Acording to literature procedure: 
154
 
 
Scheme 5.46 
To a solution of (COCl)2 (364 mg, 2.87 mmol) of dry CH2Cl2 (6 mL) at -78ºC under argon 
atmosphere, anhydrous DMSO (0.4 mL) was added dropwise, and the resulting solution 
was stirred for 30 min. To the reaction flask, a solution of compound 120 (341 mg, 0.718 
mmol) of dry CH2Cl2 (2.0 mL) was added dropwise at -78ºC. This final reaction mixture 
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stayed under magnetic stirring for 1 h at -78ºC. Then dry TEA (0.9 mL) was added and the 
reaction stayed for more 30 min under magnetic stirring at -78ºC, and then was allowed to 
warm up until 0ºC. It was carefully added NH4Cl (10 mL), and the organic layer washed 
with H2O (10 mL), dried over Na2SO4, and concentrated. The residue was purified by flash 
chromatography using [petroleum ether/EtOAc (9:1)] to give compound 121 (303 mg, 89% 
yield) as a white powder. 
1
H NMR (400 MHz, CDCl3) δ 7.49 – 7.13 (m, 15H, Ar-H), 5.86 
– 5.64 (m, 1H, H-2’), 5.18 – 5.04 (m, 2H, H-3’), 4.95 (d, J = 11.5 Hz, 1H, CH2Ph), 4.81 (d, 
J = 11.2 Hz, 1H, CH2Ph), 4.61 (d, J = 11.5 Hz, 1H, CH2Ph), 4.50 (bd, J = 11.5 Hz, 2H, 
CH2Ph), 4.41 (d, J = 11.2 Hz, 1H, CH2Ph), 4.39 (d, J = 8.9 Hz, 1H, H-3), 4.26 (t, J = 6.8 
Hz, 1H, H-1), 4.10 – 3.99 (m, 1H, H-5), 3.90 (dd, J = 8.9, 7.7 Hz, 1H, H-4), 3.68 – 3.54 
(m, 2H, H-6), 2.47 (t, J = 6.8 Hz, 2H, H-1’). 
Compound 122 
 
Scheme 5.47 
Allylmagnesium bromide 1 M solution in THF (1.6 mmol, 1.6 mL) was added to a solution 
of 121 (293 mg, 0.62 mmol) in dry toluene:CH2Cl2 (2:1) (3 mL) at -78ºC. The reaction was 
stirred at -78ºC for 2 h. The reaction mixture was warm to 0 ºC, and was slowly added a 
solution of NH4Cl (20 mL) and diluted with EtOAc (8 mL). The aqueous phase was back-
extracted with EtOAc (3 x 8 mL) and all the organic fractions were combined and dried 
over anhydrous Na2SO4. The residue was purified by flash chromatography using 
[petroleum ether/EtOAc (9.5:0.5)] to give a mixture of diastereomers (68:32) 122 (0.271 g, 
85% yield) as yellow oil. NMR characterization of the major isomer 122a, 
1
H NMR (400 
MHz, CDCl3) δ 7.45 – 7.14 (m, 15H), 6.12 – 5.68 (m, 2H, H-2’, H-2’’), 5.11 (m, 4H, H-
3a’, H-3’, H-3’’), 4.87 (d, J = 11.0 Hz, 1H, CH2Ph), 4.73 (d, J = 11.4 Hz, 1H, CH2Ph), 
4.62 (d, 2H, CH2Ph), 4.54 (d, J = 9.9 Hz, 1H, CH2Ph), 4.52 (d, J = 11.4 Hz, 1H, CH2Ph), 
3.97 (t, J = 7.8 Hz, 1H, H-4), 3.83 – 3.72 (m, 3H, H-1, H-5, H-6a), 3.68 (d, J = 7.5 Hz, 1H, 
H-6), 3.60 (d, J = 7.8 Hz, 1H, H-3), 2.74 (dd, J = 14.6, 5.6 Hz, 1H, H-1’’), 2.51 – 2.23 (m, 
2H, H-1’), 2.02 (dd, J = 14.6, 8.4 Hz, 1H, H-1’’). 13C NMR (101 MHz, CDCl3) δ 138.4, 
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138.2, 137.9, 134.8, 133.1, 128.7, 128.7, 128.5, 128.3, 128.2, 128.2, 128.0, 128.0, 127.8, 
118.6, 117.0, 82.2, 77.7, 77.6, 77.3, 77.0, 76.7, 75.6, 75.4, 74.7, 73.6, 72.8, 69.2, 38.6, 
31.2. 
Compound 123 
 
Scheme 5.48 
To a solution of 122a (768 mg 1.49 mmol) in dry CH2Cl2 (45 mL), Grubb’s 2
nd
 generation 
Hoveyda (5% weight) was added. The reaction mixture was stirred at 40ºC for 2 h. The 
crude product was concentrated and purified by flash chromatography [petroleum 
ether/EtOAc (9:1)] to give the corresponding ciclyzed product 123 (642 mg, 88% yield) as 
green oil. 
1
H NMR (400 MHz, CDCl3) δ 7.43 – 7.23 (m, 15H, Ar-H), 5.53 (bs, 1H, H-2’), 
5.49 (bs, 1H, H-3’), 4.85 (d, J = 11.2 Hz, 1H, CH2Ph), 4.73 (d, J = 10.9 Hz, 1H, CH2Ph), 
4.63 (d, J = 12.2 Hz, 1H, CH2Ph), 4.60 – 4.55 (m, 2H, 2 CH2Ph), 4.51 (d, J = 10.9 Hz, 1H, 
CH2Ph), 4.08 (dd, J = 11.6, 9.1 Hz, 1H, H-1), 3.99 – 3.90 (m, 2H, H-4, H-5), 3.65 – 3.61 
(m, 2H, H-6), 3.58 (dd, J = 11.8, 4.6 Hz, 1H, H-3), 2.62 (bd, J = 17.2 Hz, 1H, H-4’), 2.63 -
2.22 (m, 2H, H-1’ ), 1.85 (bd, 1H, H-4’). 
Compound 124 
 
Scheme 5.49 
To a solution of 123 (439 mg, 0.90 mmol) in dry CH2Cl2 (12 mL) was added BCl3 (11 
mmol, 11 mL) at -78 °C under argon. The reaction mixture was stirred 3 h at -78 °C, and 
overnight at room temperature. Then it was diluted by the addition of a solution 
MeOH/H2O (20:1) (6 mL). The reaction mixture was then concentrated under reduced 
pressure. The crude product was purified by flash chromatography (EtOAc) to give the 
corresponding compound 124 (0.138 g, 71% yield) as colourless oil. 
1
H NMR (400 MHz, 
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CD3OD) δ 5.63 – 5.42 (m, 2H, H-2’, H-3’), 4.13 (dd, J = 12.1, 8.6 Hz, 1H, H-6), 4.02 (dd,          
J = 9.5, 6.9 Hz, 1H, H-1), 3.92 (dd, J = 8.6, 4.2 Hz, 1H, H-5), 3.73 (d, J = 2.2 Hz, 1H, H-
4), 3.59 (dd, J = 12.1, 4.2 Hz, 1H, H-6), 3.50 (d, J = 2.5 Hz, 1H, H-3), 2.61 (bd, J = 18.4, 
1H, H-4’), 2.30 – 2.18 (m, 2H, H-1’), 1.87 (dd, J = 18.1, 3.7 Hz, 1H, H-4’). 
Compound 125 
 
Scheme 5.50 
To a solution of 124 (200 mg, 0.92 mmol) in dry Py (2 mL), Ac2O (4.62 mmol, 0.5 mL) 
and a catalytic amount of 4-(N, N-dimethylamino)pyridine (DMAP) were added at rt. The 
reaction mixture was stirred overnight at rt. The reaction mixture was quenched by 
addition a solution of HCl (5%) (10 mL). The aqueous layer was extracted whit EtOAc (3 
x 3 mL) and the combined organic extracts were wash with brine, dried over Na2SO4, and 
concentrated. The residue was purified by flash chromatography using [petroleum 
ether/EtOAc (3:7)] to give 125 (297 mg, 80% yield) as a yellow oil. NMR (500 MHz, 
CDCl3 ) δ 5.69 – 5.62 (m, 1H, H-2’), 5.55 – 5.48 (m, H-3’), 5.33 (t, J = 9.3 Hz, 1H, H-4), 
5.22 (d, J = 9.3 Hz, 1H, H-3), 4.24 (dd, J = 12.1, 5.0 Hz, 1H, H-6), 4.21 – 4.13 (m, 2H, H-
1, H-6), 4.00 (ddd, J = 9.4, 5.0, 2.5 Hz, H-5), 2.67 – 2.58 (m, 1H, H-1’), 2.46 – 2.34 (m, 
2H, H-1’, H-4’), 2.19 – 2.13 (m, 1H, H-4’), 2.11 (s, 6H, Me), 2.02 (s, 3H, Me). NMR (75 
MHz, CDCl3) δ 170.8, 170.3, 169.8, 123.7, 123.4, 77.4, 77.0, 76.6, 75.7, 71.5, 71.4, 69.6, 
68.2, 62.9, 34.1, 25.6, 20.8, 20.7. 
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Compound 10a 
 
Scheme 5.51 
To a solution of 126 (20 mg, 0.058 mmol) in dry EtOAc (1 mL) was added tert-butyl 
hydroperoxide in decane 5.5 M (0.304 mmol, 56 L) and 3Ǻ molecular sieves. The 
mixture was stirred for 30 min under argon at rt. Manganese (III) acetate dehydrate (0,006 
mmol, 1.6 mg) was added and the mixture was stirred for 48h at rt. The solution was 
filtered through a pad o celite. Concentration of the filtrate followed by flash 
chromatography [petroleum ether/EtOAc] (6:4) gives 10a (0.011 g, 52% yield) as 
colourless oil.
1
H NMR (400 MHz, CDCl3) δ 6.63 (bd, J = 10.0 Hz, 1H, H-2’), 6.10 (d,            
J = 10.0 Hz, 1H, H-3’), 5.20 (bs, 1H, H-4), 4.85 (d, J = 2.4 Hz, 1H, H-3), 4.66 (dt, J = 
12.6, 6.3 Hz, 1H, H-5), 4.31 (dd, J = 12.1, 5.0 Hz, 1H, H-1), 4.25 – 4.13 (m, 2H, H-6), 
2.86 (dd, J = 16.3, 12.1 Hz, 1H, H-1’), 2.59 (dd, J = 16.3, 5.0 Hz, 1H, H-1’), 2.17 (s, 3H, 
CH3), 2.12 (s, 3H, CH3), 2.09 (s, 3H, CH3).
 NMR (75 MHz, CDCl3) δ 196.4, 170.5, 168.7, 
168.6, 145.1, 133.5, 77.4, 76.9, 76.5, 74.5, 68.7, 67.8, 66.3, 66.0, 59.6, 38.4, 20.8, 20.7, 
20.6. MS: m/z calcd for [M]
+ 
=356, [M + Na]
+ 
=379; found [M + Na]
+ 
=379. 
 
5.8.8. Synthetic strategy for compound 10b 
Compound 126 
Acording to literature procedure: 
116
 
 
Scheme 5.52 
A solution of compound 107 (981 mg, 1.99 mmol), N-methylmorpholine N-oxide (492 mg, 
4.2 mmol) and osmium tetroxide (1.32 mL, 0.099 mmol) in H2O/THF (0.5:1.5) (20 mL) is 
stirred at room temperature for 1.5 h and then diluted with CH2Cl2 (30 mL). The organic 
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layer is washed with 5 N hydrochloric acid (15 mL) and 45% of sodium hydrogen sulfite 
solution (15 mL), dried over sodium sulfate and concentrated under reduced pressure. The 
residue was used without further purification. 
Compound 127 
 
Scheme 5.53 
To a solution of compound 127 (230 g, 0.44 mmol) in dry CH3CN (3 mL) at rt, 2,2-
dimethoxypropane (183 mg,1.76 mmol) and CSA (10 mg, 0.044 mmol) were added. The 
reaction mixture was stirred at room temperature for 20 min. After complete reaction dry 
Et3N (178 mg, 1.76 mmol) was added to neutralize de CSA. The reaction mixture was then 
concentrated and purified by flash chromatography [(petroleum ether/ EtOAc 8:2)] to give 
77% (over 2 steps) as green oil. 
1
H NMR (400 MHz, CDCl3) δ 7.36 – 7.22 (m, 12H, Ar-H), 
6.85 (d, J = 8.3 Hz, 2H, Ar-H), 4.93 (d, J = 10.7 Hz, 1H, CH2Ph), 4.79 (d, J = 10.7 Hz, 1H, 
CH2Ph), 4.75 (d, J = 12.1 Hz, 1H, CH2Ph), 4.62 – 4.54 (m, 3H, 2 CH2Ph, H-1), 4.43 (d,      
J = 11.6 Hz, 1H, CH2Ph), 4.12 (d, J = 8.8 Hz, 1H, H-1’), 4.01-3.95 (m, 2H, H-1’, H-3), 
3.89 (d, J = 7.9 Hz, 1H, H-5), 3.83 – 3.76 (m, 4H, H-6, ArOMe), 3.53 – 3.46 (m, 1H, H-6), 
3.42 (s, 3H, OMe), 3.20 (dd, J = 10.2, 3.6 Hz, 1H, H-2), 1.56 (s, 6H, CH3), 1.33 (s, 6H, 
CH3). 
13
C NMR (101 MHz, CDCl3) δ 159.1, 138.5, 137.9, 130.3, 129.2, 128.4, 128.2, 
128.1, 127.9, 127.7, 127.4, 113.7, 109.8, 97.3, 83.2, 79.5, 79.4, 77.3, 77.0, 76.7, 76.4, 73.4, 
72.9, 71.4, 67.8, 63.6, 55.2, 55.1, 29.7, 26.2, 25.6. 
Compound 128 
 
Scheme 5.54 
To a solution of compound 127 (248 mg, 0.45 mmol) in CH3CN (19 mL) at 0ºC, a solution 
of CAN (1.244 g, 2.27 mmol) in water (5.8 mL) was added. The reaction mixture was 
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stirred at room temperature for 20 min. and then diluted with CH2Cl2 (20 mL) and wash 
with water (2 x 15 mL). The combined organic phases were dried, concentrated and 
purified by flash chromatography using [petroleum ether/EtOAc (5:5)] to give 82% as 
orange pale oil. 
1
H NMR (400 MHz, CDCl3) δ 7.40 – 7.22 (m, 10H, Ar-H), 4.92 (d, J = 
10.7 Hz, 1H, CH2Ph), 4.81 (d, J = 10.7 Hz, 1H, CH2Ph), 4.77 (d, J = 12.1 Hz, 1H, CH2Ph), 
4.61 (d, J = 12.1 Hz, 1H, CH2Ph), 4.56 (d, J = 3.8 Hz, 1H, H-1), 4.21 – 4.05 (m, 2H, H-1’), 
4.01 (d, J = 10.3 Hz, 1H, H-3), 3.93 – 3.74 (m, 1H, H-6), 3.76 – 3.63 (m, H-6), 3.40 (s, 3H, 
OMe), 3.20 (dd, J = 10.3, 3.8 Hz, 1H, H-2), 2.40 – 2.23 (m, 1H, H-5), 1.57 (s, 6H, 2 CH3). 
Compound 129 
 
Scheme 5.55 
Dess–Martin periodinane (236 mg, 0.577 mmol) was added to a mixture of compound 128 
(165 mg, 0.371 mmol) in CH2Cl2 (3.5 ml) at rt. The reaction was stirred at rt for 30 min, 
before being quenched with saturated aqueous Na2S2O3 (8 mL) and saturated with aqueous 
NaHCO3 (8 mL). The mixture was extracted with ethyl acetate (3 x 8 mL) and the 
combined organic fraction was dried over Na2SO4. The solvent was removed under 
vacuum, and aldehyde 129 was used without further purification. 
Compound 130 
 
Scheme 5.56 
To a solution of 129 (165 mg, 0.371 mmol) in dry THF (4 mL) at -78ºC under argon 
atmosphere, a solution of vinylmagnesium bromide (1 M in THF) (1.3 mmol, 1.3 mL) was 
added dropwise. The resulting solution was stirred for 2 h and then allowed to warm up 
until 0ºC. A saturated solution of NH4Cl (15 mL) was added, and the reaction mixture was 
extracted with CH2Cl2 (3 x 6 mL). The organic extracts were dried over Na2SO4, filtered 
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and concentrated under reduced pressure. The residue was purified by flash 
chromatography [(petroleum ether/ EtOAc 8:2)] do give 80% as yellow pale oil (over 2 
steps). 
1
H NMR (400 MHz, CDCl3) δ 7.43 – 7.20 (m, 10H, Ar-H), 6.02 – 5.83 (m, 1H, H-
7), 5.39 (d, J = 17.3 Hz, 1H, H-8trans), 5.19 (d, J = 10.5 Hz, 1H, H-8cis), 4.92 (d, J = 10.7 
Hz, 1H, CH2Ph), 4.81 (d, J = 10.7 Hz, 1H, CH2Ph), 4.76 (d, J = 12.1 Hz, 1H, CH2Ph), 4.66 
(bs, 1H, H-6), 4.58 (d, J = 12.1 Hz, 1H, CH2Ph), 4.53 (d, J = 3.9 Hz, 1H, H-1), 4.42 (d,      
J = 8.7 Hz, 1H, H-1’), 4.18 (d, J = 8.7 Hz, 1H, H-1’), 3.96 (d, J = 10.3 Hz, 1H, H-3), 3.44 
(d, J = 4.3 Hz, 1H, H-5), 3.35 (s, 3H, OMe), 3.18 (dd, J = 10.3, 3.9 Hz, 1H, H-2), 1.57 (s, 
3H, CH3), 1.55 (s, 3H, CH3). 
Compound 131 
 
Scheme 5.57 
A round-bottom flask was charged with a 60% dispersion of sodium hydride in mineral oil 
(2.6 mg, 0.106 mmol). Dry DMF (2 mL) was then added, and the resulting cloudy white 
suspension was cooled to 0 °C. A solution of alcohol 130 (30 mg, 0.064 mmol) in dry 
DMF (2 mL) was added via syringe, followed by p-methoxybenzyl bromide (15.4 mg, 
0.076 mmol). The reaction mixture was stirred at 60ºC for 2 h. Upon cooling, the reaction 
was carefully quenched with saturated aqueous NH4Cl (10 mL). The layers were separated, 
and the aqueous layer was extracted with EtOAc (1 x 10mL). The combined organic layers 
were dried (MgSO4), filtered, and concentrated. Purification by flash chromatography 
[(petroleum ether/EtOAc 9:1)] afforded PMB ether 131 in 80% yield as a brown oil. 
1
H 
NMR (400 MHz, CDCl3) δ 7.45 – 7.18 (m, 12H, Ar-H), 6.83 (t, J = 12.1 Hz, 2H, Ar-H), 
5.98 (ddd, J = 16.7, 9.5, 7.8 Hz, 1H, H-7), 5.31 (d, J = 16.7 Hz, 1H, H-8trans), 5.28 (d, J = 
9.5 Hz, 1H, H-8cis), 4.95 (d, J = 10.9 Hz, 1H, CH2Ph), 4.80 (d, J = 10.9 Hz, 1H, CH2Ph), 
4.72 (d, J = 12.3 Hz, 1H, CH2Ph), 4.69 (d, J = 7.5 Hz, 1H, H-1’), 4.57 (d, J = 3.9 Hz, 1H, 
H-1), 4.55 (d, J = 12.3 Hz, 1H, CH2Ph), 4.39 (s, 2H, CH2Ph), 4.31 (d, J = 7.8 Hz, 1H, H-
6), 4.14 (d, J = 7.5 Hz, 1H, H-1’), 3.96 (d, J = 10.5 Hz, 1H, H-3), 3.82 – 3.79 (m, 1H, H-
5), 3.77 (s, 3H, ArOMe), 3.33 (s, 3H, OMe), 3.19 (dd, J = 10.5, 3.9 Hz, 1H, H-2), 1.54 (s, 
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3H, CH3), 1.42 (s, 3H, CH3). 
Compound 132 
 
Scheme 5.58 
A solution of AcOH 60% in water (4 mL) was added to a mixture of compound 131         
(20 mg, 0.034 mmol) in THF (1 mL). The reaction was stirred at 60ºC for 6 h, before being 
quenched with saturated aqueous NaHCO3 (8 mL). The mixture was extracted with ethyl 
acetate (3 x 5 mL) and the combined organic fraction was dried over Na2SO4. The solvent 
was removed under vacuum, and diol 132 was purified via flash column chromatography 
[(petroleum ether/EtOAc 8:2)] to give 100% as brown oil. 
1
H NMR (400 MHz, CDCl3) δ 
7.46 – 7.18 (m, 12H, Ar-H), 6.86 (d, J = 8.6 Hz, 2H, Ar-H), 6.15 – 5.96 (m, 1H, H-7), 5.45 
– 5.31 (m, 2H, H-8), 4.88 (d, J = 11.4 Hz, 1H, CH2Ph), 4.81 (d, J = 11.4 Hz, 1H, CH2Ph), 
4.76 (d, J = 12.0 Hz, 1H, CH2Ph), 4.60 – 4.53 (m, 3H, CH2Ph, H-1, H-1’), 4.32 – 4.24 (m, 
2H, H-6, H-1’), 3.89 (d, J = 13.1 Hz, 1H, CH2Ph), 3.86 (d, J = 10.4 Hz, 1H, H-3), 3.79 (s, 
4H, CH2Ph, ArOMe), 3.65 – 3.61 (m, 1H, H-5), 3.55 (dd, J = 10.4, 3.9 Hz, 1H, H-2), 3.32 
(s, 3H, OMe). 
 
5.8.. Synthetic strategy for Michael donor 139 
Compound 134 
Acording to literature procedure:
122
 
 
Scheme 5.59 
To a stirred solution of 2-methyl-6-nitrobenzoic acid 133 (1.0 g, 5.52 mmol) in dry 
methanol (10 mL), 10% Pd on activated charcoal (20 mg) was added and then hydrogen 
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gas was purged to it. The reaction mixture was allowed to stir for overnight. The catalyst 
was filtered off and the filtrate was concentrated under reduced pressure. 
1
H NMR (400 
MHz, CD3OD) δ 7.03 (t, J = 7.8 Hz, 1H, H-4), 6.60 (d, J = 7.8 Hz, 1H, H-3), 6.49 (d,          
J = 7.8 Hz, 1H, H-5), 2.41 (s, 3H, CH3). 
Compound 136 
Acording to literature procedure:
122
 
 
Scheme 5.60 
The solid mass obtained was dissolved into 10% aqueous H2SO4 solution (10 mL). The 
resulting solution was cooled to -5 ºC and a cold saturated solution of NaNO2 (419 mg, 
6.07 mmol) was added slowly to it with hand shaking. Then, it was left for 20 min at room 
temperature and was heated until the temperature reached to 70 ºC. Heating was continued 
until evolution of N2 ceases. The reaction mass was extracted with EtOAc (3 x 10 mL). 
The combined organic extract was washed successively with water (10 mL), brine (10 mL) 
and finally dried over Na2SO4. After removal of the solvent the crude product obtained was 
purified by flash chromatography [petroleum ether/EtOAc (8.5:1.5)] to furnish 136 (81%) 
as yellow solid. 
1
H NMR (400 MHz, CDCl3) δ 11.05 (s, 1H, COOH), 7.36 (dd, J = 8.3, 7.4 
Hz, 1H, H-4), 6.88 (d, J = 8.3 Hz, 1H, H-3), 6.78 (d, J = 7.4 Hz, 1H, H-5), 2.67 (s, 3H, 
CH3). 
13
C NMR (101 MHz, CDCl3) δ 176.4, 163.9, 143.2, 135.7, 123.5, 116.1, 111.1, 77.5, 
77.2, 76.9, 24.4. 
Compound 137 
Acording to literature procedure:
122
 
 
Scheme 5.61 
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To a solution of 136 (760 mg, 5.0 mmol) in diethyl ether (10 ml) at 0 ºC, diazomethane   
(15 mmol) in ether (10 mL) was added dropwise and stirred for 2 h. After removing the 
excess diazomethane the ether layer was washed with water, brine and finally dried over 
Na2SO4. After removal of the solvent under reduced pressure the residue obtained was 
purified by flash chromatography [petroleum ether/EtOAc (9:1)] to give the corresponding 
ester (96%) as colourless oil. 
1
H NMR (300 MHz, CDCl3):  7.25 (dd, J = 7.4, 8.3 Hz, 1H, 
H-4), 6.83 (d, J = 8.3 Hz, 1H, H-3), 6.69 (d, J = 7.4 Hz, 1H, H-5), 3.93 (s, 3H, OMe), 2.52 
(s, 3H, CH3), 
13
C NMR (75 MHz, CDCl3):  24.0, 52.1, 112.3, 115.6, 122.9, 134.2, 141.3, 
162.9, 172.2 
Compound 138 
 
Scheme 5.62 
Boc2O (350 mg, 1.60 mmol) and DMAP (20 mg, 0.16 mmol) were added to compound 
137 (243 mg, 1.46 mmol) in CH2Cl2 (8 mL). The reaction was stirred at 25°C for 90 min. 
and concentrated. Flash chromatography on silica gel [(9:1) petroleum ether/EtOAc] 
yielded the desired compound 138 (292 mg, 75%). 
1
H NMR (400 MHz, CDCl3) δ 7.33 (dd, 
J = 7.6, 8.1 Hz, 1H, H-4), 7.11 (d, J = 7.6 Hz, 1H, H-3), 7.02 (d, J = 8.1 Hz, 1H, H-5), 3.88 
(s, 3H, OMe), 2.40 (s, 3H, CH3), 1.52 (s, 9H, (CH3)3).
 13C NMR (101 MHz, CDCl3) δ 
151.9, 149.0, 138.8, 131.1, 128.5, 126.3, 120.6, 83.9, 77.6, 77.3, 76.9, 52.5, 27.9, 27.6, 
20.4. 
Compound 139 
 
Scheme 5.63 
N-Bromosuccinimide (99.6 mg, 0.56 mmol) was added to a solution of 138 (150 mg, 0.56 
mmol) in carbon tetrachloride (2.8 mL) and was heated to reflux in the presence of visible 
light. Then, a catalytic amount of AIBN was added and the reflux was continued for 2 h. 
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After cooling to room temperature the precipitated solid was filtered off and the filtrate 
was concentrated under reduced pressure and the residue was extracted with CH2Cl2 (3 x   
5 mL). The organic layer was washed successively with water (5 mL), brine (5 mL) and 
finally dried over Na2SO4. After removal of the solvent in vacuum the residue obtained 
was purified by flash chromatography [petroleum ether/EtOAc (9.5:0.5)] to furnish 139 
(62%) as yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 7.7, 8.2 Hz, 1H, H-4), 
7.32 (d, J = 7.7 Hz, 1H, H-3), 7.16 (d, J = 8.2 Hz, 1H, H-5), 4.67 (s, 2H, CH2Br), 3.94 (s, 
3H, OMe), 1.57 [s, 9H, (CH3)3].
 13C NMR (101 MHz, CDCl3) δ 165.8, 151.5, 149.4, 138.4, 
131.7, 128.4, 126.1, 123.6, 84.3, 77.5, 77.2, 76.9, 52.9, 30.3, 29.9, 27.8. 
 
5.8.1. Synthetic strategy for Michael donor 143 
Compound 141 
Acording to literature procedure:
124
 
 
Scheme 5.64 
A vigorously stirred mixture of 2,3-dimethylanisole 139 (4.12 g, 30.2 mmol), copper(II) 
sulfate pentahydrate (7.68 g, 30.7 mmol), and potassium peroxydisulfate (26.01 g, 96.2 
mmol) in acetonitrile/water (1:1, 360 mL) was heated at 75°C. After no starting material 
was present shown by TLC analysis, the mixture was cooled to rt before adding CH2Cl2 
(100 mL). The layers were separated, and the aqueous phase was further extracted with 
additional CH2Cl2 (2 x 40 mL). The combined organic solutions were dried over Na2SO4, 
filtered, and concentrated in vacuo. The residue was purified by flash chromatography 
[petroleum ether/ EtOAc (9.5:0.5)] to afford 141 (3.86 g, 85%) as a pale yellow powder. 
1
H NMR (400 MHz, CDCl3) δ 10.64 (s, 1H, CHO), 7.38 (t, J = 8.0 Hz, 1H, H-4), 6.87 – 
6.77 (m, 2H, H-3, H-5), 3.90 (s, 3H, OMe), 2.57 (s, 3H, CH3). 
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Compound 142 
Acording to literature procedure:
124
 
 
Scheme 5.65 
A mixture of 141 (844 mg, 5.62 mmol) and sulfamic acid (731 mg, 7.53 mmol) in water 
(20 mL) and THF (10 mL) is stirred at rt for 5 min before sodium chlorite (661 mg, 7.31 
mmol) dissolved in water (5 mL) is added. The mixture is stirred for 1 h followed by 
addition of ethyl acetate (10 mL). The layers are separated, and the aqueous phase is 
discarded. The ethyl acetate solution is extracted with aqueous 1 M NaOH (30 mL) by 
discarding the organic phase. The aqueous solution is acidified with concentrated HCl, and 
then extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts are dried over 
Na2SO4, filtered, and evaporated at reduced pressure. Crystallization of the residue from 
petroleum ether/EtOAc gives the product 142 (645 mg, 70%) as white solid. 
1
H NMR (400 
MHz, CDCl3) δ 7.31 (dd, J = 8.3, 7.6 Hz, 1H, H-4), 6.88 (d, J = 7.6 Hz, 1H, H-3), 6.83 (d, 
J = 8.3 Hz, 1H, H-5), 3.92 (s, 3H, OMe), 2.49 (s, 3H, CH3). 
Compound 143 
 
Scheme 5.66 
Oxalyl chloride (0.208 mL, 2.41 mmol) and dry DMF (2L) were added to compound 
142 (100 mg, 0.60 mmol) in dry CH2Cl2 (3.5 mL). The reaction was stirred at 25 °C for 1 h 
and concentrated. The resulting solid was redissolved in dry CH2Cl2 (3.5 mL). Phenol   
(113 mg, 1.20 mmol), DMAP (146 mg, 1.20 mmol), and dry triethylamine (0.59 mL,      
4.2 mmol were added. The reaction was stirred at 25 °C for 12 h and concentrated. The 
residue was redissolved in EtOAc (10 mL). The solution was washed with aqueous 1 M 
NaOH (5 mL), water (5 mL), and brine (5 mL), dried over Na2SO4, and concentrated. 
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Flash chromatography on silica gel [(petroleum ether/toluene 3:7)] yielded the desired 
product (133mg, 91%) as green pale solid. 
1
H NMR (400 MHz, CDCl3) δ 7.44 (t, J = 7.9 
Hz, 2H, H-3’, H-5’), 7.36 – 7.21 (m, 4H, H-2’, H-6’, H-4’, H-4), 6.92 – 6.78 (m, 2H, H-3, 
H-5), 3.89 (s, 3H, OMe), 2.46 (s, 3H, OMe). 
13
C NMR (101 MHz, CDCl3) δ 166.9, 156.7, 
150.9, 136.7, 130.8, 129.5, 125.9, 122.9, 122.5, 121.7, 108.5, 77.3, 77.4, 76.7, 56.0, 19.3. 
 
5.8.2. Synthetic strategy for diene 147 
Compound 145 
Acording to literature procedure:
130
 
 
Scheme 5.67 
Dry DMSO (40 mL) was added dropwise via syringe to a mixture of solid 
trimethylsulfoxonium iodide (2.9 g, 13.52 mmol) and solid sodium hydride (60% in oil, 
325 mg, 13.52 mmol) at 23 °C. Vigorous gas evolution was observed upon addition. The 
resulting cloudy gray mixture was stirred at 23 °C for 40 min, then a solution of the 2’-
bromoacetophenone 144 (2.0 g, 10.04 mmol) in dry DMSO (15 mL) was added dropwise 
via cannula. The transfer was quantitated with a portion of dry DMSO (2 mL). The 
resulting orange mixture was stirred at 23 °C for 48 h then was partitioned between brine 
(80 mL) and EtOAc (40 mL). The organic phase was separated and the aqueous phase was 
further extracted with one portion of EtOAc (40mL). The organic phases were combined 
and dried over anhydrous sodium sulfate. The dried solution was filtered and the filtrate 
was concentrated. The product was purified by flash column chromatography [petroleum 
ether/EtOAc (9.75:0.25)], affording the epoxide 145 as light yellow oil (1.84g, 86%). 
1
H 
NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 8.0, 1.0 Hz, 1H, H-2), 7.47 (dd, J = 7.7, 1.7 Hz, 
1H, H-5), 7.31 (td, J = 7.7, 1.0 Hz, 1H, H-4), 7.16 (td, J = 7.9, 1.7 Hz, 1H, H-3), 3.02 (d,    
J = 5.1 Hz, 1H, H-1’), 2.85 (d, J = 5.1 Hz, 1H, H-1’), 1.66 (s, 3H, CH3). 
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Compound 146 
Acording to literature procedure:
130
 
 
Scheme 5.68 
A solution of n-butyllithium in hexanes (1.6 M, 6 mL, 9.5 mmol) was added dropwise via 
syringe down the side of a reaction vessel containing a solution of the epoxide 145 (1.84 g, 
8.64 mmol) in dry THF (86 mL) at -78°C. The resulting solution was stirred at -78°C for 
20 min whereupon a suspension of magnesium bromide ethyl etherate (4.46 g,             
17.27 mmol) in dry THF (20 mL) was added dropwise via cannula. The transfer was 
quantitated with a portions of dry THF (2 mL). The resulting cloudy mixture was stirred at 
-78°C for 60 min, then the cooling bath was removed and the reaction mixture was allowed 
to warm to 23°C. The mixture became clear upon warming and was stirred at 23°C for 1 h. 
The reaction mixture was poured into aqueous Rochelle’s salt solution (10% wt/wt) and 
the resulting mixture was extracted with EtOAc (3 x 10 mL). The organic phases were 
combined and dried over anhydrous sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The product was purified by flash column chromatography 
[petroleum ether/EtOAc (9.5:0.5 to 9:1)], affording the trans-benzocyclobutene 146 as 
colorless oil (690mg, 60%). 
1
H NMR (400 MHz, CDCl3) δ 7.34 – 7.22 (m, 4H, Ar-H), 4.75 
(s, 1H, H-1), 3.35 (q, J = 7.0 Hz, 1H, H-2), 1.42 (d, J = 7.0 Hz, 3H, CH3). 
Compound 147 
 
Scheme 5.69 
Dry triethylamine (1.01 mL, 7.71 mmol) and triethylsilyl trifluoromethanesulfonate      
(1.51 mL, 6.69 mmol) were added in sequence to a solution of the benzocyclobutene 146 
(690 mg, 5.14 mmol) in dry CH2Cl2 (10 mL) at 23°C. The solution was stirred at 23°C for       
15 min. then was partitioned between water (20 mL) and CH2Cl2 (10 mL). The organic 
phase was separated and dried over anhydrous sodium sulfate. The dried solution was 
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filtered and the filtrate was concentrated. The product was purified by flash column 
chromatography [petroleum ether/toluene (9.5:0.5)], affording the triethyl-
silyloxybenzocyclobutene 147 as clear oil (689 mg, 54%).
1
H NMR (400 MHz, CDCl3) δ 
7.33 – 7.16 (m, 3H, Ar-H), 7.12 (d, J = 6.4 Hz, 1H, Ar-H), 4.74 (d, J = 0.9 Hz, 1H, H-1), 
3.37 (q, J = 7.0 Hz, 1H, H-2), 1.40 (d, J = 7.0 Hz, 3H, CH3), 1.03 (t, J = 7.9 Hz, 9H, 
CH3CH2Si), 0.70 (q, J = 7.9 Hz, 6H, CH3CH2Si).
13
C NMR (101 MHz, CDCl3) δ 146.9, 
146.1, 129.3, 127.7, 122.8, 122.6, 77.7, 77.6, 77.3, 76.9, 50.4, 16.7, 6.8, 4.9. 
 
5.8.3. Synthetic strategy for compound 148 
 
Scheme 5.70 
A solution of n-butyllithium in hexanes (1.6 M, 120 μL, 0.1920 mmol) was added to a 
solution of compound 139 (33.6 mg, 0.097 mmol) and enone 6a (10.0 mg, 0.024 mmol, in 
dry THF (2 mL) at –100 °C. The resulting yellow reaction mixture was allowed to warm to 
0 °C overnight then was partitioned between aqueous potassium phosphate buffer solution 
(pH=7.0, 0.2 M, 2 mL) and CH2Cl2 (2 mL). The phases were separated and the aqueous 
phase was further extracted with dichloromethane. The organic extracts were combined 
and the combined solution was dried over anhydrous sodium sulfate. The dried solution 
was filtered and the filtrate was concentrated, affording a yellow solid. The product was 
purified by flash chromatography [petroleum ether/EtOAc (7:3)], affording the product 
148 as a pale yellow oil (8 mg, 52%).
1
H NMR (400 MHz, CDCl3) δ 7.42 – 7.21 (m, 11H, 
Ar-H, H-7), 7.10 (d, J = 8.0 Hz, 1H, H-8), 7.02 (d, J = 7.6 Hz, 1H, H-6), 4.86 (d, J = 2.3 
Hz, 1H, H-1), 4.82 – 4.65 (m, 3H, 3 CH2Ph), 4.55 (d, J = 11.0 Hz, 1H, CH2Ph), 4.24 (d,      
J = 8.0 Hz, 1H, H-3), 3.86 (s, 3H, OMe), 3.82 (dd, J = 8.0, 2.3 Hz, 1H, H-2), 3.45 (s, 3H, 
OMe), 2.80 – 2.64 (m, 3H, 2 H-5, H-4), 2.55 (dd, J = 16.1, 2.6 Hz, 1H, H-10a), 2.45 – 2.35 
(m, 1H, H-4), 2.26 (dd, J = 16.1, 11.4 Hz, 1H, H-10a), 1.97 (dd, J = 17.1, 9.4 Hz, 1H, H-
4), 1.54 (s, 9H, 3 CH3). 
13
C NMR (101 MHz, CDCl3) δ 192.9, 166.7, 151.6, 149.1, 141.5, 
139.5, 137.8, 137.8, 131.1, 130.1, 128.8, 128.7, 128.5, 128.4, 128.4, 128.2, 128.1, 126.7, 
121.4, 99.0, 84.1, 77.6, 77.3, 76.9, 75.5, 74.7, 73.4, 57.0, 52.6, 44.2, 39.0, 35.9, 29.9, 27.8. 
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5.8.4. Synthetic strategy for compound 149 
 
Scheme 5.71 
To a solution of (i-Pr)2NH (1L, 0.114 mmol) in dry THF (0.6 mL) at -78 °C was added 
n-BuLi (1.6 M in hexanes, 62 L, 0.10 mmol) followed, after 20 min, by a solution of 143 
(29 mg, 0.117 mmol) in dry THF (0.3 mL) that had been precooled to -78 °C. The resulting 
deep red solution was stirred for 15 min, after which a solution of 6b (20 mg, 0.038 mmol) 
and LiBr (51mg, 0.38 mmol) in dry THF (0.7 mL) was added. The mixture was stirred at     
-78 °C for 2 h, during which the color changed from red to pale yellow. The mixture was 
allowed to warm to room temperature overnight and the reaction was quenched with satd. 
aqueous NH4Cl (6 mL). The mixture was extracted with EtOAc (3 x 2 mL), and the extract 
was washed with H2O (2 mL) and brine (2 mL) and was dried over Na2SO4. 
1
H NMR (400 
MHz, CDCl3) δ 7.36 – 7.17 (m, 12H, Ar-H), 6.86 – 6.79 (m, 1H, Ar-H), 4.79 (d, J = 12.3 
Hz, 1H, CH2Ph), 4.69 – 4.66 (m, 2H, H-1, CH2Ph), 4.62 (d, J = 13.3 Hz, 1H, CH2Ph), 4.50 
(d, J = 11.7 Hz, 1H, CH2Ph), 4.21 (t, J = 6.2 Hz, 1H, H-4), 4.02 – 3.95 (m, 1H, H-3), 3.90 
(s, 3H, ArOMe), 3.88 – 3.85 (m, 1H, H-2), 3.69 (s, 3H, OMe), 2.38 – 2.27 (m, 2H, H-5), 
1.72 – 1.63 (m, 1H, H-4a), 1.62 – 1.52 (m, 1H, H-3a), 1.00 – 0.91 (m, CH3CH2Si, 9H), 
0.81 – 0.69 (m, CH3CH2Si, 6H). 
 
5.8.5. Synthetic strategy for compound 155 
Compound 150 
 
Scheme 5.72 
To a solution of 103 (500 mg, 0.96 mmol) in dry DMF (2.5 mL), NaH (76 mg, 1.92 mmol) 
and MeI (70 L, 1.15 mmol) were added. The reaction mixture stayed under magnetic 
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stirring for 2 h at room temperature, under argon atmosphere and then MeOH was added, 
and the reaction remained for more 10 min. This solution was partitioned between aqueous 
NaHCO3 (8 mL) solution and EtOAc (4 mL). The phases were separated and the aqueous 
phase was further extracted with EtOAc (4 mL). The organic extracts were combined and 
the combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The product was purified by flash 
chromatography [petroleum ether/EtOAc (7:3)], affording the product 150 as a pale yellow 
oil (8 mg, 92%). 
1
H NMR (400 MHz, CDCl3) δ 7.41 – 7.17 (m, 12H, Ar-H), 6.86 (d, J = 
8.6 Hz, 2H, Ar-H), 5.88 – 5.59 (m, 1H, H-2’), 5.14 – 4.94 (m, 3H, H-3’, CH2Ph), 4.79 – 
4.70 (m, 2H, CH2Ph, H-1), 4.67 – 4.60 (m, 2H, CH2Ph), 4.55 (d, J = 11.7 Hz, 1H, CH2Ph), 
4.41 (d, J = 11.7 Hz, 1H, CH2Ph), 4.00 (dd, J = 10.1, 3.5 Hz, 1H, H-2), 3.95 – 3.84 (m, 2H, 
H-3, H-5), 3.82 – 3.80 (m, 1H, H-6), 3.79 (s, 3H, ArOMe), 3.55 – 3.51 (m, 1H, H-6), 3.49 
(s, 3H, OMe), 3.42 (s, 3H, OMe), 3.09 (dd, J = 13.6, 7.8 Hz, 1H, H-1’), 2.14 (dd, J = 13.6, 
7.1 Hz, 1H, H-1’). 13C NMR (101 MHz, CDCl3) δ 159.3, 139.4, 138.4, 132.5, 130.7, 129.4, 
128.6, 128.5, 128.4, 128.04, 127.54, 127.24, 119.55, 113.93, 98.28, 98.23, 79.73, 79.40, 
78.52, 77.6, 77.3, 76.9, 76.1, 73.5, 73.3, 72.4, 68.8, 55.6, 55.5, 55.5, 53.2, 53.2, 34.1. 
Compound 151 
 
Scheme 5.73 
To a solution of compound 150 (450 mg, 0.84 mmol) in CH3CN (35 mL) at 0ºC, a solution 
of CAN (2.3 g, 4.21 mmol) in water (10 mL) was added. The reaction mixture was stirred 
at room temperature for 20 min. and then diluted with CH2Cl2 (20 mL) and wash with 
water (2 x 20 mL). The combined organic phases were dried, concentrated and purified by 
flash chromatography [petroleum ether/ EtOAc (6:4)] to give compound 151 in 82% as 
yellow pale oil.
1
H NMR (400 MHz, CDCl3) δ 7.43 – 7.20 (m, 10H, Ar-H), 5.67 (td, J = 
17.1, 7.4 Hz, 1H, H-2’), 5.20 – 5.03 (m, 3H, H-3’, CH2Ph), 4.84 – 4.71 (m, 2H, H-1, 
CH2Ph), 4.65 (d, J = 8.1 Hz, 1H, CH2Ph), 4.62 (d, J = 7.6 Hz, 1H, CH2Ph), 4.02 (dd,           
J = 10.0, 3.6 Hz, 1H, H-2), 3.98 – 3.84 (m, 2H, H-3, H-6), 3.80 – 3.64 (m, 2H, H-6, H-5), 
3.53 (s, 3H, OMe), 3.39 (s, 3H, OMe), 3.13 (dd, J = 13.9, 7.2 Hz, 1H, H-1’), 2.21 (dd, J = 
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13.9, 7.6 Hz, 1H, H-1’). 13C NMR (101 MHz, CDCl3) δ 139.1, 138.3, 132.0, 128.7, 128.6, 
128.4, 128.1, 127.7, 127.3, 119.9, 98.6, 80.6, 79.4, 78.2, 77.6, 77.3, 76.9, 76.3, 73.6, 71.9, 
61.3, 55.7, 53.2, 34.0. 
Compound 152 
 
Scheme 5.74 
Alcohol 151 (250 mg, 0.59 mmol) in CH2Cl2 (1 mL) was added to a stirred solution of 
Dess-Martin periodinane (371 mg, 0.88 mmol) in CH2Cl2 (5 mL) at 0ºC, and then the 
mixture was allowed to warm to rt. The reaction was completed after 2 h, the excess of 
oxidant was destroyed by addition of saturated solution of Na2S2O3 (10 mL). After 5 min. 
of vigourous stirring, the mixture was diluted with CH2Cl2 (10 mL), the organic layer was 
sperated, and the aqueous layer extracted with CH2Cl2 (2 x 5 mL). The combined extracts 
were dried over Na2SO4, filtered and concentrated. The product was purified by flash 
chromatography [petroleum Ether/EtOAc (8.5:1.5)], affording the product 152 as yellow 
oil (221 mg, 89%). 
1
H NMR (400 MHz, CDCl3) δ 9.61 (d, J = 1.2 Hz, 1H, CHO), 7.44 – 
7.23 (m, 10H, Ar-H), 5.90 – 5.71 (m, 1H, H-2’), 5.29 – 5.12 (m, 2H, H-3’), 5.07 (d, J = 
11.4 Hz, 1H, CH2Ph), 4.84 – 4.73 (m, 2H, H-1, CH2Ph), 4.65 (m, 2H, CH2Ph), 4.08 (dd, J 
= 10.0, 3.5 Hz, 1H, H-2), 4.03 (d, J = 1.2 Hz, 1H, H-5), 3.93 (d, J = 10.0 Hz, 1H, H-3), 
3.45 (s, 3H, OMe), 3.39 (s, 3H, OMe), 3.07 (dd, J = 13.5, 7.9 Hz, 1H, H-1’), 2.46 (dd, J = 
13.5, 7.2 Hz, 1H, H-1’). 13C NMR (101 MHz, CDCl3) δ 200.7, 139.0, 138.2, 132.3, 128.7, 
128.6, 128.4, 128.2, 127.7, 127.4, 120.7, 98.9, 82.1, 78.4, 78.1, 77.6, 77.2, 76.9, 76.2, 75.7, 
73.7, 56.2, 53.4, 32.9. 
Compound 153 
 
Scheme 5.75 
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Allylmagnesium bromide 1 M solution in THF (1.17 mmol, 1.17 mL) was added to a 
solution of 152 (200 mg, 0.47 mmol) in dry THF (3 mL) at -78ºC. The reaction was stirred 
at -78ºC for 2 h. The reaction mixture was warm to 0 ºC, and was slowly added a solution 
of NH4Cl (15 mL) and diluted with EtOAc (10 mL). The aqueous phase was back-
extracted with EtOAc (3 x 5 mL) and all the organic fractions were combined and dried 
over anhydrous Na2SO4. The residue was purified by flash chromatography using 
petroleum ether/EtOAc (9:1) to give a mixture of diastereoisomers (62:38) 153 (0.200 g, 
94% yield) as yellow pale oil. NMR characterization of the major isomer: 
1
H NMR (400 
MHz, CDCl3) δ 7.44 – 7.14 (m, 10H, Ar-H), 5.97 – 5.83 (m, 1H, H-2’’), 5.74 – 5.57 (m, 
1H, H-2’), 5.28 (d, J = 17.0 Hz, 1H, H-3’’trans), 5.22 – 5.03 (m, 4H, H-3’, H-3’’cis, CH2Ph), 
4.77 – 4.70 (m, 2H, H-1, CH2Ph), 4.67 – 4.51 (m, 3H, H-1’’, CH2Ph), 4.00 (dd, J = 10.1, 
3.5 Hz, 1H, H-2), 3.86 (d, J = 10.1 Hz, 1H, H-3), 3.59 – 3.45 (m, 4H, H-5, OMe), 3.32 (s, 
3H, OMe), 3.23 (dd, J = 13.8, 6.5 Hz, 1H, H-1’), 2.38 (dd, J = 13.8, 7.6 Hz, 1H, H-1’). 
Compound 154 
 
Scheme 5.76 
To a solution of 153 (77 mg, 0.17 mmol) in dry CH2Cl2 (10 mL), Hoveyda-Grubbs catalyst 
2
nd
 generation (5% weight), was added. The reaction mixture was stirred at 40ºC for 90 
min. The crude product was concentrated and purified by flash chromatography [petroleum 
ether/ EtOAc (6:4)] to give 97% as brown pale oil. NMR characterization of the major 
isomer, 
1
H NMR (400 MHz, CDCl3) δ 7.53 – 7.15 (m, 10H, Ar-H), 6.05 – 5.86 (m, 1H, H-
5), 5.78 – 5.56 (m, 1H, H-6), 5.01 (d, J = 11.5 Hz, 1H, CH2Ph), 4.88 (d, J = 3.4 Hz, 1H, H-
1), 4.79 (d, J = 12.0 Hz, 1H, CH2Ph), 4.67 (d, J = 12.0 Hz, 1H, CH2Ph), 4.59 (d, J = 11.5 
Hz, 1H, CH2Ph), 4.17 – 3.96 (m, 2H, H-7, H-2), 3.74 (d, J = 9.5 Hz, 1H, H-3), 3.60 (d, J = 
10.8 Hz, 1H, H-7a), 3.44 (s, 3H, OMe), 3.42 (s, 3H, OMe), 2.99 (dd, J = 19.0, 5.5 Hz, 1H, 
H-4), 1.79 (bd, J = 19.0 Hz, 1H, H-4). 
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Compound 155 
 
Scheme 5.77 
Compound 154 (693 mg, 1.62 mmol) and activated MnO2 (988 mg, 11.37 mmol) were 
slurried in EtOAc (20 mL), and the mixture was armed at reflux for 4 h. After consumption 
of the starting material, the reaction mixture was filtered hot though celite and the residual 
black solid was washed copiously with EtOAc (40 mL). The filtrate was concentrated in 
vacuum, to give 155 (656 mg, 95%yield) as brown pale oil. 
1
H NMR (400 MHz, CDCl3) δ 
7.45 – 7.24 (m, 10H, Ar-H), 6.68 (ddd, J = 10.1, 5.9, 2.1 Hz, 1H, H-5), 6.06 (dd, J = 10.1, 
3.1 Hz, 1H, H-6), 5.04 (d, J = 11.2 Hz, 1H, CH2Ph), 4.84 (d, J = 3.4 Hz, 1H, H-1), 4.79 (d, 
J = 11.7 Hz, 1H, CH2Ph), 4.65 (d, J = 11.2 Hz, 1H, CH2Ph), 4.62 (d, J = 11.7 Hz, 1H, 
CH2Ph), 4.35 (s, 1H, H-7a), 4.05 (dd, J = 10.0, 3.4 Hz, 1H, H-2), 3.90 (d, J = 10.0 Hz, 1H, 
H-3), 3.42 (s, 3H, OMe), 3.38 (s, 3H, OMe), 3.16 (dd, J = 19.6, 5.9 Hz, 1H, H-4), 2.20 – 
2.11 (m, 1H, H-4). 
13
C NMR (101 MHz, CDCl3) δ 193.8, 142.2, 138.7, 138.2, 129.9, 
129.7, 129.4, 128.7, 128.4, 128.3, 128.2, 128.0, 127.8, 99.2, 82.2, 80.5, 77.6, 77.5, 77.3, 
76.9, 76.3, 76.2, 73.8, 56.3, 54.4, 30.2. 
 
5.8.. Synthetic strategy for compound 157 
 
Scheme 5.78 
To a solution of 154 (45 mg, 0.106 mmol) in 1,2-dichlorobenzene, benzocyclobutenol 156 
(203 mg, 0.817 mmol) was added. The reaction mixture was stirred at 160ºC for 90min. 
The crude product was concentrated and purified by flash chromatography [petroleum 
ether/ EtOAc (8:2)] to give 74% as yellow pale oil. 
1
H NMR (500 MHz, CDCl3) δ 7.40 – 
7.21 (m, 13H, Ar-H), 7.12 (d, J = 7.3 Hz, 1H, Ar-H), 4.91 – 4.83 (m, 2H, H-10, CH2Ph), 
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4.78 (d, J = 3.5 Hz, H-1), 4.72 (d, J = 12.1 Hz, 1H, CH2Ph), 4.61 (d, J = 12.1 Hz, CH2Ph), 
4.41 (d, J = 11.7 Hz, CH2Ph), 3.95 (s, 1H, H-11a), 3.88 (dd, J = 10.1, 3.5 Hz, 1H, H-2), 
3.50 (d, J = 10.1 Hz, 1H, H-3), 3.39 (s, 3H, OMe), 3.35 (s, 3H, OMe), 3.21 (t, J = 8.2 Hz, 
1H, H-10a), 2.91 – 2.84 (m, 1H, H-5), 2.41 – 2.36 (m, 1H, H-4a), 2.23 (dd, J = 15.0, 5.4 
Hz, 1H, H-4), 1.30 (d, J = 7.0 Hz, 3H, CH3), 0.90 (t, J = 7.9 Hz, 9H, CH3CH2Si), 0.61 (m, 
7H, H-4, CH3CH2Si). NMR (75 MHz, CDCl3) δ 203.3, 140.2, 138.6, 138.3, 138.1, 130.2, 
128.4, 128.4, 128.1, 127.8, 127.7, 127.6, 127.4, 126.1, 125.8, 124.9, 98.6, 81.8, 80.4, 78.0, 
77.42, 77.00, 76.86, 76.57, 76.15, 73.32, 68.32, 55.46, 52.85, 34.86, 34.69, 26.3, 17.1, 6.8, 
4.7. 
 
5.8.7. Synthetic strategy for tetracyclic glycofused compound 163 
 
Scheme 5.79 
A suspension containing 157 (50 mg, 0.0699 mmol) and Pd/C 10% in EtOAc:MeOH (1:1)  
(6 mL) was stirred at room temperature under H2 (1 atm) for 18h. The suspension was 
filtered and the filtrate was concentrated to give 162 (12 mg, 45%) as a yellow oil. 
1
H 
NMR (300 MHz, ) δ 7.54 – 7.45 (m, 1H, Ar-H), 7.40 – 7.23 (m, 3H, Ar-H), 5.00 (d, J = 
10.2 Hz, 1H, H-3), 4.75 (d, J = 3.8 Hz, 1H, H-1), 3.87 (s, 1H, H-10), 3.71 (dd, J = 10.2, 3.8 
Hz, 1H, H-2), 3.45 (s, 3H, OMe), 3.43 – 3.36 (m, 1H, H-10a), 3.35 (s, 1H, H-11) 3.33 (s, 
3H, OMe), 2.97 (dd, J = 7.0, 3.4 Hz, 1H, H-5), 2.60 – 2.39 (m, 2H, H-4a, H-4), 1.49 (s,     
J = 7.0 Hz, 3H, Me), 0.98 (dd, J = 9.6, 6.2 Hz, 9H, CH3CH2Si), 0.76 – 0.66 (m, 6H, 
CH3CH2Si), 0.56 – 0.45 (m, 1H, H-4). 
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5.8.8. Synthetic strategy for glucofused tetracyclic compound’s 160 and 161 
 
Scheme 5.80 
A mixture of TES ether 157 (75 mg, 0.169 mmol) and TBAF (1.0M in THF, 56.41 L,      
0.056 mmol) in dry THF (2 mL) was stirred at 5ºC for 1h. After consumption of the 
starting material, was slowly added a solution of NH4Cl (2 mL) and diluted with EtOAc    
(1 mL). The aqueous phase was back-extracted with EtOAc (3 x 1 mL) and all the organic 
fractions were combined and dried over anhydrous Na2SO4. The residue was purified by 
flash chromatography [petroleum ether/EtOAc (7:3) and (6:4)] to give a mixture (1:1) of 
tetracyclic compounds 160 and 161 in 75% overall yield. Compound 160 
1
H NMR (400 
MHz, CDCl3) δ 7.61 (d, J = 7.5 Hz, 1H, Ar-H), 7.43 – 7.20 (m, 12H, Ar-H), 7.07 (d,          
J = 7.3 Hz, 1H, Ar-H), 4.94 (d, J = 8.8 Hz, 1H, H-10), 4.90 (d, J = 2.3 Hz, 1H, H-1), 4.86 
(d, J = 11.2 Hz, 1H, CH2Ph), 4.79 (d, J = 12.2 Hz, 1H, CH2Ph), 4.73 (d, J = 12.2 Hz, 1H, 
CH2Ph), 4.65 (d, J = 11.2 Hz, 1H, CH2Ph), 4.42 (broad s, 1H, OH), 4.30 (d, J = 8.0 Hz, 
1H, H-3), 3.89 (dd, J = 8.0, 2.3 Hz, 1H, H-2), 3.49 (s, 3H, OMe), 2.95 – 2.86 (m, 1H, H-5), 
2.72 – 2.64 (m, 1H, H-4), 2.55 (dd, J = 8.8, 4.4 Hz, 1H, H-10a), 2.49 – 2.38 (m, 1H, H-4), 
2.31 – 2.19 (m, 1H, H-4a), 1.19 (d, J = 7.1 Hz, 3H, CH3). Compound 161 
1
H NMR (400 
MHz, CDCl3) δ 7.66 (d, J = 2.9 Hz, 1H, H-10), 7.50 – 7.10 (m, 14H, Ar-H), 4.96 (d, J = 
2.5 Hz, 1H, H-1), 4.88 (d, J = 11.3 Hz, 1H, CH2Ph), 4.79 (d, J = 12.1 Hz, 1H, CH2Ph), 
4.73 (d, J = 12.1 Hz, 1H, CH2Ph), 4.67 (d, J = 11.3 Hz, 1H, CH2Ph), 4.37 (d, J = 8.0 Hz, 
1H, H-3), 3.94 (dd, J = 8.0, 2.5 Hz, 1H, H-2), 3.52 (s, 3H, OMe), 3.07 – 2.93 (m, 1H, H-
4a), 3.07 – 2.93 (m, 1H, H-5), 2.66 (dd, J = 16.8, 6.7 Hz, 1H, H-4), 2.36 (dd, J = 16.8, 10.1 
Hz, 1H, H-4), 1.01 (d, J = 7.0 Hz, 3H, CH3). 
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5.8.. Synthetic strategy for glycofused quinoxaline derivative 179 
Compound 176 
 
Scheme 5.81 
A stirred solution of 175 (600 mg, 1.23 mmol) in anhydrous DMF (7 mL) under argon at      
0 ºC was treated with of NaH (60% in mineral oil, 150 mg, 3.73 mmol). After 15 min. at 
room temperature, the mixture was treated dropwise and rapidly with BnBr (3.71 mmol,   
0.44 mL) and then allowed to stand for 1 h at rt. The mixture was diluted with EtOAc     
(10 mL), and washed with saturated NaHCO3 solution (20 mL). The aqueous phase was 
back-extracted with EtOAc (10 mL), and all the organic fractions were combined, washed 
with brine, and dried over anhydrous Na2SO4. The residue was purified by flash 
chromatography [petroleum ether/EtOAc (9.5:0.5)] affording 176 (669 mg, 94% yield) as 
powder solid. 
1
H NMR (400 MHz, CDCl3) δ 7.47 – 7.07 (m, 15H, Ar-H), 5.6 – 5.51 (m, 
1H, H-2’), 5.41 – 5.30 (m, 1H, H-3’), 4.91 (d, J = 11.6 Hz, 1H, CH2Ph), 4.76 (d, J = 10.6 
Hz, 1H, CH2Ph), 4.71 (d, J = 10.1 Hz, 1H, CH2Ph), 4.68 – 4.54 (m, 4H, CH2Ph), 4.49 (d, J 
= 11.6 Hz, 1H, CH2Ph), 4.38 – 4.29 (m, 1H, H-1), 4.14 (t, J = 9.1 Hz, 1H, H-6), 3.97 – 
3.85 (m, 1H, H-5), 3.80 – 3.68 (m, 3H, H-3, H-4, H-6), 2.75 (dd, J = 17.6, 4.9 Hz, 1H, H-
4’), 2.64 – 2.32 (m, 2H, H-1’), 2.24 (d, J = 17.6 Hz, 1H, H-4’). 
Compound 177 
 
Scheme 5.82 
A solution of compound 176 (260 mg, 0.451 mmol), N-methylmorpholine N-oxide        
(126 mg, 1.04 mmol) and osmium tetroxide (0.34 mL, 0.025 mmol) in H2O/acetone (1:1) 
(4 mL) is stirred at room temperature for 1,5 h and then diluted with CH2Cl2 (15 mL). The 
organic layer is washed with 5 N hydrochloric acid (5 mL) and 45% of sodium hydrogen 
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sulfite solution (5 mL), dried over sodium sulfate and concentrated under reduced pressure. 
Flash chromatography using petroleum ether/EtOAc (6:4) of the residue affords a mixture 
of diasteoisomers (265 mg, 96%) as a yellow pale oil. 
1
H NMR (400 MHz, CDCl3) δ 7.51 
– 7.15 (m, 20H, Ar-H), 4.98 – 4.70 (m, 1H, CH2Ph), 4.70 – 4.44 (m, 7H, CH2Ph), 4.42 – 
4.19 (m, 1H, H-1), 4.17 – 4.00 (m, 1H, H-6), 4.00 – 3.90 (m, 1H, H-4’), 3.90 – 3.81 (m, 
1H, H-5), 3.79 – 3.73 (m, 1H, H-3), 3.72 – 3.65 (m, 2H, H-6, H-4), 2.31 (bd, J = 12.0 Hz, 
1H, H-1’), 2.02 – 1.88 (m, 2H, H-4’, H-1’). 
Compound 178 
 
Scheme 5.83 
To a solution of (COCl)2 (364 mg, 2.87 mmol) in dry CH2Cl2 (6 mL) at -78ºC under argon 
atmosphere, anhydrous DMSO (0.4 mL) was added dropwise, and the resulting solution 
was stirred for 30 min. To the reaction flask, a solution of 177 (341 mg, 0.718 mmol) in 
dry CH2Cl2 (2.0 mL) was added dropwise at -78ºC. This final reaction mixture stayed 
under magnetic stirring for 1 h at -78ºC. Then dry TEA (0.9 mL) was added and the 
reaction stayed for more 30 min under magnetic stirring at -78ºC, and then was allowed to 
warm up until 0ºC. It was carefully added NH4Cl (10 mL), and the organic layer was 
washed with H2O (5 mL), dried over Na2SO4, and concentrated. The residue was used 
without further purification. 
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Compounds 179 and 180 
 
Scheme 5.84 
To a solution of compound 178 (61 mg, 0.10 mmol) in dry THF (0.5 mL) 1,2-
diaminobenzene (18 mg, 0.16 mmol) was added. The reaction mixture remained under 
magnetic stirring at reflux for 3 h. Then was allowed to cool to rt, and was concentrated. 
Flash chromatography [petroleum ether/EtOAc (7:3)] of the residue affords 179 (47 mg, 
71%) as a yellow pale oil. 
1
H NMR (400 MHz, CDCl3) δ 8.05 – 7.90 (m, 2H, Ar-H), 7.73 – 
7.59 (m, 2H, Ar-H), 7.41 – 6.94 (m, 20H, Ar-H), 4.66 (d, J = 12.0 Hz, 1H, CH2Ph), 4.60 – 
4.43 (m, 7H, H-1, CH2Ph), 4.40 (d, J = 11.3 Hz, 1H, CH2Ph), 4.27 – 4.17 (m, 2H, H-4’, H-
5), 4.05 – 4.00 (m, 1H, H-3), 3.93 – 3.79 (m, 3H, H-6, H-4), 3.66 (dd, J = 18.7, 5.6 Hz, 1H, 
H-1’), 3.37 (bd, J = 18.2 Hz, 1H, H-4’), 3.29 (dd, J = 18.7, 3.1 Hz, 1H, H-1’). 13C NMR 
(101 MHz, CDCl3) δ 151.88, 151.34, 141.71, 141.49, 138.43, 138.32, 137.87, 137.49, 
129.21, 129.12, 128.75, 128.65, 128.61, 128.42, 128.34, 128.27, 128.21, 127.94, 127.91, 
127.38, 127.25, 77.60, 77.28, 77.15, 76.96, 75.60, 75.38, 73.79, 73.48, 73.15, 72.52, 68.50, 
67.92, 63.66, 35.25, 34.38. MS: m/z calcd for [M]
+ 
= 679, [M + H]
+ 
=680; found [M ]
+ 
= 
679, [M + H]
+ 
=681. Compound 180 
1
H NMR (400 MHz, CDCl3) δ 8.28 (dd, J = 6.7, 3.5 
Hz, 2H, Ar-H), 8.22 (d, J = 9.1 Hz, 2H, Ar-H), 7.99 (dd, J = 9.1, 1.7 Hz, 1H, Ar-H), 7.88 
(dd, J = 6.7, 3.5 Hz, 2H, Ar-H), 7.47 – 7.22 (m, 10H, Ar-H), 7.11 – 7.07 (m, 2H, Ar-H), 
7.01 – 6.95 (m, 2H, Ar-H), 5.01 (d, J = 3.0 Hz, 1H, H-3), 4.69 (d, J = 11.8 Hz, 1H, 
CH2Ph), 4.50 (bs, 2H, CH2Ph), 4.38 (d, J = 11.8 Hz, 1H, CH2Ph), 4.26 (d, J = 11.1 Hz, 1H, 
CH2Ph), 4.08 (m, 2H, CH2Ph, H-5), 3.81 (dd, J = 7.4, 3.0 Hz, 1H, H-4), 3.68 – 3.57 (m, 
2H, H-6), 2.60 (d, J = 6.0 Hz, 1H, N-H). 
13
C NMR (101 MHz, CDCl3) δ 143.69, 143.49, 
143.41, 142.71, 137.56, 137.56, 130.83, 130.74, 129.88, 129.76, 128.73, 128.70, 128.59, 
128.32, 128.22, 128.08, 127.83, 82.32, 79.87, 70.32, 30.06. MS: m/z calcd for [M]
+ 
= 571, 
[M + H]
+ 
=572; [M + Na]
+ 
=594, found [M + H]
+ 
= 572, [M + Na]
+ 
=594. 
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5.8.1. Synthetic strategy for pegylated derivative 83 
Compound 182 
According to literature procedure:
155
 
 
Scheme 5.85 
Triethylene glycol 181 (4 g, 26.64 mmol, 3.6 mL) was dissolved in dry CH2Cl2 (62 mL). 
The solution was cooled to 0°C before adding silver(I)oxide (6.8 g, 29.3 mmol), followed 
by MsCl (2.5 ml, 31.97 mmol). The mixture was stirred at rt for 5 days. Progress of the 
reaction was followed by TLC. It was then filtered through celite and the solvent was 
evaporated. The crude product was purified by flash chromatography on silica gel 
[EtOAc/MeOH (95:5)]. The bis-mesylated product eluted first followed by the title 
compound 182 as a colorless oil (4.54 g, 75% yield): 
1
H NMR (400 MHz, CDCl3): δ 4.40 – 
4.29 (m, 2H, CH2), 3.78 – 3.72 (m, 2H, CH2), 3.72 – 3.67 (m, 2H, CH2), 3.65 (s, 4H, CH2), 
3.60 – 3.52 (m, 2H, CH2), 3.05 (s, 3H, CH3). 
13
C NMR (101 MHz, CDCl3): δ 72.5, 70.6, 
70.3, 69.0, 61.7, 37.7. 
Compound 183 
According to literature procedure:
155
 
 
Scheme 5.86 
To a solution of the alcohol 182 (1.8 g, 7.892 mmol) in dry DMF (25 mL) at rt was added 
NaN3 (770 mg, 11.838 mmol). The reaction mixture was heated to 110 ºC, stirred at 110 ºC 
for 5.5 h, and cooled to 0 C. The resulting mixture was quenched with water (50 mL) and 
the mixture was extracted with EtOAc (3 × 25 mL). The extracts were washed with 
saturated NaCl solution, dried over Na2SO4, filtered, and concentrated. The concentrate 
was purified by flash column chromatography on silica gel [EtOAc/MeOH (98:2)] to give 
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1.285 g (93%) of azido alcohol 183. 
1
H NMR (400 MHz, CDCl3): δ 3.74 – 3.70 (m, 2H, 
CH2), 3.69 – 3.64 (m, 6H, CH2), 3.62 – 3.57 (m, 2H, CH2), 3.60 (t, J = 4.2 Hz, 2H, CH2), 
2.39 (bs, 1H, OH). 
13
C NMR (101 MHz, CDCl3): δ 72.5; 70.7; 70.5; 70.1; 61.8; 50.7. 
Compound 83 
According to literature procedure:
156
 
 
Scheme 5.87 
To a 0 °C solution of 183 (0.500 g, 2.85 mmol) in dry Et2O (10 mL) were added dry Et3N 
(1.2 mL, 8.56 mmol) and, thereafter, MsCl (0.33 mL, 4.28 mmol). The resulting white 
slurry was quenched with water (30 mL) after 24 h and extracted with Et2O (3×10 mL). 
The combined organic phases were dried (MgSO4), filtered under suction, and purified via 
flash column chromatography [pentane/EtOAc (1:1)], yielding 83 (0.600 g, 2.37 mmol, 
83%) as a clear oil. 
1
H NMR (400 MHz, CDCl3): δ 4.35−4.21 (m, 2H, CH2), 3.73−3.65 (m, 
2H, CH2), 3.63−3.53 (m, 6H, CH2), 3.31 (t, J = 5.2 Hz, 2H, CH2), 2.99 (s, 3H, CH3).      
13
C NMR (101 MHz, CDCl3): δ 70.4, 70.4, 69.8, 69.3, 68.9, 50.5, 37.4. 
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6. Glossary of terms 
 
 
 
 
 
Amyloid plaque: a largely insoluble 
deposit found in the space between nerve 
cells in the brain. Plaques are made of beta-
amyloid peptide (A), other molecules, and 
different kinds of nerve and non-nerve 
cells. 
Amyloid precursor protein (APP): the 
larger protein from which beta-amyloid is 
formed. 
Amyloidosis: A disease or disorder that 
results from a sequence of changes in 
protein folding that leads to the deposition 
of insoluble amyloid fibrils, mainly in the 
extracellular spaces of organs and tissues. 
Amyloid fibrils: Structures formed by 
many disease-causing proteins when they 
aggregate. Amyloid fibrils share common 
biochemical characteristics such as 
detergent insolubility, high β-pleated sheet 
content and a cross β-structure, protease 
resistance and the ability to bind lipophilic 
dyes, such as Congo Red, Thioflavin S and 
Thioflavin T. 
Amyloid plaques: Sites of Aβ 
accumulation and dystrophic neurites in the 
brains of mouse models and patients with 
Alzheimer's disease (AD). 
Apolipoprotein E: a protein that carries 
cholesterol in blood and that appears to play 
some role in brain function. The gene that 
produces this protein comes in several 
forms, or alleles: ε2, ε3, and ε4. The APOE 
ε2 allele is relatively rare and may provide 
some protection against AD (but it may 
increase risk of early heart disease). APOE 
ε3 is the most common allele and appears to 
play a neutral role in AD. APOE ε4 occurs 
in about 40 percent of all people with AD 
who develop the disease in later life; it 
increases the risk of developing AD. 
Axon: the long extension from a neuron 
that transmits outgoing signals to other 
cells. 
Beta-amyloid peptide (A): a part of the 
amyloid precursor protein found in plaques, 
the insoluble deposits outside neurons. 
Brain stem: the portion of the brain that 
connects to the spinal cord and controls 
automatic body functions, such as 
breathing, heart rate, and blood pressure. 
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Blood–brain barrier (BBB): A protective 
wall of capillary epithelium separating the 
brain parenchyma from the bloodstream 
that is impenetrable to most circulating 
substances. 
Calcein: also known as fluorexon, 
fluorescein complex, is a fluorescent dye 
with an excitation and emission 
wavelengths of 495/515nm, respectively. 
Capillary: a tiny blood vessel. The brain 
has billions of capillaries that carry oxygen, 
glucose (the brain’s principal source of 
energy), nutrients, and hormones to brain 
cells so they can do their work. Capillaries 
also carry away carbon dioxide and cell 
waste products. 
Cerebellum: the part of the brain 
responsible for maintaining the body’s 
balance and coordination. 
Cerebral cortex: the outer layer of nerve 
cells surrounding the cerebral hemispheres. 
Cerebral hemispheres: the largest portion 
of the brain composed of billions of nerve 
cells in two structures connected by the 
corpus callosum. The cerebral hemispheres 
control conscious thought, language, 
decision making, emotions, movement, and 
sensory functions. 
Cerebrospinal fluid: the fluid found in and 
around the brain and spinal cord. It protects 
these organs by acting like a liquid cushion 
and by providing nutrients. 
Chaperone: Proteins that reversibly bind 
unfolded segments of polypeptides 
susceptible to aggregation or diversion. 
Chromosome: a threadlike structure in the 
nucleus of a cell that contains DNA. DNA 
sequences make up genes. Most human 
cells have 23 pairs of chromosomes 
containing approximately 30,000 genes. 
Clinical trial: a research study involving 
humans that rigorously tests safety, side 
effects, and how well a medication or 
behavioral treatment works. 
Cognitive functions: all aspects of 
conscious thought and mental activity, 
including learning, perceiving, making 
decisions, and remembering. 
Dementia: a broad term referring to a 
decline in cognitive function to the extent 
that it interferes with daily life and 
activities. 
Dendrite: a branch-like extension of a 
neuron that receives messages from other 
neurons. 
Dystrophic neurites: Abnormal swelling 
that develops secondary to neuronal-cell 
stress in AD and other neurodegenerative 
diseases. 
Early-onset Alzheimer’s disease: a rare 
form of AD that usually affects people 
between ages 30 and 60. It is called familial 
Alzheimer’s disease (FAD) if it runs in the 
family. 
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Entorhinal cortex: an area deep within the 
brain where damage from AD often begins. 
Enzyme: a protein that causes or speeds up 
a biochemical reaction. 
Free radical: a highly reactive molecule 
(typically oxygen or nitrogen) that 
combines easily with other molecules 
because it contains an unpaired electron. 
The combination with other molecules 
sometimes damages cells. 
Gene: the biologic unit of heredity passed 
from parent to child. Genes are segments of 
DNA and contain instructions that tell a cell 
how to make specific proteins. 
Genetic risk factor: a variant in a cell’s 
DNA that does not cause a disease by itself 
but may increase the chance that a person 
will develop a disease. 
Glial cell: a specialized cell that supports, 
protects, or nourishes nerve cells. 
Hippocampus: a structure in the brain that 
plays a major role in learning and memory 
and is involved in converting short-term to 
long-term memory. 
Hypothalamus: a structure in the brain 
under the thalamus that monitors activities 
such as body temperature and food intake. 
Late-onset Alzheimer’s disease: the most 
common form of AD. It occurs in people 
aged 60 and older. 
Limbic system: a brain region that links the 
brain stem with the higher reasoning 
elements of the cerebral cortex. It controls 
emotions, instinctive behavior, and the 
sense of smell. 
Magnetic resonance imaging (MRI): a 
diagnostic and research technique that uses 
magnetic fields to generate a computer 
image of internal structures in the body. 
MRIs are very clear and are particularly 
good for imaging the brain and soft tissues. 
Metabolism: all of the chemical processes 
that take place inside the body. In some 
metabolic reactions, complex molecules are 
broken down to release energy. In others, 
the cells use energy to make complex 
compounds out of simpler ones (like 
making proteins from amino acids). 
Microtubule: an internal support structure 
for a neuron that guides nutrients and 
molecules from the body of the cell to the 
end of the axon. 
Microglia: Phagocytic immune cells in the 
brain that engulf and remove cells that have 
undergone apoptosis. 
Mild cognitive impairment (MCI): a 
condition in which a person has memory 
problems greater than those expected for 
his or her age, but not the personality or 
cognitive problems that characterize AD. 
Mutation: a permanent change in a cell’s 
DNA that can cause a disease. 
Myelin: a whitish, fatty layer surrounding 
an axon that helps the axon rapidly 
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transmits electrical messages from the cell 
body to the synapse. 
Nerve growth factor (NGF): a substance 
that maintains the health of nerve cells. 
NGF also promotes the growth of axons 
and dendrites, the parts of the nerve cell 
that are essential to its ability to 
communicate with other nerve cells. 
Neurodegenerative disease: a disease 
characterized by a progressive decline in 
the structure, activity, and function of brain 
tissue. These diseases include AD, 
Parkinson’s disease, frontotemporal lobar 
degeneration, and dementia with Lewy 
bodies. They are usually more common in 
older people. 
Neurofibrillary tangle: a filamentous 
collection of twisted and hyperphos-
phorylated tau found in the cell body of a 
neuron in AD. 
Neuron: a nerve cell. 
Neurotransmitter: a chemical messenger 
between neurons. These substances are 
released by the axon on one neuron and 
excite or inhibit activity in a neighboring 
neuron. 
Nucleus: the structure within a cell that 
contains the chromosomes and controls 
many of its activities. 
Oxidative damage: damage that can occur 
to cells when they are exposed to too many 
free radicals. 
Oligomers: clusters of small numbers of 
protein or peptide molecules without a 
fibrillar appearance.  
Passive immunization: The induction of 
immunity by the transfer of immune-
globulins. 
Positron emission tomography (PET): an 
imaging technique using radioisotopes that 
allows researchers to observe and measure 
activity in different parts of the brain by 
monitoring blood flow and concentrations 
of substances such as oxygen and glucose, 
as well as other specific constituents of 
brain tissues. 
Protein misfolding: the conversion of a 
protein into a structure that differs from its 
native state. 
Protofibrils: protein aggregates of isolated 
or clustered spherical beads 2–5 nm in 
diameter with β-sheet structure. 
Protofilaments: the constituent units of 
amyloid fibrils. They should not be 
confused with protofibrils. 
Synapse: the tiny gap between nerve cells 
across which neurotransmitters pass. 
Tau: a protein that helps to maintain the 
structure of microtubules in normal nerve 
cells. Abnormal tau is a principal 
component of the paired helical filaments in 
neurofibrillary tangles. 
Thalamus: a small structure in the front of 
the cerebral hemisphere that serves as a 
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way station that receives sensory 
information of all kinds and relays it to the 
cortex; it also receives information from the 
cortex. 
Transgenic: an animal that has had a gene 
(like human APP) inserted into its 
chromosomes. Mice carrying the mutated 
human APP gene often develop plaques in 
their brains as they age. 
Ventricle: a cavity within the brain that is 
filled with cerebrospinal fluid. 
Vesicle: a small container for transporting 
neurotransmitters and other molecules from 
one part of the neuron to another. 
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